AU2019204913A1 - Peptide oligonucleotide conjugates - Google Patents

Abstract

I:\sxd\Interwovn\NRPortbl\DCC\SXD\15256822 _.docx-1807/2017 Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases 5 where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Description

PEPTIDE OLIGONUCLEOTIDE CONJUGATES

This is a divisional of Australian patent application no. 2017206179, which is a divisional application of Australian patent application no. 2011367230, the entire contents of which are incorporated herein by reference.

BACKGROUND

Technical Field

The present invention is generally related to oligonucleotide compounds (oligomers) useful as antisense compounds, and more particularly to oligomer compounds conjugated to cell-penetrating peptides, and the use of such oligomer compounds in antisense applications.

Description of the Related Art

The practical utility of many drugs having potentially useful biological activity is often stymied by difficulty in delivering such drugs to their targets. Compounds to be delivered into cells must generally be delivered from a largely aqueous extracellular environment and then penetrate a lipophilic cell membrane to gain entry to the cell. Unless the substance is actively transported by a specific transport mechanism, many molecules, particularly large molecules, are either too lipophilic for practical solubilization or are too hydrophilic to penetrate the membrane.

A segment of the HIV Tat protein consisting of amino acid residues 4957 (Tat 49 57, having the sequence RKKRRQRRR) has been used to deliver biologically active peptides and proteins to cells (e.g. Barsoum et al., 1994, PCT Pubn. No. WO 94/04686). Tat (49 60) has been used to enhance delivery of phosphorothioate oligonucleotides (Astriab-Fisher, Sergueev et al. 2000; Astriab-Fisher, Sergueev et al. 2002). Reverse Tat, or rTat(57-49) (RRRQRRKKR), has been reported to deliver fluorescein into cells with enhanced efficacy compared to Tat (49 57) (Wender, Mitchell et al. 2000; Rothbard, Kreider et al. 2002). Rothbard and Wender have also disclosed other arginine-rich transport polymers (PCT Pubn. No. WO 01/62297; U.S. Patent No. 6,306,993; US Patent Appn. Pubn. No. 2003/0032593).

2019204913 09 Jul 2019

Oligonucleotides are one class of potentially useful drug compounds whose delivery has often been an impediment to therapeutic use. Phosphorodiamidatelinked morpholino oligomers (PMOs; see e.g. Summerton and Weller, 1997) have been found more promising in this regard than charged oligonucleotide analogs such as phosphorothioates. The PMOs are water-soluble, uncharged or substantially uncharged antisense molecules that inhibit gene expression by preventing binding or progression of splicing or translational machinery components. PMOs have also been to shown to inhibit or block viral replication (Stein, Skilling et al. 2001; McCaffrey, Meuse et al. 2003). They are highly resistant to enzymatic digestion (Hudziak, Barofsky et al. 10 1996). PMOs have demonstrated high antisense specificity and efficacy in vitro in cellfree and cell culture models (Stein, Foster et al. 1997; Summerton and Weller 1997), and in vivo in zebrafish, frog and sea urchin embryos (Heasman, Kofron et al. 2000; Nasevicius and Ekker 2000), as well as in adult animal models, such as rats, mice, rabbits, dogs, and pigs (see e.g. Arora and Iversen 2000; Qin, Taylor et al. 2000; 15 Iversen 2001; Kipshidze, Keane et al. 2001; Devi 2002; Devi, Oldenkamp et al. 2002;

Kipshidze, Kim et al. 2002; Ricker, Mata et al. 2002).

Antisense PMO oligomers have been shown to be taken up into cells and to be more consistently effective in vivo, with fewer nonspecific effects, than other widely used antisense oligonucleotides (see e.g. P. Iversen, Phosphoramidite 20 Morpholino Oligomers, in Antisense Drug Technology, S.T. Crooke, ed., Marcel Dekker, Inc., New York, 2001). Conjugation of PMOs to arginine rich peptides has been shown to increase their cellular uptake (see e.g., U.S. Patent No. 7,468,418); however, the toxicity of the conjugates has slowed their development as viable drug candidates.

Although significant progress has been made, there remains a need in the art for oligonucleotide conjugates with improved antisense or antigene performance. Such improved antisense or antigene performance includes; lower toxicity, stronger affinity for DNA and RNA without compromising sequence selectivity; improved pharmacokinetics and tissue distribution; improved cellular delivery and reliable and 30 controllable in vivo distribution.

2019204913 09 Jul 2019

BRIEF SUMMARY

Compounds of the present invention address these issues and provide improvements over existing antisense molecules in the art. By linking a cellpenetrating peptide to a substantially uncharged nucleic acid analogue via a glycine or 5 proline amino acid, the present inventors have addressed the toxicity issues associated with other peptide oligomer conjugates. Furthermore, modification of the intersubunit linkages and/or conjugation of terminal moieties to the 5’ and/or 3’ terminus of an oligonucleotide analogue, for example a morpholino oligonucleotide, may also improve the properties of the conjugates. For example, in certain embodiments the disclosed 10 conjugates have decreased toxicity and/or enhanced cell delivery, potency, and/or tissue distribution compared to other oligonucleotide analogues and/or can be more effectively delivered to the target organs. These superior properties give rise to favorable therapeutic indices, reduced clinical dosing, and lower cost of goods.

Accordingly, in one embodiment the present disclosure provides a 15 conjugate comprising:

(a) a carrier peptide comprising amino acid subunits; and (b) a nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid;

wherein:

two or more of the amino acid subunits are positively charged amino acids, the carrier peptide comprises a glycine (G) or proline (P) amino acid at a carboxy terminus of the carrier peptide, and the carrier peptide is covalently attached to the nucleic acid analogue. A composition comprising the above conjugate and a 25 pharmaceutically acceptable vehicle are also provided.

In another embodiment, the present disclosure provides a method of inhibiting production of a protein, the method comprising exposing a nucleic acid encoding the protein to a conjugate of the present disclosure.

Another aspect of the present disclosure includes a method for enhancing 30 the transport of a nucleic acid analogue into a cell, the method comprising conjugating the carrier peptide of claim 1 to a nucleic acid analogue, and wherein the transport of

2019204913 09 Jul 2019 the nucleic acid analogue into the cell is enhanced relative to the nucleic acid analogue in unconjugated form.

In another embodiment, the disclosure is directed to a method of treating a disease in a subject, the method comprising administering a therapeutically effective 5 amount of a disclosed conjugate to the subject. Methods of making the conjugates, methods for their use and carrier peptides useful for conjugating to nucleic acid analogues are also provided.

These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein 10 which describe in more detail certain background information, procedures, compounds and/or compositions, and are each hereby incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows an exemplary morpholino oligomer structure comprising a phosphorodiamidate linkage.

Figure IB shows a morpholino oligomer conjugated to a carrier peptide at the 5 ’ end.

Figure 1C shows a morpholino oligomer conjugated to a carrier peptide at the 3 ’ end.

Figures 1D-G show the repeating subunit segment of exemplary 20 morpholino oligonucleotides, designated ID through 1G.

Figure 2 depicts exemplary intersubunit linkages linked to a morpholino -T moiety.

Figure 3 is a reaction scheme showing preparation of a linker for solidphase synthesis.

Figure 4 demonstrates preparation of a solid support for oligomer synthesis.

Figures 5A, 5B and 5C show exon skipping data for exemplary conjugates compared to a known conjugate in mouse quadriceps, diaphragm and heart, respectively.

2019204913 09 Jul 2019

Figures 6A, 6B and 6C are alternate representations of exon skipping data for exemplary conjugates compared to a known conjugate in mouse quadriceps, diaphragm and heart, respectively.

Figures 7A and 7B are graphs depicting blood urea nitrogen (BUN) 5 levels and survival rate of mice treated with various peptide-oligomer conjugates, respectively.

Figures 8A and 8B show kidney injury marker (KIM) data and Clusterin (Clu) data for mice treated with various peptide-oligomer conjugates, respectively.

Figures 9A, 9B, 9C and 9D are graphs comparing the exon skipping,

BUN levels, precent survival and KIM levels, respectively, in mice treated with an exemplary conjugate compared to a known conjugate.

Figure 10 presents KIM data for mice treated with various conjugates.

Figure 11 shows results of BUN analysis of mice treated with various conjugates.

Figure 12 is a graph showing the concentration of various oligomers in mouse kidney tissue.

DETAILED DESCRIPTION

I. Definitions

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

Reference throughout this specification to “one embodiment” or “an 30 embodiment” means that a particular feature, structure or characteristic described in

2019204913 09 Jul 2019 connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

The terms below, as used herein, have the following meanings, unless indicated otherwise:

“Amino” refers to the -NH2 radical.

“Cyano” or “nitrile” refers to the -CN radical. “Hydroxy” or “hydroxyl” refers to the -OH radical. “Imino” refers to the =NH substituent.

“Guanidinyl” refers to the -NHC(=NH)NH2 substituent. “Amidinyl” refers to the -C(=NH)NH2 substituent. “Nitro” refers to the -NO2 radical.

“Oxo” refers to the =0 substituent.

“Thioxo” refers to the =S substituent.

“Cholate” refers to the following structure:

HO

H

O “Deoxycholate” refers to the following structure:

2019204913 09 Jul 2019

“Alkyl” refers to a straight or branched hydrocarbon chain radical which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), having from one to thirty carbon atoms, and which is attached to the rest of the 5 molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to are included. An alkyl comprising up to 30 carbon atoms is refered to as a C1-C30 alkyl, likewise, for example, an alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl. Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarily. Alkyl groups include, but are not limited to, C1-C30 10 alkyl, C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, Ci-C₈ alkyl, Ci-C₆ alkyl, C1-C4 alkyl, CiC3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (zso-propyl), n -butyl, z-butyl, .s-butyl, zz-pcntyl, 1,1-dimethylethyl (Abutyl),

3-methylhexyl, 2-methylhexyl, ethenyl, prop-l-enyl, but-l-enyl, pent-l-enyl, penta-1,4-dienyl, ethynyl, propynyl, but-2-ynyl, but-3-ynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted as described below.

“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. Alkylenes may 20 be saturated or unsaturated (i.e., contains one or more double and/or triple bonds).

Representative alkylenes include, but are not limited to, C1-C12 alkylene, Ci-Cs alkylene, Ci-Ce alkylene, C1-C4 alkylene, C1-C3 alkylene, C1-C2 alkylene, Ci alkylene. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, zz-butylcnc, ethenylene, propenylene, zz-butcnylcnc, propynylene, 25 zz-butynylcnc, and the like. The alkylene chain is attached to the rest of the molecule

2019204913 09 Jul 2019 through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.

Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted as described below.

“Alkoxy” refers to a radical of the formula -ORa where R_a is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below.

“Alkoxyalkyl” refers to a radical of the formula -RbOR_a where R_a is an 10 alkyl radical as defined and where Rb is an alkylene radical as defined. Unless stated otherwise specifically in the specification, an alkoxyalkyl group may be optionally substituted as described below.

“Alkylcarbonyl” refers to a radical of the formula -C(=O)Ra where R_a is an alkyl radical as defined above. Unless stated otherwise specifically in the 15 specification, an alkylcarbonyl group may be optionally substituted as described below.

“Alkyloxycarbonyl” refers to a radical of the formula -C(=O)ORa where Ra is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkyloxycarbonyl group may be optionally substituted as described below.

“Alkylamino” refers to a radical of the formula -NHR_a or -NR_aRa where each R_a is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.

“Amidyl” refers to a radical of the formula -N(H)C(=O) Ra where R_a is 25 an alkyl or aryl radical as defined herein . Unless stated otherwise specifically in the specification, an amidyl group may be optionally substituted as described below.

“Amidinylalkyl” refers a radical of the formula -Rb- C(=NH)NH2 where Rb is an alkylene radical as defined above. Unless stated otherwise specifically in the specification, an amidinylalkyl group may be optionally substituted as described below.

“Amidinylalkylcarbonyl” refers a radical of the formula -C(=O)RbC(=NH)NH2 where Rb is an alkylene radical as defined above. Unless stated otherwise

2019204913 09 Jul 2019 specifically in the specification, an amidinylalkylcarbonyl group may be optionally substituted as described below.

“Aminoalkyl” refers to a radical of the formula -Rb-NRaRa where Rb is an alkylene radical as defined above, and each Ra is independently a hydrogen or an alkyl radical.

“Thioalkyl” refers to a radical of the formula -SRa where Ra is an alkyl radical as defined above. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.

“Aryl” refers to a radical derived from a hydrocarbon ring system 10 comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as15 indacene, .s-indaccnc, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-“ (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.

“Aralkyl” refers to a radical of the formula -Rb-R_c where Rb is an 20 alkylene chain as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl, trityl and the like. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.

“Arylcarbonyl” refers to a radical of the formula -C(=O)Rc where R_c is one or more aryl radicals as defined above, for example, phenyl. Unless stated 25 otherwise specifically in the specification, an arylcarbonyl group may be optionally substituted.

“Aryloxycarbonyl” refers to a radical of the formula -C(=O)ORc where R_c is one or more aryl radicals as defined above, for example, phenyl. Unless stated otherwise specifically in the specification, an aryloxycarbonyl group may be optionally 30 substituted.

“Aralkylcarbonyl” refers to a radical of the formula -C(=O)Rb-Rc where Rb is an alkylene chain as defined above and R_c is one or more aryl radicals as defined

2019204913 09 Jul 2019 above, for example, phenyl. Unless stated otherwise specifically in the specification, an aralkylcarbonyl group may be optionally substituted.

“Aralkyloxycarbonyl” refers to a radical of the formula -C(=O)ORb-Rc where Rb is an alkylene chain as defined above and Rc is one or more aryl radicals as 5 defined above, for example, phenyl. Unless stated otherwise specifically in the specification, an aralkyloxycarbonyl group may be optionally substituted.

“Aryloxy” refers to a radical of the formula -ORc where Rc is one or more aryl radicals as defined above, for example, phenyl. Unless stated otherwise specifically in the specification, an arylcarbonyl group may be optionally substituted.

“Cycloalkyl” refers to a stable, non-aromatic, monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, which is saturated or unsaturated, and attached to the rest of the molecule by a single bond. Representative cycloalkyls include, but are not limited to, cycloaklyls having from three to fifteen carbon atoms and from three to eight carbon atoms, Monocyclic cyclcoalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted.

“Cycloalkylalkyl” refers to a radical of the formula -RbRd where Rb is an alkylene chain as defined above and Rd is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.

“Cycloalkylcarbonyl” refers to a radical of the formula -C(=O)Rd where Rd is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the 25 specification, a cycloalkylcarbonyl group may be optionally substituted.

Cycloalkyloxycarbonyl” refers to a radical of the formula -C(=O)ORd where Rd is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkyloxycarbonyl group may be optionally substituted.

“Fused” refers to any ring structure described herein which is fused to an existing ring structure. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.

2019204913 09 Jul 2019 “Guanidinylalkyl” refers a radical of the formula -Rb-NHC(=NH)NH2 where Rb is an alkylene radical as defined above. Unless stated otherwise specifically in the specification, a guanidinylalkyl group may be optionally substituted as described below.

“Guanidinylalkylcarbonyl” refers a radical of the formula

-C(=O)Rb-NHC(=NH)NH2 where Rb is an alkylene radical as defined above. Unless stated otherwise specifically in the specification, a guanidinylalkylcarbonyl group may be optionally substituted as described below.

“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.

“Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.

“Perhalo” or “perfluoro” refers to a moiety in which each hydrogen atom has been replaced by a halo atom or fluorine atom, respectively.

“Heterocyclyl”, “heterocycle” or “heterocyclic ring” refers to a stable 3to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, 20 phosphorous and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. 25 Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, 30 tetrahydro furyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl,

1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 12-crown-4, 15-crown-5, 18crown-6, 21-crown-7, aza-18-crown-6, diaza-18-crown-6, aza-21-crown-7, and diaza11

2019204913 09 Jul 2019

21-crown-7. Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted.

“Heteroaryl” refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms 5 selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.

Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[h][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), 15 benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 20 1-phenyl-1/7-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a 25 heteroaryl group may be optionally substituted.

All the above groups may be either substituted or unsubstituted. The term “substituted” as used herein means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl,alkylamino, amidyl, amidinylalkyl, amidinylalkylcarbonyl, aminoalkyl, aryl, aralkyl, arylcarbonyl, 30 aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, guanidinylalkyl, guanidinylalkylcarbonyl, haloalkyl, heterocyclyl and/or heteroaryl),

2019204913 09 Jul 2019 may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent. Unless stated specifically in the specification, a substituted group may include one or more substituents selected from: oxo, -CO2H, nitrile, nitro, -CONH2, hydroxyl, thiooxy, alkyl, alkylene, alkoxy, alkoxyalkyl, 5 alkylcarbonyl, alkyloxycarbonyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl 10 groups, alkyldiarylsilyl groups, triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example, trifluoromethyl or trifluoromethoxy. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, 15 and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NR_gC(=O)NR_gRh, -NR_gC(=O)ORh, -NR_gSO₂Rh, -OC(=O)NR_gR_h, -OR_g, -SR_g, -SOR_g, -SO₂R_g, -OSO₂R_g, -SO₂OR_g, =NSC>2R_g, and -SCfiNRgRh. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)R_g, -C(=O)OR_g, -CH2SO2R_g, 20 -CHzSCfiNRgRh, -SH, -SR_g or -SSR_g. In the foregoing, R_g and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, /V-hctcrocyclyl, heterocyclylalkyl, heteroaryl, /V-hctcroaryl and/or heteroarylalkyl. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the 25 above substituents. Furthermore, any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms. For example, an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group. Similarily, an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc. Amidyl moieties may be substituted with up to 2 halo 30 atoms, while other groups above may be substituted with one or more halo atoms. Any of the above groups may also be substituted with amino, monoalklyamino, guanidinyl or amidynyl. Optional substitutents for any of the above groups also include

2019204913 09 Jul 2019 arylphosphoryl, for example -RaP(Ar)3 wherein R_a is an alkylene and Ar is aryl moiety, for example phenyl.

The terms antisense oligomer or antisense compound are used interchangeably and refer to a sequence of subunits, each having a base carried on a 5 backbone subunit composed of ribose or other pentose sugar or morpholino group, and where the backbone groups are linked by intersubunit linkages that allow the bases in the compound to hybridize to a target sequence in a nucleic acid (typically an RNA) by Watson-Crick base pairing, to form a nucleic acid:oligomer heteroduplex within the target sequence. The oligomer may have exact sequence complementarity to the target 10 sequence or near complementarity. Such antisense oligomers are designed to block or inhibit translation of the mRNA containing the target sequence, and may be said to be directed to a sequence with which it hybridizes.

A morpholino oligomer or “PMO” refers to a polymeric molecule having a backbone which supports bases capable of hydrogen bonding to typical 15 polynucleotides, wherein the polymer lacks a pentose sugar backbone moiety, and more specifically a ribose backbone linked by phosphodiester bonds which is typical of nucleotides and nucleosides, but instead contains a ring nitrogen with coupling through the ring nitrogen. An exemplarymorpholino oligomer comprises morpholino subunit structures linked together by (thio)phosphoramidate or (thio)phosphorodiamidate 20 linkages, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, each subunit comprising a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. Morpholino oligomers (including antisense oligomers) are detailed, for example, in U.S. Pat. Nos. 5,698,685; 5,217,866; 5,142,047; 5,034,506; 5,166,315; 5,185,444; 5,521,063;

5,506,337 and pending US patent applications 12/271,036; 12/271,040; and PCT publication number WO/2009/064471 all of which are incorporated herein by reference in their entirety. Representative PMOs include PMOs wherin the intersubunit linkages are linkage (Al).

“PMO+” refers to phosphorodiamidate morpholino oligomers comprising 30 any number of (l-piperazino)phosphinylideneoxy, (l-(4-(co-guanidino-alkanoyl))piperazino)phosphinylideneoxy linkages (A2 and A3) that have been described

2019204913 09 Jul 2019 previously (see e.g., PCT publication WO/2008/036127 which is incorporated herein by reference in its entirety.

“PMO-X”refers to phosphorodiamidate morpholino oligomers disclosed herein comprising at least one (B) linkage or at least one of the disclosed terminal 5 modifications.

A phosphoramidate group comprises phosphorus having three attached oxygen atoms and one attached nitrogen atom, while a phosphorodiamidate group (see e.g., Figures 1D-E) comprises phosphorus having two attached oxygen atoms and two attached nitrogen atoms. In the uncharged or the modified intersubunit linkages of 10 the oligomers described herein and co-pending US Patent Application Nos. 61/349,783 and 11/801,885, one nitrogen is always pendant to the backbone chain. The second nitrogen, in a phosphorodiamidate linkage, is typically the ring nitrogen in a morpholino ring structure.

“Thiophosphoramidate” or “thiophosphorodiamidate” linkages are 15 phosphoramidate or phosphorodiamidate linkages, respectively, wherein one oxygen atom, typically the oxygen pendant to the backbone, is replaced with sulfur.

“Intersubunit linkage” refers to the linkage connecting two morpholino subunits, for example structure (I).

“Charged, uncharged, cationic and anionic as used herein refer to 20 the predominant state of a chemical moiety at near-neutral pH, e.g., about 6 to 8. For example, the term may refer to the predominant state of the chemical moiety at physiological pH, that is, about 7.4.

Lower alkyl refers to an alkyl radical of one to six carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl. In 25 certain embodiments, a lower alkyl group has one to four carbon atoms. In other embodiments a lower alkyl group has one to two carbon atoms; i.e. methyl or ethyl. Analogously, lower alkenyl refers to an alkenyl radical of two to six, preferably three or four, carbon atoms, as exemplified by allyl and butenyl.

A non-interfering substituent is one that does not adversely affect the 30 ability of an antisense oligomer as described herein to bind to its intended target. Such substituents include small and/or relatively non-polar groups such as methyl, ethyl, methoxy, ethoxy, or fluoro.

2019204913 09 Jul 2019

An oligonucleotide or antisense oligomer specifically hybridizes to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions, with a Tm greater than 37 °C, greater than 45 °C, preferably at least 50 °C, and typically 60 °C-80 °C or higher. The Tm of an oligomer is the temperature at 5 which 50% hybridizes to a complementary polynucleotide. Tm is determined under standard conditions in physiological saline, as described, for example, in Miyada et al., Methods Enzymol. 154:94-107 (1987). Such hybridization may occur with near or substantial complementary of the antisense oligomer to the target sequence, as well as with exact complementarity.

Polynucleotides are described as complementary to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides. Complementarity (the degree that one polynucleotide is complementary with another) is quantifiable in terms of the proportion of bases in opposing strands that are expected to form hydrogen bonds with each other, according 15 to generally accepted base-pairing rules.

A first sequence is an antisense sequence with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically binds to, or specifically hybridizes with, the second polynucleotide sequence under physiological conditions.

The term targeting sequence is the sequence in the oligonucleotide analog that is complementary (meaning, in addition, substantially complementary) to the target sequence in the RNA genome. The entire sequence, or only a portion, of the analog compound may be complementary to the target sequence. For example, in an analog having 20 bases, only 12-14 may be targeting sequences. Typically, the 25 targeting sequence is formed of contiguous bases in the analog, but may alternatively be formed of non-contiguous sequences that when placed together, e.g., from opposite ends of the analog, constitute sequence that spans the target sequence.

The backbone of an oligonucleotide analog (e.g., an uncharged oligonucleotide analogue) refers to the structure supporting the base-pairing moieties;

e.g., for a morpholino oligomer, as described herein, the backbone includes morpholino ring structures connected by intersubunit linkages (e.g., phosphoruscontaining linkages). A “substantially uncharged backbone” refers to the backbone of

2019204913 09 Jul 2019 an oligonuceltoide analogue wherein less than 50% of the intersubunit linkages are charged at near-neutral pH. For example, a substantially uncharged backbone may comprise less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5% or even 0% intersubunit linkages which are charged at near neutral pH. In 5 some embodiments, the substantially uncharged backbone comprises at most one charged (at physiological pH) intersubunit linkage for every four uncharged (at physiological pH) linkages, at most one for every eight or at most one for every sixteen uncharged linkages. In some embodiments, the nucleic acid analogs described herein are fully uncharged.

Target and targeting sequences are described as complementary to one another when hybridization occurs in an antiparallel configuration. A targeting sequence may have near or substantial complementarity to the target sequence and still function for the purpose of the presently described methods, that is, still be complementary. Preferably, the oligonucleotide analog compounds employed in the presently described methods have at most one mismatch with the target sequence per every 10 nucleotides, and preferably at most one mismatch out of 20. Alternatively, the antisense oligomers employed have at least80%, at least 90% sequence homology or at least 95% sequence homology, with the exemplary targeting sequences as designated herein. For purposes of complementary binding to an RNA target, and as discussed 20 below, a guanine base may be complementary to either a cytosineor uracil RNA base.

A heteroduplex refers to a duplex between an oligonculeotide analog and the complementary portion of a target RNA. A nuclease-resistant heteroduplex refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to in vivo 25 degradation by intracellular and extracellular nucleases, such as RNAse H, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.

An agent is actively taken up by mammalian cells when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane. The agent may be transported, for example, by active transport, referring to transport 30 of agents across a mammalian cell membrane by e.g. an ATP-dependent transport mechanism, or by facilitated transport, referring to transport of antisense agents across the cell membrane by a transport mechanism that requires binding of the agent to

2019204913 09 Jul 2019 a transport protein, which then facilitates passage of the bound agent across the membrane.

The terms modulating expression and/or “antisense activity” refer to the ability of an antisense oligomer to either enhance or, more typically, reduce the 5 expression of a given protein, by interfering with the expression or translation of RNA.

In the case of reduced protein expression, the antisense oligomer may directly block expression of a given gene, or contribute to the accelerated breakdown of the RNA transcribed from that gene. Morpholino oligomers as described herein are believed to act via the former (steric blocking) mechanism. Preferred antisense targets for steric 10 blocking oligomers include the ATG start codon region, splice sites, regions closely adjacent to splice sites, and 5'-untranslated region of mRNA, although other regions have been successfully targeted using morpholino oligomers.

An amino acid subunit is generally an a-amino acid residue (-COCHR-NH-); but may also be a β- or other amino acid residue (e.g. -CO-CH2CHR-NH-), 15 where R is an amino acid side chain.

The term “naturally occurring amino acid” refers to an amino acid present in proteins found in nature. The term “non-natural amino acids” refers to those amino acids not present in proteins found in nature; examples include beta-alanine (βAla) and 6-aminohexanoic acid (Ahx).

An effective amount or therapeutically effective amount refers to an amount of antisense oligomer administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect, typically by inhibiting translation of a selected target nucleic acid sequence.

Treatment of an individual (e.g. a mammal, such as a human) or a cell 25 is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of a pharmaceutical composition, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent.

2019204913 09 Jul 2019

II. Carrier Peptides

A. Properties of the Carrier Peptide

As noted above, the present disclosure is directed to conjugates of carrier peptides and nucleic acid analogues. The carrier peptides are generally effective to 5 enhance cell penetration of the nucleic acid analogues. Furthermore, Applicants have surprisingly discovered that including a glycine (G) or proline (P) amino acid subunit between the nucleic acid analogue and the remainder of the carrier peptide (e.g., at the carboxy or amino terminus of the carrier peptide) reduces the toxicity of the conjugate, while the efficacy remains the same or is improved relative to conjugates without the 10 glycine or proline amino acid subunit. Thus the presently disclosed conjugates have a better therapeutic window and are more promising drug candidates than other peptideoligomer conjugates.

In addition to reduced toxicity, the presence of a glycine or proline amino acid subunit between the nucleic acid analogue and the carrier peptide is 15 believed to provide additional advantages. For example, glycine is inexpensive and is easily coupled to the nucleic acid analogue (or optional linker) without any possibility of racemization. Similarily, proline is easily coupled without racemization and also provides carrier peptides which are not helix formers. The hydrophobicity of proline may also confer certain advantages with respect to interaction of the carrier peptide 20 with the lipid bilayer of cells, and carrier peptides comprising multiple prolines (for example in certain embodiments) may resist G-tetraplex formation. Finally, in certain embodiments, when the proline moiety is adjacent to an arginine amino acid subunit, the proline moiety confers metabolic to the conjugates since the argine-proline amide bond is not cleavable by common endopeptidases.

As noted above, conjugates comprising carrier peptides linked to nucleic acid analogues via a glycine or proline amino acid subunit have lower toxicity and similar efficacy compared to other known conjugates. Experiments performed in support of the present application show that kidney toxicity markers are much lower with the presently disclosed conjugates compared to other conjugates (see e.g., kidney 30 injury marker (KIM) and blood urea nitrogen (BUN) data described inExample 30).

While not wishing to be bound by theory, the present inventors believe the reduced

2019204913 09 Jul 2019 toxicity of the disclosed conjugates is related to the absence of unnatural amino acids such as aminohexanoic acid or β-alanine in the portion of the peptide which is attached to the nucleic acid analogue (e.g., the carboxy terminus). Since these unnatural amino acids are not cleaved in vivo, it is believed that toxic concentrations of the uncleaved 5 peptides (e.g., XR and BR dimmers) accumulate and cause toxic effects. Some embodiments of the present disclosure are directed to carrier peptides which do not comprise any unnatural amino acid subunits. In this regard, Applicants have discovered that replacing an internal aminohexanoic acid subunit with an amino acid dimer such as alanine-alanine or glycine-glycine substantially reduces the toxicity of the conjugate 10 while maintaining a similar efficacy.

The glycine or proline moiety may be at either the amino or carboxy terminus of the carrier peptide, and in some instances, the carrier peptide may be linked to the nucleic acid analogue directly via the glycine or proline subunit or the carrier peptide may be linked to the nucleic acid analogue via an optional linker.

In one embodiment, the present disclosure is directed to a conjugate comprising:

(a) a carrier peptide comprising amino acid subunits; and (b) a nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid;

wherein:

two or more of the amino acid subunits are positively charged amino acids, the carrier peptide comprises a glycine (G) or proline (P) amino acid subunit at a carboxy terminus of the carrier peptide and the carrier peptide is covalently attached to 25 the nucleic acid analogue. In some embodiments, no more than seven contiguous amino acid subunits are arginine. In some embodiments, the carrier peptide comprises a glycine amino acid subunit at the carboxy terminus. In other embodiments, the carrier peptide comprises a proline amino acid subunit at the carboxy terminus. In still other embodiments, the carrier peptide comprises a single glycine or proline at the carboxy 30 terminus (i.e., does not comprise a glycine or proline dimmer or trimer, etc. at the carboxy terminus).

2019204913 09 Jul 2019

In certain embodiments, the carrier peptide, when conjugated to an antisense oligomer having a substantially uncharged backbone, is effective to enhance the binding of the antisense oligomer to its target sequence, relative to the antisense oligomer in unconjugated form, as evidenced by:

(i) a decrease in expression of an encoded protein, relative to that provided by the unconjugated oligomer, when binding of the antisense oligomer to its target sequence is effective to block a translation start codon for the encoded protein, or (ii) an increase in expression of an encoded protein, relative to that provided by the unconjugated oligomer, when binding of the antisense oligomer to its target sequence is effective to block an aberrant splice site in a pre-mRNA which encodes said protein when correctly spliced. Assays suitable for measurement of these effects are described further below. In one embodiment, conjugation of the peptide provides this activity in a cell-free translation assay, as described herein. In some embodiments, activity is enhanced by a factor of at least two, a factor of at least five or a factor of at least ten.

Alternatively or in addition, the carrier peptide is effective to enhance the transport of the nucleic acid analog into a cell, relative to the analog in unconjugated form. In certain embodiments, transport is enhanced by a factor of at least two, a factor 20 of at least two, a factor of at least five or a factor of at least ten.

In other embodiments, the carrier peptide is effective to decrease the toxicity (i.e., increase maximum tolerated dose) of the conjugate, relative to a conjugate comprising a carrier peptide lacking the terminal glycine or proline amino subunits. In certain embodiments, toxicity is decreased by a factor of at least two, a factor of at least 25 two, a factor of at least five or a factor of at least ten.

A further benefit of the peptide transport moiety is its expected ability to stabilize a duplex between an antisense oligomer and its target nucleic acid sequence. While not wishing to be bound by theory, this ability to stabilize a duplex may result from the electrostatic interaction between the positively charged transport moiety and 30 the negatively charged nucleic acid.

The length of the carrier peptide is not particularly limited and varies in different embodiments. In some embodiments, the carrier peptide comprises from 4 to

2019204913 09 Jul 2019 amino acid subunits. In other embodiments, the carrier peptide comprises from 6 to

30, from 6 to 20, from 8 to 25 or from 10 to 20 amino acid subunits. In some embodiments, the carrier peptide is straight, while in other embodiments it is branched.

In some embodiments, the carrier peptides are rich in positively charged amino acid subunits. A carrier peptide is rich in positively charged amino acids if at least 10% of the amino acid subunits are positively charged. For example, in some embodiments at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the amino acid subunits are positively charged. In even other embodiments, all the amino acid subunits, except the glycine or 10 proline amino acid subunit, are positively charged. In still other embodiment, all of the positively charged amino acid subunits are arginine.

In other embodiments, the number of positively charged amino acid subunits in the carrier peptide ranges from 1 to 20, for example from 1 to 10 or from 1 to 6. In certain embodiments, the number of positively charged amino acids in the 15 carrier peptide is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

The positively charged amino acids can be naturally occurring, nonnaturally occurring, synthetic, modified or analogues of naturally occurring amino acids. For instance, modified amino acids with a net positive charge may be specifically designed for use in the invention as described in more detail below. A 20 number of different types of modification to amino acids are well known in the art. In certain embodiments, the positively charged amino acids are histidine (H), lysine (K) or arginine (R). In other embodiments, the carrier peptide comprises only natural amino acid subunits (i.e., does not contain unnatural amino acids). In other embodiments, the terminal amino acids may be capped, for example with an acetyl, benzoyl or stearyl 25 moiety, for example on the N-terminal end.

Any number, combination and/or sequence of Η, K and/or R may be present in the carrier peptide. In some embodiments, all of the amino acid subunits, except the carboxy terminal glycine or proline, are positively charged amino acids. In other embodiments, at least one of the positively charged amino acids is arginine. For 30 example, in some embodiments, all of the positively charged amino acids are arginine, and in even other embodiments the carrier peptide consists of arginine and the carboxy terminal glycine or proline. In yet other embodiments, the carrier peptide comprises no

2019204913 09 Jul 2019 more than seven contiguous arginines, for example no more than six contiguous arginines.

Other types of positively charged amino acids are also envisioned. For example, in certain embodiments, at least one of the positively charged amino acids is 5 an arginine analog. For example, the arginine analog may be a cationic a-amino acid comprising a side chain of the structure R^aN=C(NH2)R^b, where R^a is H or R^c; R^b is R^c, NH2, NHR, or N(R^c)₂, where R^c is lower alkyl or lower alkenyl and optionally comprises oxygen or nitrogen or R^a and R^b may together form a ring; and wherein the side chain is linked to the amino acid via R^a or R^b. The carrier peptides may comprise 10 any number of these arginine analogues.

The positively charged amino acids may occur in any sequence within the carrier peptide. For example, in some embodiments the positively charged amino acids may alternate or may be sequential. For example, the carrier peptide may comprise the sequence (R^d)_m, wherein R^d is independently, at each occurrence, a 15 positively charged amino acid and m is an integer ranging from 2 to 12, from 2 to 10, from 2 to 8 or from 2 to 6. For example, in certain embodiments, R^d is arginine, and the carrier peptide comprises a sequence selected from (R)4, (R)s, (R)e, (R)7 and (R)s, or selected from (R)4, (R)s, (R)e and (R)7 for example in specific embodiments the carrier peptide comprises the sequence (R)e, for example (R)eG or (RjeP.

In other embodiments, the carrier peptide consists of the sequence (R^d)_m and the carboxy terminal glycine or proline, wherein R^d is independently, at each occurrence, a positively charged amino acid and m is an integer ranging from 2 to 12, from 2 to 10, from 2 to 8 or from 2 to 6. In certain embodiments Rd is independently, at each occurrence, arginine, histidine or lysine. For example, in certain embodiments, 25 R^d is arginine, and the carrier peptide consists of a sequence selected from (R)4, (R)s, (R)e, (R)7 and (R)s and the carboxy terminal glycine or proline. For example in specific embodiments the carrier peptide consists of the sequence (R)eG or (RjeP.

In some other embodiments, the (R^d)_m sequence may be interrupted by one or more amino acid subunits, for example a hydrophobic amino comprising a 30 substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or aralkyl side chain wherein the alkyl, alkenyl and alkynyl side chain includes at most one heteroatom for every six carbon atoms acid. In some embodiments, the hydrophobic amino acid is phenylalanine

2019204913 09 Jul 2019 (F) or alanine (A). For example, the (R^d)_m sequence may be interrupted by two or more contingous hydrophobic amino acid such as phenylalanine (F) or alanine (A), for example two contiguous phenylalanine or alanine moieties. The hydrophobic amino acid(s) may be at any point in the (R^d)_m sequence. In some other embodiments, the (R^d) m sequence may be interrupted by one or more glycine amino acid subunits, which may occur at any point in the (R^d)_m sequence.

In other embodiments, the carrier peptide comprises the sequence [(R^dY^bR^d)x(R^dR^dY^b)y]_z, or [(R^dR^dY^b)y(R^dY^bR^d)x]_z wherein R^d is independently, at each occurrence, a positively charged amino acid, x and y are independently, at each 10 occurrence, 0 or 1, provided that x + y is 1 or 2, z is 1, 2, 3, 4, 5 or 6 and Y^b is

-C(O)-(CHR^e)_n-NH(Y^b) wherein n is 2 to 7 and each R^e is independently, at each occurrence, hydrogen or methyl. In some of these embodiments, R^d is independently, at each occurrence 15 arginine, histidine or lysine. In other embodiments, each R^d is arginine. In other embodiments, n is 5 and Y^b is an aminohexanoic acid moiety. In other embodiments, n is 2 and Y^b is a β-alanine moiety. In yet other embodiments, R^e is hydrogen.

In certain embodiments of the foregoing, x is 1 and y is 0, and the carrier peptide comprises the sequence (R^dY^bR^d)_z. In other embodiments, n is 5 and Y^b is an 20 aminohexanoic acid moiety. In other embodiments, n is 2 and Y^b is a β-alanine moiety.

In yet other embodiments, R^e is hydrogen.

In still other embodiments of the foregoing, x is 0 and y is 1, and the carrier peptide comprises the sequence (R^dR^dY^b)_z. In other embodiments, n is 5 and Y^b is an aminohexanoic acid moiety. In other embodiments, n is 2 and Y^b is a β-alanine 25 moiety. In yet other embodiments, R^e is hydrogen.

In other embodiments, the carrier peptide comprises the sequence (R^dY^b)_p, wherein R^d and Y^b are as defined above and p is an integer ranging from 2 to 8. In other embodiments, each R^d is arginine. In other embodiments, n is 5 and Y^b is an aminohexanoic acid moiety. In other embodiments, n is 2 and Y^b is a β-alanine moiety.

In yet other embodiments, R^e is hydrogen.

2019204913 09 Jul 2019

In other embodiments, the carrier peptide comprises the sequence ILFQY. The peptides may comprise the ILFQY sequence in addition to any of the other sequences disclosed herein. For example the carrier peptide may comprise ILFQY and [(R^dY^bR^d)x(R^dR^dY^b)y]_z, [(R^dR^dY^b)y(R^dY^bR^d)x]_z, (R^dY^b)_P or combinations 5 thereof wherein R^d, x, y and Y^b are as defined above. The [(R^dY^bR^d)x(R^dR^dY^b)y]_z, [(R^dR^dY^b)y(R^dY^bR^d)x]_z or (R^dY^b)_p sequence may be on the amino terminus, carboxy terminus or both of the ILFQY sequence. In certain embodiments, x is 1 and y is 0 and the carrier peptide comprises (R^dY^bR^d)_z linked to the ILFQY sequence via an optional Z linker.

In other related embodiments, the carrier peptide comprises the sequence

ILFQ, IWFQ or ILIQ. Other embodiments include carrier peptides which comprise the sequence PPMWS, PPMWT, PPMFS or PPMYS. The carrier peptide may comprise these sequences in addition to any of the other sequences described herein, for example in addition to the sequences [(R^dY^bR^d)x(R^dR^dY^b)y]_z, [(R^dR^dY^b)y(R^dY^bR^d)x]_z or (R^dY^b)_p 15 wherein R^d, x, y and Y^b are as defined above.

In still other embodiments, the carrier peptide comprises at least one hydrophobic amino acid, the hydrophobic amino acid comprising a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or aralkyl side chain wherein the alkyl, alkenyl and alkynyl side chain includes at most one heteroatom for every six carbon 20 atoms. In some embodiments, at least one of the hydrophobic amino acids is phenylalanine (F) or alanine (A), while in other embodiments each of the hydrophobic amino acids is phenylalanine, or in other embodiments each of the hydrophobic amino acids is alanine. The carrier peptide may comprise two or more hydrophobic amino acids, for example two contiguous hydrophobic amino acids, wherein the contiguous 25 hydrophobic amino acids are phenylalanine or alanine. In other embodiments, the carrier peptide comprises two ot more contiguous glycine subunits or two or more contiguous alanine subunits.

Some embodiments of the carrier peptide include modifications to naturally occurring amino acid subunits, for example the amino terminal or carboxy 30 terminal amino acid subunit may be modified. Such modifications include capping the free amino or free carboxy with a hydrophobic group. For example, the amino terminus may be capped with an acetyl, benzoyl or stearoyl moiety. For example, any of the pepetide sequences in Table 1 may have such modifications even if not specifically depticted in the table. In these embodiments, the amino terminus of the carrier peptide

2019204913 09 Jul 2019 can be depicted as follows:

In yet other embodiments, the carrier peptide comprises at least one of alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine or threonine.

In some of the embodiments disclosed herein, the carrier peptide consists of the noted sequences and the carboxy terminal glycine or proline amino acid subunit.

In some embodiments the carrier peptide does not consist of the following sequences (amino terminal to carboxy terminal): ReG, R7G, RsG, R5GR4G, R5F2R4G, Tat-G, rTat-G, (RXR2G2)2 or (RXRsX)2G. In yet other embodiments, the carrier peptide does not consist of RsG, R9G or R9F2G. In still other embodiments, the carrier peptide does not consist of the following sequences: Tat-G, rTat-G, R9F2G,

R5F2R4, R4G, R₅G, R₆G, R?G, RsG, R9G, (RXR)₄G, (RXR)sG, (RXRRBR)₂G, (RAR)₄F₂ or (RGR)₄F₂. In other embodiments, the carrier peptide does not consist of “Penetratin’’ or “RePen”.

In another aspect, the present disclosure provides a peptide-nucleic acid analog conjugate, comprising a nucleic acid analog having a substantially uncharged backbone and a targeting base sequence, and covalently linked to the nucleic acid analog, a peptide comprising a carboxy terminal glycine or proiline amino acid subunit and consisting of 8 to 16 other subunits selected from R^d subunits, Y subunits, and optional Z subunits, including 25 at least eight R^d subunits, at least two Y subunits, and at most three Z subunits, where >50% of said subunits are R^d subunits, and where (a) each R^d subunit independently represents arginine or an arginine analog, the arginine analog being a cationic a-amino acid comprising a side chain of the structure R^aN=C(NH2)R^b, where R^a is H or R^c; R^b is R^c, NH2, NHR, or

2019204913 09 Jul 2019

N(R^c)₂, where R^c is lower alkyl or lower alkenyl and optionally comprises oxygen or nitrogen or R^a and R^b may together form a ring; and wherein the side chain is linked to the amino acid via R^a or R^b;

(b) the at least two Y subunits are Y^a or Y^b, wherein:

(i) each Y^a is independently a neutral a-amino acid subunits having side chains independently selected from substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, and aralkyl, wherein said side chain, when selected from substituted alkyl, alkenyl, and alkynyl, includes at most one heteroatom for every two, preferably every four, and more preferably every six carbon atoms, and wherein said 10 subunits are contiguous or are flanking a linker moiety, and (ii) Y^b is:

-C(O)-(CHR^e)_n-NH(Y^b) wherein n is 2 to 7 and each R^e is independently, at each occurrence, 15 hydro gen or methyl.; and (c) Z represents an amino acid subunit selected from alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine, threonine and amino acids having side chains which are one- or two-carbon homologs of naturally occurring side chains, excluding side chains which are negatively charged at physiological pH (e.g. carboxylate side chains). In some embodiments, the side chains are neutral. In other embodiments, the Z side chains are side chains of naturally occurring amino acids. The optional Z subunits in some embodiments are selected from alanine, glycine, methionine, serine, and threonine. The carrier peptide may include zero, one, two, or three Z subunits, and in some embodiments includes at most two Z 25 subunits.

In selected embodiments, the carrier peptide has exactly two Y subunits of type Y^a, which are contiguous or are flanking a cysteine subunit. In some embodiments, the two Y^a subunits are contiguous. In other embodiments, side chains for Y^a subunits include side chains of naturally occurring amino acids and one- or two30 carbon homologs thereof, excluding side chains which are charged at physiological pH.

Other possible side chains are side chains of naturally occurring amino acids. In further

2019204913 09 Jul 2019 embodiments, the side chain is an aryl or aralkyl side chain; for example, each Y^a may be independently selected from phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine.

In selected embodiments, each Y^a is independently selected from phenylalanine and tyrosine; in further embodiments, each Y^a is phenylalanine. This includes, for example, conjugates which consist of arginine subunits, phenylalanine subunits, the glycine or proline amino acid subunit, an optional linker moiety, and the nucleic acid analog. One such conjugate includes a peptide having the formula Arg9Phe2aa, where aa is glycine or proline.

The foregoing carrier peptides may also comprise ILFQY, ILFQ, IWFQ or ILIQ. Other embodiments include the foregoing carrier peptides which comprise the sequence PPMWS, PPMWT, PPMFS or PPMYS.

The pep tide-oligomer conjugates of the invention are more effective than the unconjugated oligomer in various functions, including: inhibiting expression of 15 targeted mRNA in a protein expression system, including cell free translation systems; inhibiting splicing of targeted pre-mRNA; and inhibiting replication of a virus, by targeting cis-acting elements which control nucleic acid replication or mRNA transcription of the virus.

Also included within the scope of the present invention are conjugates of 20 other pharmacological agents (i.e., not a nucleic acid analog) and the carrier peptide. Specifically, some embodiments provide a conjugate comprising:

(a) a carrier peptide comprising amino acid subunits; and (b) a pharmacological agent;

wherein:

two or more of the amino acid subunits are positively charged amino acids, the carrier peptide comprises a glycine (G) or proline (P) amino acid subunit at a carboxy terminus of the carrier peptide and the carrier peptide is covalently attached to the pharmacological agent. The carrier peptide in these embodiments may be any of the carrier peptides described herein. Methods for delivering the pharmacological agent by 30 conjugating it to the carrier peptide are also provided.

The pharmacological agent to be delivered is may be a biologically active agent, e.g. a therapeutic or diagnostic agent, although it may be a compound

2019204913 09 Jul 2019 employed for detection, such as a fluorescent compound. Biologically active agents include drug substances selected from biomolecules, e.g. peptides, proteins, saccharides, or nucleic acids, particularly antisense oligonucleotides, or small molecule organic or inorganic compounds. A small molecule compound may be 5 defined broadly as an organic, inorganic, or organometallic compound which is not a biomolecule as described above. Typically, such compounds have molecular weights of less than 1000, or, in one embodiment, less than 500.

In one embodiment, the pharmacological agent to be delivered does not include single amino acids, dipeptides, or tripeptides. In another embodiment, it does 10 not include short oligopeptides; that is, oligopeptides having fewer than six amino acid subunits. In a further embodiment, it does not include longer oligopeptides; that is, oligopeptides having between seven and 20 amino acid subunits. In a still further embodiment, it does not include polypeptides, having greater than 20 amino acid subunits, or proteins.

The carrier peptide is effective to enhance the transport of the pharmacological agent into a cell relative to the pharmacological agent in unconjugated form and/or with less toxicity, relative to the pharmacological agent conjugated to a corresponding peptide lacking the glycing or proline subunits. In some embodiments, transport is enhanced by a factor of at least two, at least five or at least ten. In other 20 embodiments, toxicity is decreased (i.e., maximum tolerated dose increased) by a factor of at least two, at least five or at least ten.

B. Peptide Linkers

The carrier peptide can be linked to the agent to be delivered (e.g., nuceleic acid analogue, pharmacological agent, etc.) by a variety of methods available 25 to one of skill in the art. In some embodiments, the carrier peptide is linked to the nucleic acid analogue directly without an intervening linker. In this regard, formation of an amide bond between the terminal amino acid and a free amine of free carboxyl on the nucleic acid analogue may be useful for forming the conjugate. In certain embodiments, the carboxy terminal glycine or proline subunit is linked directly to the 3’ 30 end of the nucleic acid analogue, for example the carrier peptide may be linked by

2019204913 09 Jul 2019 forming an amide bond between the carboxy terminal glycine or proline moiety and the

3’ morpholino ring nitrogen (see e.g., Figure IC).

In some embodiments, the nucleic acid analog is conjugated to the carrier peptide via a linker moiety selected from a Y^a or Y^b subunit, a cysteine subunit, 5 and an uncharged, non-amino acid linker moiety. In other embodiments, the nucleic acid analogue is linked to the carrier peptide directly via the glycine or proline moiety at either the 5’ or 3’ end of the nucleic acid analogue. In some embodiments, the carrier peptide is linked directly via the glycine or proline amino acid subunit to the 3’ of the nucleic acid analogue, for example directly linked to the 3 ’ morpholino nitrogen via an 10 amide bond.

In other embodiments, the conjugates comprise a linking moiety between the terminal glycine or proline amino acid subunit. In some of the embodiments, the linker is up to 18 atoms in length comprising bonds selected from alkyl, hydroxyl, alkoxy, alkylamino, amide, ester, carbonyl, carbamate, phosphorodiamidate, 15 phosphoroamidate, phosphorothioate and phosphodiester. In certain embodiments, the linker comprises phosphorodiamidate and piperazine bonds. For example, in some embodiments the linker has the following structure (XXIX):

N—P=O

WWW (XXIX) wherein R²⁴ is absent, H or Ci-Ce alkyl. In certain embodiments, R24 is absent and in other embodiments structure (XXIX) links the 5’ end of a nucleic acid analogue (e.g., a morpholino oligomer) to the carrier peptide (see e.g., Figure IB).

In some embodiments, the side chain moieties of the R^d subunits are independently selected from guanidyl (HN=C(NH2)NH-), amidinyl (HN=C(NH2)C<),

2019204913 09 Jul 2019

2-aminodihydropyrimidyl, 2-aminotetrahydropyrimidyl, 2-aminopyridinyl and 2-amino pyrimidinyl.

Multiple carrier peptides can be attached to a single compound if desired; alternatively, multiple compounds can be conjugated to a single transporter.

The linker between the carrier peptide and the nucleic acid analogue may also consist of natural or non-natural amino acids (e.g., 6-aminohexanoic acid or β-alanine). The linker may also comprise a direct bond between the carboxy terminus of a transporter peptide and an amine or hydroxy group of the nucleic acid analogue (e.g., at the 3’ morpholino nitrogen or 5’ OH), formed by condensation promoted by e.g.

carbodiimide.

In general, the linker may comprise any nonreactive moiety which does not interfere with transport or function of the conjugate. Linkers can be selected from those which are non-cleavable under normal conditions of use, e.g., containing an ether, thioether, amide, or carbamate bond. In other embodiments, it may be desirable to 15 include a linkage between the carrier peptide and compound (e.g., oligonucleotide analogue, pharmacological agent, etc.) which is cleavable in vivo. Bonds which are cleavable in vivo are known in the art and include, for example, carboxylic acid esters, which are hydrolyzed enzymatically, and disulfides, which are cleaved in the presence of glutathione. It may also be feasible to cleave a photolytically cleavable linkage, such 20 as an ortho-nitrophenyl ether, in vivo by application of radiation of the appropriate wavelength. Exemplary heterobifunctional linking agents which further contain a cleavable disulfide group include N-hydroxysuccinimidyl 3-[(4azidophenyl)dithio]propionate and others described in Vanin, E.F. and Ji, T.H., Biochemistry 20:6754-6760 (1981).'

C. Exemplary Carrier Peptides

A Table of sequences of exemplary carrier peptides and oligonucleotide sequences is provided below in Table 1. In some embodiments, the present disclosure provides a peptide oligomer conjugate, wherein the peptide comprises or consists of any one of the peptide sequences in Table 1. I nother embodiments, the the nucleic acid 30 analogue comprises or consists of any of the oligonucleotide sequences in Table 1. In still other embodiments, the present disclosure provides a peptide oligomer conjugate,

2019204913 09 Jul 2019 wherein the peptide comprises or consists of any one of the peptide sequences in Table

1, and the nucleic acid analogue comprises or consists of any of the oligonucleotide sequences in Table 1. In other embodiments, the disclosure provides a peptide comprising or consisting of any one of the sequences in Table 1.

Table 1. Exemplary Carrier Peptides and Oligonucleotide Sequences

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
(RFF)3; CP0407	RFFRFFRFF-aa	89
RTR	RTRTRFLRRT-aa	90
RFFR	RFFRFFRFFR-aa	91
KTR	KTRTKFLKKT-aa	92
KFF	KFFKFFKFF-aa	93
KFFK	KFFKFFKFFK-aa	94
(RFF)2	RFFRFF-aa	95
(RFF)2R	RFFRFFR-aa	96
RX	RXXRXXR-aa	97
(RXR)4; P007	RXRRXRRXRRXR-aa	98
Tat47-58	YGRKKRRQRRR-aa	99
Tat48-58	GRKKRRQRRR-aa	100
Tat49-58	RKKRRQRRR-aa	101
Penetratin	RQIKIWFQNRRMKWKKGG-aa	102
Transportan	GWTLNSAGYLLGKINLKALAALAKKIL-aa	103
2XHph-l	YARVRRRGPRGYARVRRRGPRR-aa	104
Hph-1	YARVRRRGPRR-aa	105
Sim-2	AKAARQAAR-aa	106
HSV1 VP22	DAATATRGRSAASRPTERPRAPARSASRPR RPVE-aa	107
Pep-1	KETWWETWWTEWSQPKKKRKV-aa	108
Pep-2	KETWFETWFTEWSQPKKKRKV-aa	109
ANTP	RQIKIWFQNRRMKWKK-aa	110
RePen	RRRRRR-RQIKIWFQNRRMKWKKGG-aa	111
rTat	RRRQRRKKRC-aa	112
pTat	C YGRKKRRQRRR-aa	113
R9F2	RRRRRRRRRFFC-aa	114
R9CF2 RRRRRRRRRCFF	RRRRRRRRRCFF-aa	115

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
r8cf2r	RRRRRRRRCFFR-aa	116
r6cf2r3	RRRRRRCFFRRR-aa	117
R5FCFR4	RRRRRFCFRRRR-aa	118
R5F2R4	RRRRRFFRRRR-aa	119
R4CF2R5	RRRRCFFRRRRR-aa	120
R2CF2R7	RRCFFRRRRRRR-aa	121
CF2R9	CFFRRRRRRRRR-aa	122
CR9F2	CRRRRRRRRRFF-aa	123
F2R9	FFRRRRRRRRR-aa	124
R5F2CF2R4	RRRRRFFCFFRRRR-aa	125
R9I2	RRRRRRRRRII-aa	126
R8F3	RRRRRRRRFFF-aa	127
R9F4	RRRRRRRRRFFFF-aa	128
R8F2	RRRRRRRRFF-aa	129
r6f2	RRRRRRFF-aa	130
R5F2	RRRRRFF-aa	131
(RRX)sRR	RRXRRXRRXRR-aa	132
(RXR)4	RXRRXRRXRRXR-aa	133
(XRR)4	XRRXRRXRRXRR-aa	134
(RX)sRR	RXRXRXRXRXR-aa	135
(RXR)3	RXRRXRRXR-aa	136
(RXR)2R	RXRRXRR-aa	137
(RXR)2	RXRRXR-aa	138
(RKX)3RK	RKXRKXRKXRK-aa	139
(RHX)3RH	RHXRHXRHXRH-aa	140
r8cf2r	RRRRRRRRCFFR-aa	141
(RRX)3RR	RRXRRXRRXRR-aa	142
(RXR)4; P007	RXRRXRRXRRXR-aa	143
(XRR)4	XRRXRRXRRXRR-aa	144
(RX)sR	RXRXRXRXRXR-aa	145
(RX)vR	RXRXRXRXRXRXR-aa	146
(RXR)s	RXRRXRRXRRXRRXR-aa	147
(RXRRBR)2; B	RXRRBRRXRRBR-aa	148
(RXR)3RBR	RXRRXRRXRRBR-aa	149
(RB)sRXRBR	RBRBRBRBRBRXRBR-aa	150
RBRBRBRXRBRBRB	RBRBRBRXRBRBRBR-aa	151

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
R
X(RB)3RX(RB)3R-X	XRBRBRBRXRBRBRBR-aa	152
(RBRX)4	RBRXRBRXRBRXRBR-aa	153
(RB)4(RX)3R	RBRBRBRBRXRXRXR-aa	154
RX(RB)2RX(RB)3R	RXRBRBRXRBRBRBR-aa	155
(RB)7R	RBRBRBRBRBRBRBR-aa	156
r4	tg-RRRR-aa	157
Rs	tg-RRRRR-aa	158
Re	tg-RRRRRR-aa	159
R?	tg-RRRRRRR-aa	160
Rs	tg-RRRRRRRR-aa	161
RsGR4	tg-RRRRRGRRRR-aa	162
RsF2R4	tg-RRRRRFFRRRR-aa	163
Tat	tg-RKKRRQRRR-aa	164
rTat	tg-RRRQRRKKR-aa	165
(RXR2G2)2	tg-RXRRGGRXRRG-aa	166
(RXR3X)2	tg-RXRRRXRXRRR-aa	167
r4a2r2	tg-RRRRAARR-aa	168
r4ar2	tg-RRRRARR-aa	169
r3ar2	tg-RRRARR-aa	170
r4g2r2	tg-RRRRGGRR-aa	171
r4gr2	tg-RRRRGRR-aa	172
r3gr2	tg-RRRGRR-aa	173
r4k2r2	tg-RRRRKKRR-aa	174
r4kr2	tg-RRRRKRR-aa	175
r3kr2	tg-RRRKRR-aa	176
	RXRRXR-aa	177
	RBRRBR-aa	178
	RXRRBR-aa	179
	RBRRXR-aa	180
	RXRYbRXR-aa	181
	RBRYbRBR-aa	182
	RXRYbRBR-aa	183
	RBRYbRXR-aa	184
	RXRILFQYRXR-aa	185
	RBRILFQYRBR-aa	186

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRILFQYRBR-aa	187
	RBRIEFQYRXR-aa	188
	RXRRXRRXR-aa	189
	RBRRBRRBR-aa	190
	RXRRBRRXR-aa	191
	RXRRBRRBR-aa	192
	RXRRXRRBR-aa	193
	RBRRXRRBR-aa	194
	RBRRXRRXR-aa	195
	RBRRBRRXR-aa	196
	RXRYbRXRRXR-aa	197
	RXRRXRYbRXR-aa	198
	RXRIEFQYRXRRXR-aa	199
	RXRRXRIEFQYRXR-aa	200
	RXRYbRXRYbRXR-aa	201
	RXRIEFQYRXRIEFQYRXR-aa	202
	RXRIEFQYRXRYbRXR-aa	203
	RXRYbRXRIEFQYRXR-aa	204
	RBRYbRBRRBR-aa	205
	RBRRBRYbRBR-aa	206
	RBRIEFQYRBRRBR-aa	207
	RBRRBRIEFQYRBR-aa	208
	RBRYRBRYbRBR-aa	209
	RBRIEFQYRBRIEFQYRBR-aa	210
	RBRYbRBRIEFQYRBR-aa	211
	RBRIEFQYRBRYbRBR-aa	212
	RXRYbRBRRXR-aa	213
	RXRRBRYbRXR-aa	214
	RXRIEFQYRBRRXR-aa	215
	RXRRBRIEFQYRXR-aa	216
	RXRYbRBRYbRXR-aa	217
	RXRIEFQYRBRIEFQYRXR-aa	218
	RXRYbRBRIEFQYRXR-aa	219
	RXRIEFQYRBRYbRXR-aa	220
	RXRYbRBRRBR-aa	221
	RXRRBRYbRBR-aa	222

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRILFQYRBRRBR-aa	223
	RXRRBRILFQYRBR-aa	224
	RXRYbRBRYbRBR-aa	225
	RXRILFQYRBRILFQYRBR-aa	226
	RXRYbRBRILFQYRBR-aa	227
	RXRILFQYRBRYbRBR-aa	228
	RXRYbRXRRBR-aa	229
	RXRRXRYbRBR-aa	230
	RXRILFQYRXRRBR-aa	231
	RXRRXRILFQYRBR-aa	232
	RXRYbRXRYbRBR-aa	233
	RXRILFQYRXRILFQYRBR-aa	234
	RXRYbRXRILFQYRBR-aa	235
	RXRILFQYRXRYbRBR-aa	236
	RBRYbRXRRBR-aa	237
	RBRRXRYbRBR-aa	238
	RBRILFQYRXRRBR-aa	239
	RBRRXRILFQYRBR-aa	240
	RBRYbRXRYbRBR-aa	241
	RBRILFQYRXRILFQYRBR-aa	242
	RBRYbRXRILFQYRBR-aa	243
	RBRILFQYRXRYbRBR-aa	244
	RBRYbRXRRXR-aa	245
	RBRRXRYbRXR-aa	246
	RBRILFQYRXRRXR-aa	247
	RBRRXRILFQYRXR-aa	248
	RBRYbRXRYbRXR-aa	249
	RBRILFQYRXRILFQYRXR-aa	250
	RBRYbRXRILFQYRXR-aa	251
	RBRILFQYRXRYbRXR-aa	252
	RBRYbRBRRXR-aa	253
	RBRRBRYbRXR-aa	254
	RBRILFQYRBRRXR-aa	255
	RBRRBRILFQYRXR-aa	256
	RBRYbRBRYbRXR-aa	257
	RBRILFQYRBRILFQYRXR-aa	258

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RBRYbRBRILFQYRXR-aa	259
	RBRILFQYRBRYbRXR-aa	260
	RXRRXRRXRRXR-aa	261
	RXRRBRRXRILFQYRXRBRXR-aa	262
	RXRRBRRXRRBR-aa	263
	YGRKKRRQRRRP-aa	264
	RXRRXRRXRRXRXBASSLNIAXC-aa	265
	RXRRBRRXRILFQYRXRBRXRBASSLNIAX C-aa	266
	RXRRBRRXRASSLNIARXRBRXRBC-aa	267
	RXRRBRRXRRBRXBASSLNIA-aa	268
	THRPPMWSPVWP-aa	269
	HRPPMWSPVWP-aa	270
	THRPPMWSPV-aa	271
	THRPPMWSP-aa	272
	THRPPMWSPVFP-aa	273
	THRPPMWSPVYP-aa	274
	THRPPMWSPAWP-aa	275
	THRPPMWSPLWP-aa	276
	THRPPMWSPIWP-aa	277
	THRPPMWTPVVWP-aa	278
	THRPPMFSPVWP-aa	279
	THRPPMWS-aa	280
	HRPPMWSPVW-aa	281
	THRPPMYSPVWP-aa	282
	THRPPnleWSPVWP-aa (nle = norleucine)	283
	THKPPMWSPVWP-aa	284
	SHRPPMWSPVWP-aa	285
	STFTHPR-aa	286
	YDIDNRR-aa	287
	AYKPVGR-aa	288
	HAIYPRH-aa	289
	HTPNSTH-aa	290
	ASSPVHR-aa	291
	SSLPLRK-aa	292
	KKRS-aa	293

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	KRSK-aa	294
	KKRSK-aa	295
	KSRK-aa	296
	SRKR-aa	297
	RKRK-aa	298
	KSRKR-aa	299
	QHPPWRV-aa	300
	THPPTTH-aa	301
	YKHTPTT-aa	302
	QGMHRGT-aa	303
	SRKRK-aa	304
	KS RKRK-aa	305
	PKKKRKV-aa	306
	GKKRSKV-aa	307
	KSRKRKL-aa	308
	HSPSKIP-aa	309
	HMATFHY-aa	310
	AQPNKFK-aa	311
	NLTRLHT-aa	312
	KKKR-aa	313
	KKRK-aa	314
	KKKRK-aa	315
	RRRRRRQIKIWFQNRRMKWKKGGC-aa	316
	RRRRRRRQIKIWFQNRRMKWKKGGC-aa	317
	RQIKIWFQNRRMKWKKGGC-aa	318
	RRRRRRRQIKIWFQNRRMKWKKC-aa	319
	RXRRXRRXRRQIKIWFQNRRMKWKKGGC- aa	320
	RRRRRRRQIKILFQNRXRXRXRXC-aa	321
	RXRRXRRXRRXRC-aa	322
	RXRRXRRXRRXRXC-aa	323
	RXRRXRRXRIKILFQNRRMKWKKGGC-aa	324
	RXRRXRRXRIKILFQNRRMKWKKC-aa	325
	RXRRXRRXRIKILFQNRMKWKKC-aa	326
	RXRRXRRXRIKILFQNXRMKWKKC-aa	327
	RXRRXRRXRIKILFQNHRMKWKKC-aa	328

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRRXRRXRIKILFQNXRMKWKKC-aa	329
	RXRRXRRXRIKILFQNXRMKWKKC-aa	330
	RXRRXRRXRIKILFQNXRMKWKAC-aa	331
	RXRRXRRXRIKILFQNXRMKWHKAC-aa	332
	RXRRXRRXRIKILFQNXRMKWHRC-aa	333
	RXRXRXRXRIKILFQNRRMKWKKC-aa	334
	RARARARARIKILFQNRRMKWKKC-aa	335
	RXRRXRRXRIXILFQNXRMKWHKAC-aa	336
	RXRRXRRXRIHILFQNXRMKWHKAC-aa	337
	RXRRXRRXRIRILFQNXRMKWHKAC-aa	338
	RXRRXRRXRIXILFQYXRMKWHKAC-aa	339
	RXRRXRRXRLYSPLSFQXRMKWHKAC-aa	340
	RXRRXRRXRISILFQYXRMKWHKAC-aa	341
	RXRRXRRXRILFQYXRMKWHKAC-aa	342
	RXRRXRIXILFQYXRMKWHKAC-aa	343
	RXRRARRXRIHILFQYXRMKWHKAC-aa	344
	RARRXRRARIHILFQYXRMKWHKAC-aa	345
	RXRRXRRXRIHILFQYXRMKWHKAC-aa	346
	RXRRXRRXRIXILFQNXRMKWHKAC-aa	347
	RXRRXRRXRIHILFQNXRMKWHKAC-aa	348
	RXRRXRRXRIKILFQNRRMKWHK-aa	349
	RXRRXRRXRIKILFQNXRMKWHK-aa	350
	RXRRXRRXRIXILFQNRRMKWHK-aa	351
	RXRRXRRXRIXILFQNXRMKWHK-aa	352
	RXRRXRRXRIHILFQNRRMKWHK-aa	353
	RXRRXRRXRIHILFQNXRMKWHK-aa	354
	RXRRXRRXRIRILFQNRRMKWHK-aa	355
	RXRRXRRXRIRILFQNXRMKWHK-aa	356
	RXRRXRRXRIILFQNRRMKWHK-aa	357
	RXRRXRRXRIILFQNXRMKWHK-aa	358
	RXRRXRRXRKILFQNRRMKWHK-aa	359
	RXRRXRRXRKILFQNXRMKWHK-aa	360
	RXRRXRRXRXILFQNRRMKWHK-aa	361
	RXRRXRRXRXILFQNXRMKWHK-aa	362
	RXRRXRRXRHILFQNRRMKWHK-aa	363
	RXRRXRRXRHILFQNXRMKWHK-aa	364

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRRXRRXRRILFQNRRMKWHK-aa	365
	RXRRXRRXRRILFQNXRMKWHK-aa	366
	RXRRXRRXRILFQNRRMKWHK-aa	367
	RXRRXRRXRILFQNXRMKWHK-aa	368
	RXRRXRRXRIKILFQYRRMKWHK-aa	369
	RXRRXRRXRIKILFQYXRMKWHK-aa	370
	RXRRXRRXRIXILFQYRRMKWHK-aa	371
	RXRRXRRXRIXILFQYXRMKWHK-aa	372
	RXRRXRRXRIHILFQYRRMKWHK-aa	373
	RXRRXRRXRIHILFQYXRMKWHK-aa	374
	RXRRXRRXRIRILFQYRRMKWHK-aa	375
	RXRRXRRXRIRILFQYXRMKWHK-aa	376
	RXRRXRRXRIILFQYRRMKWHK-aa	377
	RXRRXRRXRIILFQYXRMKWHK-aa	378
	RXRRXRRXRKILFQYRRMKWHK-aa	379
	RXRRXRRXRKILFQYXRMKWHK-aa	380
	RXRRXRRXRXILFQYRRMKWHK-aa	381
	RXRRXRRXRXILFQYXRMKWHK-aa	382
	RXRRXRRXRHILFQYRRMKWHK-aa	383
	RXRRXRRXRHILFQYXRMKWHK-aa	384
	RXRRXRRXRRILFQYRRMKWHK-aa	385
	RXRRXRRXRRILFQYXRMKWHK-aa	386
	RXRRXRRXRILFQYRRMKWHK-aa	387
	RXRRXRRXRILFQYXRMKWHK-aa	388
	RXRRXRRXR-aa	389
	RXRRXRRXRRXR-aa	390
	RARRAR-aa	391
	RARRARRAR-aa	392
	RARRARRARRAR-aa	393
	RXRRXRI-aa	394
	RXRRARRXR-aa	395
	RARRXRRAR-aa	396
	RRRRR-aa	397
	RRRRRR-aa	398
	RRRRRRR-aa	399
	RXRRXRRXRRXRC-aa	400

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRRXRRXRRXRXC-aa	401
	RXRRXRRXRIKILFQNRRMKWKKGGC-aa	402
	RXRRXRRXRIKILFQNRRMKWKKC-aa	403
	RXRRXRRXRIKILFQNRMKWKKC-aa	404
	RXRRXRRXRIKILFQNXRMKWKKC-aa	405
	RXRRXRRXRIKILFQNHRMKWKKC-aa	406
	RXRRXRRXRIKILFQNXRMKWKKC-aa	407
	RXRRXRRXRIKILFQNXRMKWKKC-aa	408
	RXRRXRRXRIKILFQNXRMKWKAC-aa	409
	RXRRXRRXRIKILFQNXRMKWHKAC-aa	410
	RXRRXRRXRIKILFQNXRMKWHRC-aa	411
	RXRXRXRXRIKILFQNRRMKWKKC-aa	412
	RARARARARIKILFQNRRMKWKKC-aa	413
	RXRRXRRXRIXILFQNXRMKWHKAC-aa	414
	RXRRXRRXRIHILFQNXRMKWHKAC-aa	415
	RXRRXRRXRIRILFQNXRMKWHKAC-aa	416
	RXRRXRRXRIXILFQYXRMKWHKAC-aa	417
	RXRRXRRXRLYSPLSFQXRMKWHKAC-aa	418
	RRMKWHK-aa	419
	XRMKWHK-aa	420
	XXXXXXXXXXXXXXILFQXXRMKWHK-aa	421
	XXXXXXXXXXXXXXILFQXXRMKWHK-aa	422
	RRRRRRRQIKILFQNPKKKRKVGGC-aa	423
	HHFFRRRRRRRRRFFC-aa	424
	HHHHHHRRRRRRRRRFFC-aa	425
	HHHHHHFFRRRRRRRRRFFC-aa	426
	HHHHHXXRRRRRRRRRFFC-aa	427
	HHHHHHXXFFRRRRRRRRRFFC-aa	428
	HHHXRRRRRRRRRFFXHHHC-aa	429
	XRMKWHK-aa	430
	XRWKWHK-aa	431
	RXRARXR-aa	432
	RXRXRXR-aa	433
	RARXRAR-aa	434
	RXRAR-aa	435
	XXXXXXXXXXXXXXILFQXXHMKWHK-aa	436

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	XXXXXXXXXXXXXXILFQXXRWKWHK-aa	437
	XXXXXXXXXXXXXXILFQXXHWKWHK- aa	438
	XXXXXXXXXXXXXXILFQXRXRARXR-aa	439
	XXXXXXXXXXXXXXILFQXRXRXRXR-aa	440
	XXXXXXXXXXXXXXILFQXRXRRXR-aa	441
	XXXXXXXXXXXXXXILFQXRARXRAR-aa	442
	XXXXXXXXXXXXXXILFQXRXRARXR-aa	443
	XXXXXXXXXXXXXXILFQXRXRAR-aa	444
	XXXXXXXXXXXXXXILIQXXRMKWHK-aa	445
	XXXXXXXXXXXXXXILIQXXHMKWHK-aa	446
	XXXXXXXXXXXXXXILIQXXRWKWHK-aa	447
	XXXXXXXXXXXXXXILIQXXHWKWHK-aa	448
	XXXXXXXXXXXXXXILIQXRXRARXR-aa	449
	XXXXXXXXXXXXXXILIQXRXRXRXR-aa	450
	XXXXXXXXXXXXXXILIQXRXRRXR-aa	451
	XXXXXXXXXXXXXXILIQXRARXRAR-aa	452
	XXXXXXXXXXXXXXILIQXRXRARXR-aa	453
	XXXXXXXXXXXXXXILIQXRXRAR-aa	454
	XXXXXXXXXXXXXXILFQXXHMKWHK-aa	455
	XXXXXXXXXXXXXXILFQXXRWKWHK-aa	456
	XXXXXXXXXXXXXXILFQXXHWKWHK- aa	457
	XXXXXXXXXXXXXXILFQXRXRARXR-aa	458
	XXXXXXXXXXXXXXILFQXRXRXRXR-aa	459
	XXXXXXXXXXXXXXILFQXRXRRXR-aa	460
	XXXXXXXXXXXXXXILFQXRARXRAR-aa	461
	XXXXXXXXXXXXXXILFQXRXRARXR-aa	462
	XXXXXXXXXXXXXXILFQXRXRAR-aa	463
	XXXXXXXXXXXXXXILIQXXRMKWHK-aa	464
	XXXXXXXXXXXXXXILIQXXHMKWHK-aa	465
	XXXXXXXXXXXXXXILIQXXRWKWHK-aa	466
	XXXXXXXXXXXXXXILIQXXHWKWHK-aa	467
	XXXXXXXXXXXXXXILIQXRXRARXR-aa	468
	XXXXXXXXXXXXXXILIQXRXRXRXR-aa	469
	XXXXXXXXXXXXXXILIQXRXRRXR-aa	470

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	XXXXXXXXXXXXXXILIQXRARXRAR-aa	471
	XXXXXXXXXXXXXXILIQXRXRARXR-aa	472
	XXXXXXXXXXXXXXILIQXRXRAR-aa	473
	RXRRARRXRRARXA-aa	474
	RXRRARRXRILFQYXHMKWHKAC-aa	475
	RXRRARRXRILFQYXRMKWHKAC-aa	476
	RXRRARRXRILFQYXRWKWHKAC-aa	477
	RXRRXRRXRRXRC-aa	478
	RXRRXRRXRIXILFQNXRMKWHKAC-aa	479
	RXRRXRRXRIHILFQNXRMKWHKAC-aa	480
	RXRRXRRXRIXILFQYXRMKWHKAC-aa	481
	RXRRXRRXRLYSPLSFQXRMKWHKAC-aa	482
	RXRRXRRXRILFQYXRMKWHKAC-aa	483
	RXRRXRIXILFQYXRMKWHKAC-aa	484
	RARRXRRARILFQYXRMKWHKAC-aa	485
	RXRRARRXRILFQYXRMKWHKAC-aa	486
	RARRXRRARILFQYXRMKWHKAC-aa	487
	RXRRARRXRILFQYXRMKWHKAC-aa	488
	RXRRARRXRILFQYXHMKWHKAC-aa	489
	RXRRARRXRILFQYXRMKWHKAC-aa	490
	RXRRARRXRILFQYXRWKWHKAC-aa	491
	RXRRARRXRILFQYXHWKWHKAC-aa	492
	RXRRARRXRILFQYRXRARXRAC-aa	493
	RXRRARRXRILFQYRXRXRXRAC-aa	494
	RXRRARRXRILIQYXRMKWHKAC-aa	495
	RXRRXRILFQYRXRRXRC-aa	496
	RXRRARRXRILFQYRXRARXRAC-aa	497
	RXRRARRXRILFQYRXRXRXRAC-aa	498
	RXRRARRXRILIQYXRMKWHKAC-aa	499
	RXRRXRILFQYRXRRXRCYS-aa	500
	RARRXRRARILFQYRARXRARAC-aa	501
	RARRXRRARILFQYRXRARXRAC-aa	502
	RARRXRRARILFQYRXRRXRAC-aa	503
	RARRXRRARILFQYRXRARXAC-aa	504
	RXRRARRXRILFQYRXRRXRAC-aa	505
	RXRRARRXRILFQYRXRARXAC-aa	506

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RXRRARRXRIHILFQNXRMKWHKAC-aa	507
	RXRRARRXRRARXAC-aa	508
	RXRRARRXRILFQYXHMKWHK-aa	509
	RXRRARRXRILFQYXRMKWHK-aa	510
	RXRRARRXRILFQYXRWKWHK-aa	511
	RXRRARRXRILFQYXRMKWHK-aa	512
	RXRRARRXRILFQYRXRARXR-aa	513
	RXRRARRXRILFQYRXRXRXR-aa	514
	RXRRARRXRILFQYRXRRXR-aa	515
	RXRRARRXRILFQYRARXRAR-aa	516
	RXRRARRXRILFQYRXRAR-aa	517
	RXRRARRXRILIQYXHMKWHK-aa	518
	RXRRARRXRILIQYXRMKWHK-aa	519
	RXRRARRXRILIQYXRWKWHK-aa	520
	RXRRARRXRILIQYXRMKWHK-aa	521
	RXRRARRXRILIQYRXRARXR-aa	522
	RXRRARRXRILIQYRXRXRXR-aa	523
	RXRRARRXRILIQYRXRRXR-aa	524
	RXRRARRXRILIQYRARXRAR-aa	525
	RXRRARRXRILIQYRXRAR-aa	526
	RARRXRRARILFQYXHMKWHK-aa	527
	RARRXRRARILFQYXRMKWHK-aa	528
	RARRXRRARILFQYXRWKWHK-aa	529
	RARRXRRARILFQYXRMKWHK-aa	530
	RARRXRRARILFQYRXRARXR-aa	531
	RARRXRRARILFQYRXRXRXR-aa	532
	RARRXRRARILFQYRXRRXR-aa	533
	RARRXRRARILFQYRARXRAR-aa	534
	RARRXRRARILFQYRXRAR-aa	535
	RARRXRRARILIQYXHMKWHK-aa	536
	RARRXRRARILIQYXRMKWHK-aa	537
	RARRXRRARILIQYXRWKWHK-aa	538
	RARRXRRARILIQYXRMKWHK-aa	539
	RARRXRRARILIQYRXRARXR-aa	540
	RARRXRRARILIQYRXRXRXR-aa	541
	RARRXRRARILIQYRXRRXR-aa	542

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	RARRXRRARILIQYRARXRAR-aa	543
	RARRXRRARILIQYRXRAR-aa	544
	RXRRXRILFQYXHMKWHK-aa	545
	RXRRXRILFQYXRMKWHK-aa	546
	RXRRXRILFQYXRWKWHK-aa	547
	RXRRXRILFQYXRMKWHK-aa	548
	RXRRXRILFQYRXRARXR-aa	549
	RXRRXRILFQYRXRXRXR-aa	550
	RXRRXRILFQYRXRRXR-aa	551
	RXRRXRILFQYRARXRAR-aa	552
	RXRRXRILFQYRXRAR-aa	553
	RXRRXRILIQYXHMKWHK-aa	554
	RXRRXRILIQYXRMKWHK-aa	555
	RXRRXRILIQYXRWKWHK-aa	556
	RXRRXRILIQYXRMKWHK-aa	557
	RXRRXRILIQYRXRARXR-aa	558
	RXRRXRILIQYRXRXRXR-aa	559
	RXRRXRILIQYRXRRXR-aa	560
	RXRRXRILIQYRARXRAR-aa	561
	RXRRXRILIQYRXRAR-aa	562
	PRPXXXXXXXXXXXPRG-aa	563
	RRRRRRRR-aa	564
	RRMKWKK-aa	565
	PKKKRKV-aa	566
	CKDEPQRRSARLSAKPAPPKPEPKPKKAPA KK-aa	567
	RKKRRQRRR-aa	568
	RKKRRQRR-aa	569
	RKKRRQR-aa	570
	KKRRQRRR-aa	571
	KKRRQRRR-aa	572
	AKKRRQRRR-aa	573
	RAKRRQRRR-aa	574
	RKARRQRRR-aa	575
	RKKARQRRR-aa	576
	CRWRWKCCKK-aa	577

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
	tg-RRRRAARR-aa	578
	tg-RRRRGGRR-aa	579
	tg-RGGRRGGRRGGR-aa	580
	tg-RAARRAARRAAR-aa	581
	tg-(RGGR)4-aa	582
	tg-(RAAR)4-aa	583
	tg-ReP	584
	tg-RsPRP	585
	tg-R4PRPRP	586
	tg-(RP)6	587
	tg-R6P4	588
	tg-RePG	589
	tg-RsPRPG	590
	tg-R4PRPRPG	591
	tg-(RP)6G	592
	tg-R6P4G	593
Dengue	CGGTCCACGTAGACTAACAACT	1
JEV	GAAGTTCACACAGATAAACTTCT	2
M1/M2AUG.20.22	CGGTTAGAAGACTCATCTTT	3
M1/M2AUG.25.26	TTTCGACATCGGTTAGAAGACTCAT	4
NP-AUG	GAGACGCCATGATGTGGATGTC	5
Picornavirus	GAAACACGGACACCCAAAGTAGT	6
Dengue 3’-CS	TCCCAGCGTCAATATGCTGTTT	7
Arenaviruses	GCCTAGGATCCACGGTGCGC	8
RSV-L target	GGGACAAAATGGATCCCATTATTAATGG AAATTCTGCTAA	9
RSV-AUG-2	TAATGGGATCCATTTTGTCCC	10
RSV-AUG3	AATAATGGGATCCATTTTGTCCC	11
RSV-AUG4	CATTAATAATGGGATCCATTTTGTCCC	12
RSV-AUG5	GAATTTCCATTAATAATGGGATCCATTTT G	13
RSV-AUG6	CAGAATTTCCATTAATAATGGGATCCATT	14
M23D	GGCCAAACCTCGGCTTACCTGAAAT	15
AVI-5225	GGCCAAACCTCGGCTTACCTGAAAT- RXRRBRRXRRBRXB	16
eGFP654	GCTATTACCTTAACCCAG	17

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
huMSTN target	GAAAAAAGATTATATTGATTTTAAAATC ATGCAAAAACTGCAACTCTGTGTT	18
muMSTN25-104	CATACATTTGCAGTTTTTGCATCAT	19
muMSTN25-183	TCATTTTTAAAAATCAGCACAATCTT	20
muMSTN25-194	CAGTTTTTGCATCATTTTTAAAAATC	21
Exon44-A	GATCTGTCAAATCGCCTGCAGGTAA	22
Exon44-B	AAACTGTTCAGCTTCTGTTAGCCAC	23
Exon44-C	TTGTGTCTTTCTGAGAAACTGTTCA	24
Exon45-A	CTGACAACAGTTTGCCGCTGCCCAA	25
Exon45-B	CCAATGCCATCCTGGAGTTCCTGTAA	26
Exon45-C	CATTCAATGTTCTGACAACAGTTTGCCGC T	27
Exon50-A	CTTACAGGCTCCAATAGTGGTCAGT	28
Exon50-B	CCACTCAGAGCTCAGATCTTCTAACTTCC	29
Exon50-C	GGGATCCAGTATACTTACAGGCTCC	30
Exon51-A	ACATCAAGGAAGATGGCATTTCTAGTTTG G	31
Exon51-B	CTCCAACATCAAGGAAGATGGCATTTCT AG	32
Exon51-C	GAGCAGGTACCTCCAACATCAAGGAA	33
Exon53-A	CTGAAGGTGTTCTTGTACTTCATCC	34
Exon53-B	TGTTCTTGTACTTCATCCCACTGATTCTG A	35
SMN2-A	CTTTCATAATGCTGGCAG	36
SMN2-B	CATAATGCTGGCAG	37
SMN2-C	GCTGGCAG	38
CAG 9mer	CAG CAG CAG	39
CAG 12mer	CAG CAG CAG CAG	40
CAG 15mer	CAG CAG CAG CAG CAG	41
CAG 18mer	CAG CAG CAG CAG CAG CAG	42
AGC 9mer	AGC AGC AGC	43
AGC 12mer	AGC AGC AGC AGC	44
AGC 15mer	AGC AGC AGC AGC AGC	45
AGC 18mer	AGC AGC AGC AGC AGC AGC	46
GCA 9mer	GCA GCA GCA	47
GCA 12mer	GCA GCA GCA GCA	48
GCA 15mer	GCA GCA GCA GCA GCA	49

2019204913 09 Jul 2019

Name	Sequence (Amino to Carboxy Terminus or 5’ to 3’)	SEQ ID NO.
GCA 18mer	GCA GCA GCA GCA GCA GCA	50
AGC 25mer	AGC AGC AGC AGC AGC AGC AGC AGC A	51
CAG 25mer	CAG CAG CAG CAG CAG CAG CAG CAG C	52
CAGG 9mer	CAG GCA GGC	53
CAGG 12mer	CAG GCA GGC AGG	54
CAGG 24mer	CAG GCA GGC AGG CAG GCA GGC AGG	55

aa = glycine or proline; B = β-alanine; X = 6-aminohexanoic acid; tg = unmodifed amino terminus, or the amino terminal capped with an acetyl, benzoyl or stearoyl group (i.e, an acetyl amide, benzoyl amide or stearoyl amide) and Y^b is:

-C(O)-(CHR^e)_n-NH5 wherein n is 2 to 7 and each R^e is independently, at each occurrence, hydrogen or methyl. For simplicity, not all sequences are noted with a terminal tg group; however, each of the above sequences may comprise an unmodifed amino terminus or an amino terminus capped with an acetyl, benzoyl or stearoyl group

III. Antisense Oligomers

Nucleic acid analogs included in the conjugates of the invention are substantially uncharged synthetic oligomers capable of base-specific binding to a target sequence of a polynucleotide, e.g. antisense oligonucleotide analogs. Such analogs include, for example, methylphosphonates, peptide nucleic acids, substantially uncharged N3'->P5' phosphoramidates, and morpholino oligomers.

The base sequence of the nucleic acid analog, provided by base pairing groups supported by the analog backbone, can be any sequence, where the supported base pairing groups include standard or modified A, T, C, G and U bases or the nonstandard inosine (I) and 7-deaza-G bases.

In some embodiments, the nucleic acid analog is a morpholino oligomer, i.e. an oligonucleotide analog composed of morpholino subunit structures of the form shown in Fig. 1, where (i) the structures are linked together by phosphoruscontaining linkages, one to three atoms long, preferably two atoms long, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, and (ii) Pi and Pj are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. The purine or

2019204913 09 Jul 2019 pyrimidine base-pairing moiety is typically adenine, cytosine, guanine, uracil or thymine. The synthesis, structures, and binding characteristics of morpholino oligomers are described further below and detailed in U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, and 5,506,337, all of which are 5 incorporated herein by reference.

Desirable chemical properties of the morpholino-based oligomers include the ability to selectively hybridize with a complementary-base target nucleic acid, including target RNA, with high Tm, even with oligomers as short as 8-14 bases, the ability to be actively transported into mammalian cells, and the ability of an 10 oligomer:RNA heteroduplex to resist RNAse degradation.

In a preferred embodiment, the morpholino oligomer is about 8-40 subunits in length. More typically, the oligomer is about 8-20, about 8-16, about 10-30, or about 12-25 subunits in length. For some applications, such as antibacterial, short oligomers, e.g. from about 8-12 subunits in length, can be especially advantageous, 15 particularly when attached to a peptide transporter as disclosed herein.

A. Oligomers with Modified Intersubunit Linkages

One embodiment of the present disclosure is directed to peptideoligomer conjugates comprising nucleic acid analogues (e.g., morpholino oligomers) comprising modified intersubunit linkages. In some embodiments, the conjugates have 20 higher affinity for DNA and RNA than do the corresponding unmodified oligomers and demonstrate improved cell delivery, potency, and/or tissue distribution properties compared to oligomers having other intersubunit linkages. In one embodiment, the conjugates comprise one or more intersubunit linkages of type (A) as defined below. In other embodiments, the conjugates comprise at least one intersubunit linkage of type 25 (B) as defined below. In still other embodiments, the conjugates comprise intersubunit linkages of type (A) and type (B). In yet other embodiments, the conjugates comprise a morpholino oligomer as described in more detail below. The structural features and properties of the various linkage types and oligomers are described in more detail in the following discussion.

2019204913 09 Jul 2019

1. Linkage (A)

Applicants have found that enhancement of antisense activity, biodistribution and/or other desirable properties can be optimized by preparing oligomers having various intersubunit linkages. For example, the oligomers may 5 optionally comprise one or more intersubunit linkages of type (A), and in certain embodiments the oligomers comprise at least one linkage of type (A), for example each linkage may be of type (A). In some other embodiments each linkage of type (A) has the same structure. Linkages of type (A) may include linkages disclosed in co-owned U.S. Patent No. 7,943,762 which is hereby incorporated by reference in its entirety.

Linkage (A) has the following structure (I), wherein 3’ and 5’ indicate the point of attachment to the 3’ and 5’ ends, respectively, of the morpholino ring (i.e., structure (i) discussed below):

5' or a salt or isomer thereof, wherein:

W is, at each occurrence, independently S or O;

X is, at each occurrence, independently -N(CHs)2, -NR*R², -OR³ or ;

R⁶ R⁶

(Π)

Y is, at each occurrence, independently O or -NR²,

R¹ is, at each occurrence, independently hydrogen or methyl;

R² is, at each occurrence, independently hydrogen or -LNR⁴R⁵R⁷;

R³ is, at each occurrence, independently hydrogen or Ci-Ce alkyl;

2019204913 09 Jul 2019

R⁴ is, at each occurrence, independently hydrogen, methyl, -C(=NH)NH₂, -Z-L-NHC(=NH)NH₂ or -[C(=O)CHR'NH]_mH, where Z is -C(=O)- or a direct bond, R' is a side chain of a naturally occurring amino acid or a one- or twocarbon homolog thereof, and m is 1 to 6;

R⁵ is, at each occurrence, independently hydrogen, methyl or an electron pair;

R⁶ is, at each occurrence, independently hydrogen or methyl;

R⁷ is, at each occurrence, independently hydrogen Ci-Ce alkyl or Ci-Ce alkoxyalkyl; and

L is an optional linker up to 18 atoms in length comprising alkyl, alkoxy or alkylamino groups, or combinations thereof.

In some examples, the oligomer comprises at least one linkage of type (A). In some other embodiments, the oligomer includes at least two consecutive linkages of type (A). In further embodiments, at least 5% of the linkages in the 15 oligomer are type (A); for example in some embodiments, 5%-95%, 10% to 90%, 10% to 50%, or 10% to 35% of the linkages may be linkage type (A). In some specific embodiments, at least one type (A) linkage is -N(CH₃)₂. In other embodiments, each linkage of type (A) is -N(CH₃)₂, and in even other embodiments each linkage in the oligomer is -N(CH₃)₂. In other embodiments, at least one type (A) linkage is piperizin20 1-yl, for example unsubstituted piperazin-l-yl (e.g., A2orA3). In other embodiments, each linkage of type (A) is piperizin-l-yl, for example unsubstituted piperazin-l-yl.

In some embodiments, W is, at each occurrence, independently S or O, and in certain embodiments W is O.

In some embodiments, X is, at each occurrence, independently 25 -N(CH₃)₂, -NR*R², -OR³. In some embodiments X is -N(CH₃)₂. In other aspects X is

-NR*R², and in other examples X is -OR³.

In some embodiments, R¹ is, at each occurrence, independently hydrogen or methyl. In some embodiments, R¹ is hydrogen. In other embodiments X is methyl.

In some embodiments, R² is, at each occurrence, hydrogen. In other embodiments R² is, at each occurrence, -LNR⁴R⁵R⁷. In some embodiments, R³ is, at each occurrence, independently hydrogen or Ci-Ce alkyl. In other embodiments, R³ is

2019204913 09 Jul 2019 methyl. In yet other embodiments, R³ is ethyl. In some other embodiments, R³ is npropyl or isopropyl. In some other embodiments, R³ is C4 alkyl. In other embodiments, R³ is C5 alkyl. In some embodiments, R³ is Ce alkyl.

In certain embodiments, R⁴ is, at each occurrence, independently hydrogen. In other embodiments, R⁴ is methyl. In yet other embodiments, R⁴ is -C(=NH)NH2, and in other embodiments, R⁴ is -Z-L-NHC(=NH)NH2. In still other embodiments, R⁴ is -[C(=O)CHR’NH]_mH. Z is -C(=O)- in one embodiment and Z is a direct bond in another embodiment. R' is a side chain of a naturally occurring amino acid. In some embodiments R’ is a one- or two-carbon homolog of a side chain of a 10 naturally occurring amino acid.

m is and integer from 1 to 6. m may be 1. m may be 2 m may be 3 m may be 4 m may be 5 m may be 6

In some embodiments, R⁵ is, at each occurrence, independently hydrogen, methyl or an electron pair. In some embodiments, R⁵ is hydrogen. In other 15 embodiments, R⁵ is methyl. In yet other embodiments, R⁵ is an electron pair.

In some embodiments, R⁶ is, at each occurrence, independently hydrogen or methyl. In some embodiments, R⁶ is hydrogen. In other embodiments, R⁶ is methyl.

In other embodiments, R⁷ is, at each occurrence, independently hydrogen 20 Ci-Ce alkyl or C2-C6 alkoxyalkyl. In some embodiments R7 is hydrogen. In other embodiments, R⁷ is Ci-Ce alkyl. In yet other embodiments, R⁷ is C2-C6 alkoxyalkyl. In some embodiments, R⁷ is methyl. In other embodiments, R⁷ is ethyl. In yet other embodiments, R⁷ is n-propyl or isopropyl. In some other embodiments, R⁷ is C4 alkyl. In some embodiments, R⁷ is C5 alkyl. In some embodiments, R⁷ is Ce alkyl. In yet 25 other embodiments, R⁷ is C2 alkoxyalkyl. In some other embodiments, R⁷ is C3 alkoxyalkyl. In yet other embodiments, R⁷ is C4 alkoxyalkyl. In some embodiments, R⁷ is C5 alkoxyalkyl. In other embodiments, R⁷ is Ce alkoxyalkyl.

The linker group L, as noted above, contains bonds in its backbone selected from alkyl (e.g. -CH2-CH2-), alkoxy (e.g., -C-O-C-), and alkylamino (e.g. 30 CH2-NH-), with the proviso that the terminal atoms in L (e.g., those adjacent to carbonyl or nitrogen) are carbon atoms. Although branched linkages (e.g. -CH2CHCH3-) are possible, the linker is generally unbranched. In one embodiment, the

2019204913 09 Jul 2019 linker is a hydrocarbon linker. Such a linker may have the structure (CH2)_n-, where n is 1-12, preferably 2-8, and more preferably 2-6.

Oligomers having any number of linkage type (A) are provided. In some embodiments, the oligomer contains no linkages of type (A). In certain embodiments, 5 5, 10, 20, 30, 40, 50, 60, 70, 80 or 90 percent of the linkages are linkage (A). In selected embodiments, 10 to 80, 20 to 80, 20 to 60, 20 to 50, 20 to 40, or 20 to 35 percent of the linkages are linkage (A). In still other embodiments, each linkage is type (A).

2. Linkage (B)

In some embodiments, the oligomers comprise at least one linkage of type (B). For example the oligomers may comprise 1, 2, 3, 4, 5, 6 or more linkages of type (B). The type (B) linkages may be adjacent or may be interspersed throughout the oligomer. Linkage type (B) has the following structure (I):

W

5' (I) or a salt or isomer thereof, wherein:

W is, at each occurrence, independently S or O;

X is, at each occurrence, independently -NR⁸R⁹ or -OR^{(I) * 3}; and

Y is, at each occurrence, independently O or -NR¹⁰,

R³ is, at each occurrence, independently hydrogen or Ci-Ce alkyl;

R⁸ is, at each occurrence, independently hydrogen or C2-C12 alkyl;

R⁹ is, at each occurrence, independently hydrogen, C1-C12 alkyl, C1-C12 aralkyl or aryl;

R¹⁰ is, at each occurrence, independently hydrogen, C1-C12 alkyl or 25 -LNR⁴R^{5 *}R⁷;

2019204913 09 Jul 2019 wherein R⁸ and R⁹ may join to form a 5-18 membered mono or bicyclic heterocycle or R⁸, R⁹ or R³ may join with R¹⁰ to form a 5-7 membered heterocycle, and wherein when X is 4-piperazino, X has the following structure (III):

R¹²

R¹² (HI) wherein:

R¹¹ is, at each occurrence, independently C2-C12 alkyl, C1-C12 aminoalkyl, C1-C12 alkylcarbonyl, aryl, heteroaryl or heterocyclyl;

R is, at each occurrence, independently an electron pair, hydrogen or Ci10 C 12 alkyl; and

R¹² is, at each occurrence, independently, hydrogen, C1-C12 alkyl, C1-C12 aminoalkyl, -NH2, -CONH2, -NR¹³R¹⁴, -NR¹³R¹⁴R¹⁵, C1-C12 alkylcarbonyl, oxo, -CN, trifluoromethyl, amidyl, amidinyl, amidinylalkyl, amidinylalkylcarbonyl guanidinyl, guanidinylalkyl, guanidinylalkylcarbonyl, cholate, deoxycholate, aryl, heteroaryl, 15 heterocycle, -SR¹³ or C1-C12 alkoxy, wherein R¹³, R¹⁴ and R¹⁵ are, at each occurrence, independently C1-C12 alkyl.

In some examples, the oligomer comprises one linkage of type (B). In some other embodiments, the oligomer comprises two inkages of type (B). In some other embodiments, the oligomer comprises three linkages of type (B). In some other 20 embodiments, the oligomer comprises four linkages of type (B). In still other embodiments, the linkages of type (B) are consecutive (i.e., the type (B) linkages are adjacent to each other). In further embodiments, at least 5% of the linkages in the oligomer are type (B); for example in some embodiments, 5%-95%, 10% to 90%, 10% to 50%, or 10% to 35% of the linkages may be linkage type (B).

In other embodiments, R³ is, at each occurrence, independently hydrogen or Ci-Ce alkyl. In yet other embodiments, R³ may be methyl. In some embodiments, R³ may be ethyl. In some other embodiments, R³ may be n-propyl or isopropyl. In yet other embodiments, R³ may be C4 alkyl. In some embodiments, R³ may be C5 alkyl. In some embodiments, R³ may be Ce alkyl.

2019204913 09 Jul 2019

In some embodiments, R⁸ is, at each occurrence, independently hydrogen or C2-C12 alkyl. In some embodiments, R⁸ is hydrogen. In yet other embodiments, R⁸ is ethyl. In some other embodiments, R⁸ is n-propyl or isopropyl. In some embodiments, R⁸ is C4 alkyl. In yet other embodiments, R⁸ is C5 alkyl. In other 5 embodiments, R⁸ is Ce alkyl. In some embodiments, R⁸ is C7 alkyl. In yet other embodiments, R⁸ is Cs alkyl. In other embodiments, R⁸ is C9 alkyl. In yet other embodiments, R⁸ is C10 alkyl. In some other embodiments, R⁸ is C11 alkyl. In yet other embodiments, R⁸ is C12 alkyl. In some other embodiments, R⁸ is C2-C12 alkyl and the C2-C12 alkyl includes one or more double bonds (e.g., alkene), triple bonds (e.g., 10 alkyne) or both. In some embodiments, R⁸ is unsubstituted C2-C12 alkyl.

In some embodiments, R⁹ is, at each occurrence, independently hydrogen, C1-C12 alkyl, C1-C12 aralkyl or aryl. In some embodiments, R⁹ is hydrogen. In yet other embodiments, R⁹ is C1-C12 alkyl. In other embodiments, R⁹ is methyl. In yet other embodiments, R⁹ is ethyl. In some other embodiments, R⁹ is n-propyl or 15 isopropyl. In some embodiments, R⁹ is C4 alkyl. In some embodiments, R⁹ is C5 alkyl.

In yet other embodiments, R⁹ is Ce alkyl. In some other embodiments, R⁹ is C7 alkyl. In some embodiments, R⁹ is Cs alkyl. In some embodiments, R⁹ is C9 alkyl. In some other embodiments, R⁹ is C10 alkyl. In some other embodiments, R⁹ is Ci 1 alkyl. In yet other embodiments, R⁹ is C12 alkyl.

In some other embodiments, R⁹ is C1-C12 aralkyl. For example, n some embodiments R⁹ is benzyl and the benzyl may be optionally substituted on either the phenyl ring or the benzylic carbon. Substituents in this regards include alkyl and alkoxy groups, for example methyl or methoxy. In some embodiments, the benzyl group is substituted with methyl at the benzylic carbon. For example, in some 25 embodiments, R⁹ has the following structure (XIV):

2019204913 09 Jul 2019

R¹⁶ (XIV)

In other embodiments, R⁹ is aryl. For example, in some embodiments R⁹ is phenyl, and the phenyl may be optionally substituted. Substituents in this regard 5 substitutuents include alkyl and alkoxy groups, for example methyl or methoxy. In other embodiments, R⁹ is phenyl and the phenyl comprises a crown ether moiety, for example a 12-18 membered crown ether. In one embodiment the crown ether is 18 membered and may further comprise and additional phenyl moiety. For example, in one embodiment R⁹ has one of the following structures (XV) or XVI):

(XV) (XVI)

In some embodiments, R¹⁰ is, at each occurrence, independently hydrogen, C1-C12 alkyl or -LNR⁴R⁵R⁷, wherein R⁴, R⁵ and R⁷ are as defined above with respect to linkage (A). In other embodiments, R¹⁰ is hydrogen. In other embodiments, 15 R¹⁰ is C1-C12 alkyl, and in other embodimens R¹⁰ is -LNR⁴R⁵R⁷. In some embodiments,

R¹⁰ is methyl. In yet other embodiments, R¹⁰ is ethyl. In some embodiments, R¹⁰ is C3 alkyl. In some embodiments, R¹⁰ is C4 alkyl. In yet other embodiments, R¹⁰ is C5 alkyl. In some other embodiments, R¹⁰ is Ce alkyl. In other embodiments, R¹⁰ is C7 alkyl. In yet other embodiments, R¹⁰ is Cs alkyl. In some embodiments, R¹⁰ is C9 alkyl. 20 In other embodiments, R¹⁰ is C10 alkyl. In yet other embodiments, R¹⁰ is Ci 1 alkyl. In some other embodiments, R¹⁰ is C12 alkyl.

In some embodiments, R⁸ and R⁹ join to form a 5-18 membered mono or bicyclic heterocycle. In some embodiments the heterocycle is a 5 or 6 membered

2019204913 09 Jul 2019 monocyclic heterocycle. For example, in some embodiments linkage (B) has the following structure (IV):

W

5' (IV) wherein Z represents a 5 or 6 membered monocyclic heterocycle.

In other embodiments, heterocycle is bicyclic, for example a 12membered bicyclic heterocycle. The heterocycle may be piperizinyl. The heterocycle may be morpholino. The heterocycle may be piperidinyl. The heterocycle may be decahydroisoquinoline. Representative heterocycles include the following:

(HI) (V) (VI) (VII)

(VIII)

In some embodiments, R¹¹ is, at each occurrence, independently C2-C12 alkyl, C1-C12 aminoalkyl, aryl, heteroaryl or heterocyclyl.

In some embodiments, R¹¹ is C2-C12 alkyl. In some embodiments, R¹¹ is ethyl. In other embodiments, R¹¹ is C3 alkyl. In yet other embodiments, R¹¹ is isopropyl. In some other embodiments, R¹¹ is C₄ alkyl. In other embodiments, R¹¹ is C5 alkyl. In some embodiments, R¹¹ is Ce alkyl. In other embodiments, R¹¹ is C7 alkyl.

2019204913 09 Jul 2019

In some embodiments, R¹¹ is Cs alkyl. In other embodiments, R¹¹ is C9 alkyl. In yet other embodiments, R¹¹ is C10 alkyl. In some other embodiments, R¹¹ is Ci 1 alkyl. In some embodiments, R¹¹ is C12 alkyl.

In other embodiments, R¹¹ is C1-C12 aminoalkyl. In some embodiments,

R¹¹ is methylamino. In some embodiments, R¹¹ is ethylamino. In other embodiments,

R¹¹ is C3 aminoalkyl. In yet other embodiments, R¹¹ is C4 aminoalkyl. In some other embodiments, R¹¹ is C5 aminoalkyl. In other embodiments, R¹¹ is Ce aminoalkyl. In yet other embodiments, R¹¹ is C7 aminoalkyl. In some embodiments, R¹¹ is Cs aminoalkyl. In other embodiments, R¹¹ is C9 aminoalkyl. In yet other embodiments,

R¹¹ is C10 aminoalkyl. In some other embodiments, R¹¹ is C11 aminoalkyl. In other embodiments, R¹¹ is C12 aminoalkyl.

In other embodiments, R¹¹ is C1-C12 alkylcarbonyl. In yet other embodiments, R¹¹ is Ci alkylcarbonyl. In other embodiments, R¹¹ is C2 alkylcarbonyl. In some embodiments, R¹¹ is C3 alkylcarbonyl. In yet other embodiments, R¹¹ is C4 15 alkylcarbonyl. In some embodiments, R¹¹ is C5 alkylcarbonyl. In some other embodiments, R¹¹ is Ce alkylcarbonyl. In other embodiments, R¹¹ is C7 alkylcarbonyl. In yet other embodiments, R¹¹ is Cs alkylcarbonyl. In some embodiments, R¹¹ is C9 alkylcarbonyl. In yet other embodiments, R¹¹ is C10 alkylcarbonyl. In some other embodiments, R¹¹ is C11 alkylcarbonyl. In some embodiments, R¹¹ is C12 alkylcarbonyl. In yet other embodiments, R¹¹ is -C(=O)(CH2)_nCO2H, where n is 1 to 6.

For example, in some embodiments, n is 1. In other embodiments, n is 2. In yet other embodiments, n is 3. In some other embodiments, n is 4. In yet other embodiments, n is 5. In other embodiments, n is 6.

In other embodiments, R¹¹ is aryl. For example, in some embodiments,

R¹¹ is phenyl. In some embodiments, the phenyl is substituted, for example with a nitro group.

In other embodiments, R¹¹ is heteroaryl. For example, in some embodiments, R¹¹ is pyridinyl. In other embodiments, R¹¹ is pyrimidinyl.

In other embodiments, R¹¹ is heterocyclyl. For example, in some 30 embodiments, R¹¹ is piperidinyl, for example piperidin-4-yl.

In some embodiments, R¹¹ is ethyl, isopropyl, piperidinyl, pyrimidinyl, cholate, deoxycholate, or -C(=O)(CH2)_nCO2H, where n is 1 to 6.

2019204913 09 Jul 2019

In some embodiments, R is an electron pair. In other embodiments, R is hydrogen, and in other embodiments R is C1-C12 alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In other embodiments, R is C3 alkyl. In yet other embodiments, R is isopropyl. In some other embodiments, R is C4 alkyl. In yet 5 other embodiments, R is C5 alkyl. In some embodiments, R is Ce alkyl. In other embodiments, R is C7 alkyl. In yet other embodiments, R is Cs alkyl. In other embodiments, R is C9 alkyl. In some embodiments, R is C10 alkyl. In yet other embodiments, R is C11 alkyl. In some embodiments, R is C12 alkyl.

In some embodiments, R¹² is, at each occurrence, independently, hydrogen, C1-C12 alkyl, C1-C12 aminoalkyl, -NH2, -CONH2,-NR¹³R¹⁴, -NR¹³R¹⁴R¹⁵, oxo, -CN, trifluoromethyl, amidyl, amidinyl, amidinylalkyl, amidinylalkylcarbonyl guanidinyl, guanidinylalkyl, guanidinylalkylcarbonyl, cholate, deoxycholate, aryl, heteroaryl, heterocycle, -SR¹³ or C1-C12 alkoxy, wherein R¹³, R¹⁴ and R¹⁵ are, at each occurrence, independently C1-C12 alkyl

In some embodiments, R¹² is hydrogen. In some embodiments, R¹² is

C1-C12 alkyl. In some embodiments, R¹² is C1-C12 aminoalkyl. In some embodiments, R¹² is -NH2. In some embodiments, R¹² is -CONH2. In some embodiments, R¹² is -NR¹³R¹⁴. In some embodiments, R¹² is -NR¹³R¹⁴R¹⁵. In some embodiments, R¹² is CiC12 alkylcarbonyl. In some embodiments, R¹² is oxo. In some embodiments, R¹² is 20 CN. In some embodiments, R¹² is trifluoromethyl. In some embodiments, R¹² is amidyl. In some embodiments, R¹² is amidinyl. In some embodiments, R¹² is amidinylalkyl. In some embodiments, R¹² is amidinylalkylcarbonyl. In some embodiments, R¹² is guanidinyl, for example mono methylguanidynyl or dimethylguanidinyl. In some embodiments, R¹² is guanidinylalkyl. In some 25 embodiments, R¹² is amidinylalkylcarbonyl. In some embodiments, R¹² is cholate. In some embodiments, R¹² is deoxycholate. In some embodiments, R¹² is aryl. In some embodiments, R¹² is heteroaryl. In some embodiments, R¹² is heterocycle. In some embodiments, R¹² is -SR¹³. In some embodiments, R¹² is C1-C12 alkoxy. In some embodiments, R¹² is dimethyl amine.

In other embodiments, R¹² is methyl. In yet other embodiments, R¹² is ethyl. In some embodiments, R¹² is C3 alkyl. In some embodiments, R¹² is isopropyl. In some embodiments, R¹² is C4 alkyl. In other embodiments, R¹² is C5 alkyl. In yet

2019204913 09 Jul 2019 other embodiments, R¹² is Ce alkyl. In some other embodiments, R¹² is C7 alkyl. In some embodiments, R¹² is Cs alkyl. In yet other embodiments, R¹² is C9 alkyl. In some embodiments, R¹² is C10 alkyl. In yet other embodiments, R¹² is C11 alkyl. In other embodiments, R¹² is C12 alkyl. In yet other embodiments, the alkyl moiety is 5 substituted with one or more oxygen atom to form an ether moiety, for example a methoxymethyl moiety.

In some embodiments, R¹² is methylamino. In other embodiments, R¹² is ethylamino. In yet other embodiments, R¹² is C3 aminoalkyl. In some embodiments, R¹² is C4 aminoalkyl. In yet other embodiments, R¹² is C5 aminoalkyl. In some other 10 embodiments, R¹² is Ce aminoalkyl. In some embodiments, R¹² is C7 aminoalkyl. In some embodiments, R¹² is Cs aminoalkyl. In yet other embodiments, R¹² is C9 aminoalkyl. In some other embodiments, R¹² is C10 aminoalkyl. In yet other embodiments, R¹² is Ci 1 aminoalkyl. In other embodiments, R¹² is C12 aminoalkyl. In some embodiments, the amino alkyl is a dimethylamino alkyl.

In yet other embodiments, R¹² is acetyl. In some other embodiments,

R¹² is C2 alkylcarbonyl. In some embodiments, R¹² is C3 alkylcarbonyl. In yet other embodiments, R¹² is C4 alkylcarbonyl. In some embodiments, R¹² is C5 alkylcarbonyl. In yet other embodiments, R¹² is Ce alkylcarbonyl. In some other embodiments, R¹² is C7 alkylcarbonyl. In some embodiments, R¹² is Cs alkylcarbonyl. In yet other 20 embodiments, R¹² is C9 alkylcarbonyl. In some other embodiments, R¹² is C10 alkylcarbonyl. In some embodiments, R¹² is C11 alkylcarbonyl. In other embodiments, R¹² is C12 alkylcarbonyl. The alkylcarbonyl is substituted with a carboxy moiety, for example the alkylcarbonyl is substituted to form a succinic acid moiety (i.e., a 3carboxyalkylcarbonyl). In other embodiments, the alkylcarbonyl is substituted with a 25 terminal -SH group.

In some embodiments, R¹² is amidyl. In some embodiments, the amidyl comprises an alkyl moiety which is further substituted, for example with -SH, carbamate, or combinations thereof. In other embodiments, the amidyl is substituted with an aryl moiety, for example phenyl. In certain embodiments, R¹² may have the 30 following structure (IX):

2019204913 09 Jul 2019

R¹⁶

wherein R¹⁶ is, at each occurrence, independently hydrogen, C1-C12 alkyl, C1-C12 alkoxy, -CN, aryl or heteroaryl.

In some embodiments, R¹² is methoxy. In other embodiments, R¹² is ethoxy. In yet other embodiments, R¹² is C3 alkoxy. In some embodiments, R¹² is C4 alkoxy. In some embodiments, R¹² is C5 alkoxy. In some other embodiments, R¹² is Ce alkoxy. In other embodiments, R¹² is C7 alkoxy. In some other embodiments, R¹² is Cs alkoxy. In some embodiments, R¹² is C9 alkoxy. In other embodiments, R¹² is C10 10 alkoxy. In some embodiments, R¹² is Ci 1 alkoxy. In yet other embodiments, R¹² is C12 alkoxy.

In certain embodiments, R¹² is pyrrolidinyl, for example pyrrolidin-l-yl. In other embodiments, R¹² is piperidinyl, for example piperidin-l-yl or piperidin-4-yl. In other embodiment, R¹² is morpholino, for example morpholin-4-yl. In other 15 embodiments, R¹² is phenyl, and in even further embodiments, the phenyl is substituted, for example with a nitro group. In still other embodiments, R¹² is pyrimidinyl, for example pyrimidin-2-yl.

In other embodiments, R¹³, R¹⁴ and R¹⁵ are, at each occurrence, independently C1-C12 alkyl. In some embodiments, R¹³, R¹⁴ or R¹⁵ is methyl. In yet 20 other embodiments, R¹³, R¹⁴ or R¹⁵ is ethyl. In other embodiments, R¹³, R¹⁴ or R¹⁵ is C3 alkyl. In yet other embodiments, R¹³, R¹⁴ or R¹⁵ is isopropyl. In other embodiments, R¹³, R¹⁴ or R¹⁵ is C4 alkyl. In some embodiments, R¹³, R¹⁴ or R¹⁵ is C5 alkyl. In some other embodiments, R¹³, R¹⁴ or R¹⁵ is Ce alkyl. In other embodiments, R¹³, R¹⁴ or R¹⁵ is C7 alkyl. In yet other embodiments, R¹³, R¹⁴ or R¹⁵ is Cs alkyl. In other embodiments, 25 R¹³, R¹⁴ or R¹⁵ is C9 alkyl. In some embodiments, R¹³, R¹⁴ or R¹⁵ is C10 alkyl. In some embodiments, R¹³, R¹⁴ or R¹⁵ is Ci 1 alkyl. In yet other embodiments, R¹³, R¹⁴ or R¹⁵ is C12 alkyl.

As noted above, in some embodiments, R¹² is amidyl substituted with an aryl moiety. In this regard, each occurrence of R¹⁶ may be the same or differerent. In

2019204913 09 Jul 2019 certain of these embodiments, R¹⁶ is hydrogen. In other embodiments, R¹⁶ is -CN. In other embodiments, R¹⁶ is heteroaryl, for example tretrazolyl. In certain other embodiments, R¹⁶ is methoxy. In other embodiments, R¹⁶ is aryl, and the aryl is optionally substituted. Optional substitutents in this regard include: C1-C12 alkyl, Ci5 C12 alkoxy, for example methoxy; trifluoromethoxy; halo, for example chloro; and trifluoromethyl.

In other embodiments, R¹⁶ is methyl. In yet other embodiments, R¹⁶ is ethyl. In some embodiments, R¹⁶ is C3 alkyl. In some other embodiments, R¹⁶ is isopropyl. In yet other embodiments, R¹⁶ is C4 alkyl. In other embodiments, R¹⁶ is C5 10 alkyl. In yet other embodiments, R¹⁶ is Ce alkyl. In some other embodiments, R¹⁶ is C7 alkyl. In some embodiments, R¹⁶ is Cs alkyl. In yet other embodiments, R¹⁶ is C9 alkyl. In some other embodiments, R¹⁶ is C10 alkyl. In other embodiments, R¹⁶ is Ci 1 alkyl. In some other embodiments, R¹⁶ is C12 alkyl.

In some embodiments, R¹⁶ is methoxy. In some embodiments, R¹⁶ is 15 ethoxy. In yet other embodiments, R¹⁶ is C3 alkoxy. In some other embodiments, R¹⁶ is C4 alkoxy. In other embodiments, R¹⁶ is C5 alkoxy. In some other embodiments, R¹⁶ is Ce alkoxy. In yet other embodiments, R¹⁶ is C7 alkoxy. In some other embodiments, R¹⁶ is Cs alkoxy. In yet other embodiments, R¹⁶ is C9 alkoxy. In some other embodiments, R¹⁶ is C10 alkoxy. In some embodiments, R¹⁶ is C11 alkoxy. In some 20 other embodiments, R¹⁶ is C12 alkoxy.

In some other embodiments, R⁸ and R⁹ join to form a 12-18 membered crown ether. For example, in some embodiments, the crown ether s 18 membered, and in other embodiments the crown ether is 15 membered. In certain embodiments, R⁸ and R⁹ join to form a heterocycle having one of the following structures (X) or (XI):

2019204913 09 Jul 2019

In some embodiments, R⁸, R⁹ or R³ join with R¹⁰ to form a 5-7 membered heterocycle. For example, in some embodiments, R³ joins with R¹⁰ to form a 5-7 membered heterocycle. In some embodiments, the heterocycle is 5-membered. In other embodiments, the heterocycle is 6-membered. In other embodiments, the 5 heterocycle is 7-memebered. In some embodiments, the heterocycle is represented by the following structure (XII):

5' (XII) wherein Z’ represents a 5-7 membered heterocycle. In certain embodiments of structure (XI), R¹² is hydrogen at each occurrence. For example, linkage (B) may have one of the following structures (Bl), (B2) or (B3):

(Bl) (B2) (B3)

In certain other embodiments, R¹² is C1-C12 alkylcarbonyl or amidyl which is further substituted with an arylphosphoryl moiety, for example a triphenyl phosporyl moiety. Examples of linkages having this structure include B56 and B55.

In certain embodiment, linkage (B) does not have any of the the structures A1-A5. Table 2 shows representative linkages of type (A) and (B).

2019204913 09 Jul 2019

Table 2, Representative Intersubunit Linkages

No.	Name	Structure
Al	PMO	0 A A '/. / 3' jvww 1 5'
A2	PMO+ (unprotonated form depicted)	0 __/ οίς 3 ΑΛΑΛΑ. 1 5'
A3	PMO+ (+)	0 /Άηυ cU 3' JVWW 1 5'
A4	PMOmepip (m+)	λλλλλ. 1 5'
A5	pmogux	+nh2 W 3 ΛΧ uwwv ° 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
Bl	PMOcp	0. 3' o-PA^<5. u
B2	PMOcps	%x3' cXP-n^/5.
B3	PMOcpr	V/y O' u
B4	PMOShc	Y4 rγ 4/, 0 ( °> \ UWWO SH | 5'
B5	p^gmorpholmo (m)	Οχ3' »/wvw 1 5'
B6	PMOfrl (0	/ 0 °\ /? 11 \o ΧχΑΧ^ χ * °\ S'

2019204913 09 Jul 2019

No.	Name	Structure
B7	PMOhex (h)	0 Vn O ’ jwvw 1 5'
B8	PMOdodec	0 A < ’ jwwv 1 5'
B9	PMOdlhex	»zwuw 1 5'
BIO	PMOapn (a)	0 ZV// 3· JWVW 1 5'
Bll	PMOpyr (P)	0 009. 0» F *- J JWVW 1 5’
B12	PMOpyr (HC1 Salt)	C-Ό / - \____/ HCI 1 5’

2019204913 09 Jul 2019

No.	Name	Structure
B13	PMOrba	wvww 1 5'
B14	PMOsba	wvww 1 5'
B15	PMOdimethylapn	/0¾ / wvvw 1 5'
B16	PMOetpip	^0¾ ’ WWVW 1 5'
B17	PMOiprpip	0 \ A Ό 3' y-o 3 / WWVW 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B18	PMOpyrQMe	1 5'
B19	PMOcb	%/vww 1 5'
B20	PMOma	Q ί r/V a· ' % JWWV 1 5'
B21	PMObu	jvvvw 1 5'
B22	PMObl	ΛΛΛΛΛ, 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B23	PMOpip	θ-Ό 1 5'
B24	PMOodmb	o t twwv 1 5'
B25	PMOtfb	F3C\ / Λ °^A 0 H OA-<X - «svww 1 5'
B26	PMOctfb	ci 0 fl JVWW 1 5'
B27	PMOptfb	F3C^0\^=\ Nx 7 0 VJ N'V-0 JVWW 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B28	PMOdcb	Cl 0 || AAA AX WWW 1 5'
B29	PMOdmb	A 0 ii rp 3' V/ hXA www 1 5'
B30	PMOhy	\ 0 NXp>t / cA 3' www 1 5'
B31	PMO6ce	AjAi / <A 3 «/WWW 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B32	PMOb	JVUWU 1 5'
B33	PMOq	0 3' 5’
B34	PMOnpp	,ry (7¾ ’ O2N ΛΛΛΛΛ. 5’
B35	PMO°	0 11 - τννννυ 1 5'
B36	PMO4ce	/--0 0---' \x θ / \ 11 < N—P^/ Vjf V1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B37	PMO5ce	/—0 0---' \< 0 / \ Ϊ < N— > < ' θ» / ΛΛΛΛΛ 1 \ / 5'
B38	ΡΜΟβρ	TV/V 3 λλλλλ 1 5'
B39	PMOcyp	0 a· NC^y λλλαλ 1 5'
B40	PMOmop	0 r 3· 1 5'
B41	PMOPP	0 :__n Γ XN''/Pg<,, f yN^ °<3 ^\-=S^N ^VVVW 5'

2019204913 09 Jul 2019

No.	Name	Structure
B42	PMOdmepip	rC t ’ | / 5'
B43	PMONPpip	ry JVVWU 5'
B44	PMObipip	0 /y <3 jvvwv 5'
B45	PMOSUC	0 0 ;rN^ °>3' ° 1 5'
46	PMOglutaric	0 H°\ 11 Z“\ »/vww ° 1 5'

2019204913 09 Jul 2019

No.	Name	Structure
B47	PMOtet	/A N\ II HN—\ °>3' Z-X «/wvw ° 1 5'
B48	PMOthio1 (SH)	0 SH II ( €^.ν7ρ7 y vj 7 \ «/WWW ° 1 5'
B49	PMOpros	A wvwvw 1 5'
B50	PMOpror	A = 0 A 11 0 i(' ’ «/vww 1 5'
B51	PMOtme	y a3Z' / WWW 1 5’

2019204913 09 Jul 2019

No.	Name	Structure
B52	PMOca	0 ΛΑιΑζ σννννν CA = Cholate
B53	PMOdca	0 ΛΑΑζ -N / Ω Z 3' dCA \__uy «ΛΛΛΛΛ. dCA = Deoxycholate
B54	PMOguan (g)	0 NH X II H2NA TAvV 3' A «/wvw 1 5'
B55	PMO+phos	0 ο ΛΑΑί. y VJ 3 ΟΎθ T ό 7
B56	PMOapnphos	Q „ ΑΓΑ A t - \ \\ JVUWb

2019204913 09 Jul 2019

In the sequences and discussion that follows, the above names for the linkages are often used. For example, a base comprising a PMO^apn linkage is illustrated as ^apnB, where B is a base. Other linkages are designated similarily. In addition, abbreviated designations may be used, for example, the abbreviated designations in 5 parenthses above may be used (e.g., ^aB, refers to ^apnB). Other readily identifiable abbreviations may also be used.

B. Oligomers with Modified Terminal Groups

In addition to the carrier peptide, the conjugate may also comprise an oligomer comprising modified terminal groups. Applicants have found that 10 modification of the 3’ and/or 5’ end of the oligomer with various chemical moieties provides beneficial therapeutic properties (e.g., enhanced cell delivery, potency, and/or tissue distribution, etc.) to the conjugates. In various embodiments, the modified terminal groups comprise a hydrophobic moiety, while in other embodiments the modified terminal groups comprise a hydrophilic moiety. The modified terminal 15 groups may be present with or without the linkages described above. For example, in some embodiments, the oligomers to which the carrier peptide is conjugated comprise one or more modified terminal groups and linkages of type (A), for example linkages wherein X is -N(CH3)2. In other embodiments, the oligomers comprise one or more modified terminal group and linkages of type (B), for example linkages wherein X is 420 aminopiperidin-l-yl (i.e., APN). In yet other embodiments, the oligomers comprise one or more modified terminal group and a mixture of linkages (A) and (B). For example, the oligomers may comprise one or more modified terminal group (e.g., trityl or triphenyl acetyl) and linkages wherein X is -N(CH3)2 and linkages wherein X is 4aminopiperidin-l-yl. Other combinations of modified terminal groups and modified 25 linkages also provide favorable therapeutic properties to the oligomers.

In one embodiment, the oligomers comprising terminal modifications have the following structure (XVII):

2019204913 09 Jul 2019

5' terminus

R¹⁷ R¹⁸

3' terminus (XVII) or a salt or isomer thereof, wherein X, W and Y are as defined above for any of linkages (A) and (B) and:

R¹⁷ is, at each occurrence, independently absent, hydrogen or Ci-Ce alkyl;

R¹⁸ and R¹⁹ are, at each occurrence, independently absent, hydrogen, the carrier peptide, a natural or non-natural amino acid, C2-C30 alkylcarbonyl, -C(=O)OR²¹ or R²⁰;

R²⁰ is, at each occurrence, independently guanidinyl, heterocyclyl, CiC30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C7-C30 aralkyl, C3-C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C7-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, or -P(=O)(R²²)2;

Pi is independently, at each occurrence, a base-pairing moiety;

L¹ is an optional linker up to 18 atoms in length comprising bonds selected from alkyl, hydroxyl, alkoxy, alkylamino, amide, ester, disulfide, carbonyl,

2019204913 09 Jul 2019 carbamate, phosphorodiamidate, phosphoroamidate, phosphorothioate, piperazine and phosphodiester; and x is an integer of 0 or greater; and wherein at least one of R¹⁸ or R¹⁹ is R²⁰; and wherein at least one of R¹⁸ or R¹⁹ is R²⁰ and provided that both of R¹⁷ and R¹⁸ are not absent.

The oligomers with modified terminal groups may comprise any number of linkages of types (A) and (B). For example, the oligomers may comprise only linkage type (A). For example, X in each linkage may be -N(CHs)2. Alternatively, the 10 oligomers may only comprise linkage (B). In certain embodiments, the oligomers comprise a mixture of linkages (A) and (B), for example from 1 to 4 linkages of type (B) and the remainder of the linkages being of type (A). Linkages in this regard include, but are not limited to, linkages wherein X is aminopiperidinyl for type (B) and dimethyl amino for type (A).

In some embodiments, R¹⁷ is absent. In some embodiments, R¹⁷ is hydrogen. In some embodiments, R¹⁷ is Ci-Ce alkyl. In some embodiments, R¹⁷ is methyl. In yet other embodiments, R¹⁷ is ethyl. In some embodiments, R¹⁷ is C3 alkyl. In some other embodiments, R¹⁷ is isopropyl. In other embodiments, R¹⁷ is C4 alkyl. In yet other embodiments, R¹⁷ is C5 alkyl. In some other embodiments, R¹⁷ is Ce alkyl.

In other embodiments, R¹⁸ is absent. In some embodiments, R¹⁸ is hydrogen. In some embodiments, R¹⁸ is the carrier peptide. In some embodiments, R¹⁸ is a natural or non-natural amino acid, for example trimethylglycine. In some embodiments, R¹⁸ is R²⁰.

In other embodiments, R¹⁹ is absent. In some embodiments, R¹⁹ is 25 hydrogen. In some embodiments, R¹⁹ is the carrier peptide. In some embodiments, R¹⁹ is a natural or non-natural amino acid, for example trimethylglycine. In some embodiments, R¹⁹ is-C(=O)OR¹⁷, for example R¹⁹ may have the following structure:

2019204913 09 Jul 2019

Ο

In other embodiments R¹⁸ or R¹⁹ is C2-C30 alkylcarbonyl, for example C(=O)(CH2)_nCO₂H, where n is 1 to 6, for example 2. In other examples, R¹⁸ or R¹⁹ is acetyl.

In some embodiments, R²⁰ is, at each occurrence, independently guanidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C₃oaryl, C7-C30 aralkyl, C3C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C6-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, 10 -C(=O)OR²¹, or -P(=O)(R²²)2, wherein R²¹ is C1-C30 alkyl comprising one or more oxygen or hydroxyl moieties or combinations thereof and each R²² is C⁶-C¹² aryloxy.

In certain other embodiments, R¹⁹ is -C(=O)OR²¹ and R¹⁸ is hydrogen, guanidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C3-C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C7-C30 15 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, or -P(=O)(R²²)2, wherein each R²² is C⁶-C¹² aryloxy.

In other embodiments, R²⁰ is, at each occurrence, independently guanidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C3-C30 20 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C7-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, or -P(=O)(R²²)2. While in other examples, R²⁰ is, at each occurrence, independently guanidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C₃oaryl, C7-C30 aralkyl, C325 Cs cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C7-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, or -P(=O)(R²²)2.

In some embodiments R²⁰ is guanidinyl, for example mono methylguanidynyl or dimethylguanidinyl. In other embodiments, R²⁰ is heterocyclyl.

For example, in some embodiments, R²⁰ is piperidin-4-yl. In some embodiments, the

2019204913 09 Jul 2019 piperidin-4-yl is substituted with trityl or Boe groups. In other embodiments, R²⁰ is C3Cs cycloalkyl. In other embodiments, R²⁰ is C6-C30 aryl.

In some embodiments, R²⁰ is C7-C30 arylcarbonyl. For example, In some embodiments, R²⁰ has the following structure (XVIII):

O

p23 (XVIII) wherein R²³ is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, C1-C30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, and wherein one R²³ may join with another R²³ to form a heterocyclyl 10 ring. In some embodiments, at least one R²³ is hydrogen, for example, in some embodiments, each R²³ is hydrogen. In other embodiments, at least one R²³ is C1-C30 alkoxy, for example in some embodiments, each R²³ is methoxy. In other embodiments, at least one R²³ is heteroaryl, for example in some embodiments, at least one R²³ has one of the following structures (XVIIIa) of (XVIIIb):

O

(XVIIIa) (XVIIIb)

In still other embodiments, one R²³ joins with another R²³ to form a heterocyclyl ring. For example, in one embodiment, R²⁰ is 5-carboxyfluorescein.

In other embodiments, R²⁰ is C7-C30 aralkylcarbonyl. For example, in various embodiments, R²⁰ has one of the following structures (XIX), (XX) or (XXI):

2019204913 09 Jul 2019

(XIX) (XX)

R²³

(xxi) wherein R²³ is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, C1-C30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, wherein one R²³ may join with another R²³ to form a heterocyclyl ring, X is -OH or halo and m is an integer from 0 to 6. In some specific embodiments, m is 0. In other embodimens, m is 1, while in other embodiments, m is 2. In other 10 embodiments, at least one R²³ is hydrogen, for example in some embodiments each R²³ is hydrogen. In some embodiments, X is hydrogen. In other embodiments, X is -OH. In other embodiments, X is Cl. In other embodiments, at least one R²³ is C1-C30 alkoxy, for example methoxy.

In still other embodiments, R²⁰ is C7-C30 aralkyl, for example trityl. In other embodiments, R²⁰ is methoxy trityl. In some embodiments, R²⁰ has the following structure (XXII):

2019204913 09 Jul 2019 _R23

(XXII) wherein R²³ is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, C1-C30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or 5 heterocyclalkyl, and wherein one R²³ may join with another R²³ to form a heterocyclyl ring. For example, in some embodiments each R²³ is hydrogen. In other embodiments, at least one R²³ is C1-C30 alkoxy, for example methoxy.

In yet other embodiments, R²⁰ is C7-C30 aralkyl and R²⁰ has the following structure (XXIII):

R²³

_R23 (XXIII)

In some embodiments, at least one R²³ is halo, for example chloro. In some other embodiments, one R²³ is chloro in the para position.

In other embodiments, R²⁰ is C1-C30 alkyl. For example, In some 15 embodiments, R²⁰ is a C4-C20 alkyl and optionally comprises one or more double bonds.

For example, In some embodiments, R²⁰ is a C4-10 alkyl comprising a triple bond, for example a terminal triple bond. In some embodiments, R²⁰ is hexyn-6-yl. In some embodiments, R²⁰ has one of the following structures (XXIV), (XXV), (XXVI) or (XXVII):

2019204913 09 Jul 2019

(XXIV) (XXV) (XXVI) (XXVII)

In still other embodiments, R²⁰ is a C3-C30 alkylcarbonyl, for example a C3-C10 alkyl carbonyl. In some embodiments, R²⁰ is -C(=O)(CH2)_PSH or 5 -C(=O)(CH2)_PSSHet, wherein p is an integer from 1 to 6 and Het is a heteroaryl. For example, p may be 1 or p may be 2. In other example Het is pyridinyl, for example pyridin-2-yl. In other embodiments, the C3-C30 alkylcarbonyl is substituted with a further oligomer, for example in some embodiments the oligomer comprises a C3-C30 alkyl carbonyl at the 3’ position which links the oligomer to the 3’ position of another 10 oligomer. Such terminal modifications are included within the scope of the present disclosure.

In other embodiments, R²⁰ is a C3-C30 alkyl carbonyl which is futher substituted with an arylphosphoryl moiety, for example triphenyl phosphoryl. Examples of such R²⁰ groups include structure 33 in Table 3.

In other examples, R²⁰ is C3-C8 cycloalkylcarbonyl, for example C5-C7 alkyl carbonyl. In these embodiments, R20 has the following structure (XXVIII):

2019204913 09 Jul 2019

Ο

wherein R²³ is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, C1-C30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, and wherein one R²³ may join with another R²³ to form a heterocyclyl ring. In some embodiments, R²³ is heterocyclylalkyl, for example in some embodiments R²³ has the following structure:

Ο

In some other embodiments, R²⁰ is C3-C8 cycloalkylalkylcarbonyl. In other embodiments, R²⁰ is C2-C30 alkyloxycarbonyl. In other embodiments, R²⁰ is C3Cs cycloalkyloxycarbonyl. In other embodiments, R²⁰ is C7-C30 aryloxycarbonyl. In other embodiments, R²⁰ is C8-C30 aralkyloxycarbonyl. In other embodiments, R²⁰ is -P(=O)(R²²)2, wherein each R²² is C⁶-C¹² aryloxy, for example in some embodiments R²⁰ has the following structure (C24):

(C24)

In other embodiments, R²⁰ comprises one or more halo atoms. For example, in some embodiments R²⁰ comprises a perfluoro analogue of any of the above R²⁰ moieties. In other embodiments, R²⁰ is p-trifluoromethylphenyl, 20 trifluoromethyltrityl, perfluoropentyl or pentafluorophenyl.

In some embodiments the 3’ terminus comprises a modification and in other embodiments the 5’ terminus comprises a modification. In other embodiments

2019204913 09 Jul 2019 both the 3’ and 5’ termini comprise modifications. Accordingly, in some embodiments, R¹⁸ is absent and R¹⁹ is R²⁰. In other embodiments, R¹⁹ is absent and R¹⁸ is R²⁰. In yet other embodiments, R¹⁸ and R¹⁹ are each R²⁰.

In some embodiments, the oligomer comprises a cell-penetrating peptide 5 in addition to a 3’ or 5’ modification. Accordingly, in some embodiments R¹⁹ is a cellpenetrating peptide and R¹⁸ is R²⁰. In other embodiments, R¹⁸ is a cell-penetrating peptide and R¹⁹ is R²⁰. In further embodiments of the foregoing, the cell-penetrating peptide is an arginine-rich peptide.

In some embodiments, the linker L¹ which links the 5’terminal group (i.e., R¹⁹) to the oligomer may be present or absent. The linker comprises any number of functional groups and lengths provided the linker retains its ability to link the 5’ terminal group to the oligomer and provided that the linker does not interfere with the oligomer’s ability to bind to a target sequence in a sequence specific manner. In one embodiment, L comprises phosphorodiamidate and piperazine bonds. For example, in some embodiments L has the following structure (XXIX):

N—P=O

WWW (XXIX) wherein R²⁴ is absent, hydrogen or Ci-Ce alkyl. In some embodiments, R²⁴ is absent. In some embodiments, R²⁴ is hydrogen. In some embodiments, R²⁴ is Ci-Ce alkyl. In 20 some embodiments, R²⁴ is methyl. In other embodiments, R²⁴ is ethyl. In yet other embodiments, R²⁴ is C3 alkyl. In some other embodiments, R²⁴ is isopropyl. In yet other embodiments, R²⁴ is C4 alkyl. In some embodiments, R²⁴ is C5 alkyl. In yet other embodiments, R²⁴ is Ce alkyl.

In yet other embodiments, R²⁰ is C3-C30 alkylcarbonyl, and R²⁰ has the 25 following structure (XXX):

2019204913 09 Jul 2019

Ο

(XXX) wherein R²⁵ is hydrogen or -SR²⁶, wherein R²⁶ is hydrogen, C1-C30 alkyl, heterocyclyl, aryl or heteroaryl, and q is an integer from 0 to 6.

In further embodiments of any of the above, R²³ is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, aryl, heteroaryl, heterocyclyl or heterocyclalkyl.

In some other embodiments, only the 3’ terminus of the oligomer is conjugated to one of the groups noted above. In some other embodiments, only the 5’ 10 terminus of the oligomer is conjugated to one of the groups noted above. In other embodiments, both the 3’ and 5’ termini comprise one of the groups noted above. The terminal group may be selected from any one of the groups noted above or any of the specific groups illustrated in Table 3.

Table 3. Representative Terminal Groups

No.	Name	Structure
Cl	T rimethoxyb enzoyl	O och3
C2	9-fluorene-carboxyl	/==- 0

2019204913 09 Jul 2019

2019204913 09 Jul 2019

2019204913 09 Jul 2019

No.	Name	Structure
C14	Trityl (Tr)	Q
C15	Methoxytrityl (MeOTr)		c	) fb
C16	Methylsuccinimidylcyclohexoyl	< 0
C17	Thioacetyl	0
C18	COCH2CH2SSPy	/N	0
C19	Guanidinyl	NH
C20	T rimethylglycine	zU/
C21	Lauroyl

2019204913 09 Jul 2019

No.	Name	Structure
C22	T riethyleneglycoloyl (EG3)	O h°\ JU
C23	Succinicacetyl	0 0
C24	Diphenylphosphoryl	QiP o—P—0 1 'VWW' 1
C25	Piperidin-4-yl	o* HN\>
C26	T ritylpiperidin-4-yl	Qrf θο
C27	Boc- Piperidin-4-yl	ov 0
C28	Hexyn-6-yl

2019204913 09 Jul 2019

No.	Name	Structure
C29	5-carboxyfluorescein	0 vrf
C30	Benzhydryl			La kJ1
C31	p-Chlorobenzhydryl			La Ύ Cl
C32	Piperazinyl (pip)
C33	Triphenylphos	U - Λ

2019204913 09 Jul 2019

No.	Name	Structure
		0 0 %	NH2	0
C34	Dimerized	oligo^ N a H
		Oligo = a further oligomer

C. Properties of the Conjugates

As noted above, the present disclosure is directed to conjugates of carrier peptides and oligonucleotide analogues (i.e., oligomers). The oligomers may comprise various modifications which impart desirable properties (e.g., increased antisense 5 activity) to the oligomers. In certain embodiments, the oligomer comprises a backbone comprising a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3’-end of one morpholino ring structure to a 5’-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific 10 manner to a target nucleic acid. The morpholino ring structures may have the following structure (i):

3' (i) wherein Pi is, at each occurrence, independently a base-pairing moiety.

Each morpholino ring structure supports a base pairing moiety (Pi), to form a sequence of base pairing moieties which is typically designed to hybridize to a selected antisense target in a cell or in a subject being treated. The base pairing moiety may be a purine or pyrimidine found in native DNA or RNA (A, G, C, T, or U) or an analog, such as hypoxanthine (the base component of the nucleoside inosine) or 520 methyl cytosine. Analog bases that confer improved binding affinity to the oligomer

2019204913 09 Jul 2019 can also be utilized. Exemplary analogs in this regard include C5-propynyl-modifed pyrimidines, 9-(aminoethoxy)phenoxazine (G-clamp) and the like.

As noted above, the oligomer may be modified, in accordance with an aspect of the invention, to include one or more (B) linkages, e.g. up to about 1 per every 5 2-5 uncharged linkages, typically 3-5 per every 10 uncharged linkages. Certain embodiments also include one or more linkages of type (B). In some embodiments, optimal improvement in antisense activity is seen where up to about half of the backbone linkages are type (B). Some, but not maximum enhancement is typically seen with a small number e.g., 10-20% of (B) linkages.

In one embodiment, the linkage types (A) and (B) are interspersed along the backbone. In some embodiments, the oligomer does not have a strictly alternating pattern of (A) and (B) linkages along its entire length. In addition to the carrier peptide, the oligomers may optionally comprise a 5’ and/or 3’ modification as described above.

Also considered are oligomers having blocks of (A) linkages and blocks of (B) linkages; for example, a central block of (A) linkages may be flanked by blocks of (B) linkages, or vice versa. In one embodiment, the oligomer has approximately equal-length 5’, 3; and center regions, and the percentage of (B) or (A) linkages in the center region is greater than about 50%, o greater than about 70%. Oligomers for use in antisense applications generally range in length from about 10 to about 40 subunits, 20 more preferably about 15 to 25 subunits. For example, an oligomer of the invention having 19-20 subunits, a useful length for an antisense oligomer, may ideally have two to seven, e.g. four to six, or three to five, (B) linkages, and the remainder (A) linkages.

An oligomer having 14-15 subunits may ideally have two to five, e.g. 3 or 4, (B) linkages and the remainder (A) linkages.

The morpholino subunits may also be linked by non-phosphorus-based intersubunit linkages, as described further below.

Other oligonucleotide analog linkages which are uncharged in their unmodified state but which could also bear a pendant amine substituent can also be used. For example, a 5’nitrogen atom on a morpholino ring could be employed in a 30 sulfamide linkage (or a urea linkage, where phosphorus is replaced with carbon or sulfur, respectively).

2019204913 09 Jul 2019

In some embodiments for antisense applications, the oligomer may be 100% complementary to the nucleic acid target sequence, or it may include mismatches, e.g., to accommodate variants, as long as a heteroduplex formed between the oligomer and nucleic acid target sequence is sufficiently stable to withstand the action of cellular 5 nucleases and other modes of degradation which may occur in vivo. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. The number of mismatches allowed will depend on the length of the oligomer, the percentage of G:C base pairs in the duplex, and the position of the mismatch(es) in the duplex, according to well understood principles of duplex stability. Although such 10 an antisense oligomer is not necessarily 100% complementary to the nucleic acid target sequence, it is effective to stably and specifically bind to the target sequence, such that a biological activity of the nucleic acid target, eg., expression of encoded protein(s), is modulated.

The stability of the duplex formed between an oligomer and the target 15 sequence is a function of the binding T_m and the susceptibility of the duplex to cellular enzymatic cleavage. The T_m of an antisense compound with respect to complementarysequence RNA may be measured by conventional methods, such as those described by Hames et al., Nucleic Acid Hybridization, IRL Press, 1985, pp.107-108 or as described in Miyada C.G. and Wallace R.B., 1987, Oligonucleotide hybridization techniques, 20 Methods Enzymol. Vol. 154 pp. 94-107.

In some embodiments, each antisense oligomer has a binding T_m, with respect to a complementary-sequence RNA, of greater than body temperature or in other embodiments greater than 50°C. In other embodiments T_m's are in the range 6080°C or greater. According to well known principles, the T_m of an oligomer compound, 25 with respect to a complementary-based RNA hybrid, can be increased by increasing the ratio of C:G paired bases in the duplex, and/or by increasing the length (in base pairs) of the heteroduplex. At the same time, for purposes of optimizing cellular uptake, it may be advantageous to limit the size of the oligomer. For this reason, compounds that show high T_m (50°C or greater) at a length of 20 bases or less are generally preferred 30 over those requiring greater than 20 bases for high T_m values. For some applications, longer oligomers, for example longer than 20 bases may have certain advantages. For

2019204913 09 Jul 2019 example, in certain embodiments longer oligomers may find particular utility for use in exon skippin or splice modulation.

The targeting sequence bases may be normal DNA bases or analogues thereof, e.g., uracil and inosine that are capable of Watson-Crick base pairing to target5 sequence RNA bases.

The oligomers may also incorporate guanine bases in place of adenine when the target nucleotide is a uracil residue. This is useful when the target sequence varies across different viral species and the variation at any given nucleotide residue is either cytosine or uracil. By utilizing guanine in the targeting oligomer at the position 10 of variability, the well-known ability of guanine to base pair with uracil (termed C/U:G base pairing) can be exploited. By incorporating guanine at these locations, a single oligomer can effectively target a wider range of RNA target variability.

The compounds (e.g., oligomers, intersubunit linkages, terminal groups) may exist in different isomeric forms, for example structural isomers (e.g., tautomers).

With regard to stereoisomers, the compounds may have chiral centers and may occur as racemates, enantiomerically enriched mixtures, individual enantiomers, mixture or diastereomers or individual diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. The compounds may also possess axial chirality which may result in atropisomers. Furthermore, some of the crystalline 20 forms of the compounds may exist as polymorphs, which are included in the present invention. In addition, some of the compounds may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.

The oligomers described herein may be used in methods of inhibiting production of a protein or replication of a virus. Accordingly, in one embodiment a nucleic acid encoding such a protein is exposed to an oligomer as disclosed herein. In further embodiments of the foregoing, the antisense oligomer comprises either a 5 ’ or 3 ’ modified terminal group or combinations thereof, as disclosed herein, and the base pairing moieties B form a sequence effective to hybridize to a portion of the nucleic acid at a location effective to inhibit production of the protein. In one embodiment, the location is an ATG start codon region of an mRNA, a splice site of a pre-mRNA, or a viral target sequence as described below.

2019204913 09 Jul 2019

In one embodiment, the oligomer has a T_m with respect to binding to the target sequence of greater than about 50 °C, and it is taken up by mammalian cells or bacterial cells. In another embodiment, the oligomer may be conjugated to a transport moiety, for example an arginine-rich peptide, as described herein to facilitate such 5 uptake. In another embodiment, the terminal modifications described herein can function as a transport moiety to facilitate uptake by mammalian and/or bacterial cells.

The preparation and properties of morpholino oligomers is described in more detail below and in U.S. Patent No. 5,185,444 and WO/2009/064471, each of which is hereby incorporated by reference in their entirety.

D. Formulation and Administration of the Conjugates

The present disclosure also provides for formulation and delivery of the disclosed conjugate. Accordingly, in one embodiment the present disclosure is directed to a composition comprising a peptide-oligomer conjugate as disclosed herein and a pharmaceutically acceptable vehicle.

Effective delivery of the conjugate to the target nucleic acid is an important aspect of treatment. Routes of antisense oligomer delivery include, but are not limited to, various systemic routes, including oral and parenteral routes, e.g., intravenous, subcutaneous, intraperitoneal, and intramuscular, as well as inhalation, transdermal and topical delivery. The appropriate route may be determined by one of skill in the art, as appropriate to the condition of the subject under treatment. For example, an appropriate route for delivery of an antisense oligomer in the treatment of a viral infection of the skin is topical delivery, while delivery of a antisense oligomer for the treatment of a viral respiratory infection is by inhalation. The oligomer may also be delivered directly to the site of viral infection, or to the bloodstream.

The conjugate may be administered in any convenient vehicle which is physiologically and/or pharmaceutically acceptable. Such a composition may include any of a variety of standard pharmaceutically acceptable carriers employed by those of ordinary skill in the art. Examples include, but are not limited to, saline, phosphate buffered saline (PBS), water, aqueous ethanol, emulsions, such as oil/water emulsions 30 or triglyceride emulsions, tablets and capsules. The choice of suitable physiologically acceptable carrier will vary dependent upon the chosen mode of administration.

2019204913 09 Jul 2019

The compounds (e.g., conjugates) of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in 5 the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and 10 nitric acids. Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 215 hydroxyethylammonium, and the like). Thus, the term “pharmaceutically acceptable salt” of structure (I) is intended to encompass any and all acceptable salt forms.

In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are 20 generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of 25 prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.

In some instances, liposomes may be employed to facilitate uptake of the 30 antisense oligonucleotide into cells. (See, e.g., Williams, S.A., Leukemia 10(12): 19801989, 1996; Lappalainen et al., Antiviral Res. 23:119, 1994; Uhlmann et al., antisense oligonucleotides: a new therapeutic principle, Chemical Reviews, Volume 90, No. 4,

2019204913 09 Jul 2019 pages 544-584, 1990; Gregoriadis, G., Chapter 14, Liposomes, Drug Carriers in Biology and Medicine, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or 5 microparticles. (See, e.g., Wu, G.Y. and Wu, C.H., J. Biol. Chem. 262:4429-4432, 1987). Alternatively, the use of gas-filled microbubbles complexed with the antisense oligomers can enhance delivery to target tissues, as described in US Patent No. 6,245,747. Sustained release compositions may also be used. These may include semipermeable polymeric matrices in the form of shaped articles such as films or 10 microcapsules.

In one embodiment, antisense inhibition is effective in treating infection of a host animal by a virus, by contacting a cell infected with the virus with an antisense agent effective to inhibit the replication of the specific virus. The antisense agent is administered to a mammalian subject, e.g., human or domestic animal, infected with a 15 given virus, in a suitable pharmaceutical carrier. It is contemplated that the antisense oligonucleotide arrests the growth of the RNA virus in the host. The RNA virus may be decreased in number or eliminated with little or no detrimental effect on the normal growth or development of the host.

In one aspect of the method, the subject is a human subject, e.g., a 20 patient diagnosed as having a localized or systemic viral infection. The condition of a patient may also dictate prophylactic administration of an antisense oligomer of the invention, e.g. in the case of a patient who (1) is immunocompromised; (2) is a bum victim; (3) has an indwelling catheter; or (4) is about to undergo or has recently undergone surgery. In one preferred embodiment, the oligomer is a 25 phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered orally. In another preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered intravenously (i.v.).

In another application of the method, the subject is a livestock animal, 30 e.g., a chicken, turkey, pig, cow or goat, etc, and the treatment is either prophylactic or therapeutic. The invention also includes a livestock and poultry food composition containing a food grain supplemented with a subtherapeutic amount of an antiviral

2019204913 09 Jul 2019 antisense compound of the type described above. Also contemplated is, in a method of feeding livestock and poultry with a food grain supplemented with subtherapeutic levels of an antiviral, an improvement in which the food grain is supplemented with a subtherapeutic amount of an antiviral oligonucleotide composition as described above.

In one embodiment, the conjugate is administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. Typically, one or more doses of antisense oligomer are administered, generally at regular intervals, for a period of about one to two weeks. Preferred doses for oral administration are from about 1-1000 mg oligomer per 70 kg.

In some cases, doses of greater than 1000 mg oligomer/patient may be necessary. For

i.v. administration, preferred doses are from about 0.5 mg to 1000 mg oligomer per 70 kg. The conjugate may be administered at regular intervals for a short time period, e.g., daily for two weeks or less. However, in some cases the conjugate is administered intermittently over a longer period of time. Administration may be followed by, or concurrent with, administration of an antibiotic or other therapeutic treatment. The treatment regimen may be adjusted (dose, frequency, route, etc.) as indicated, based on the results of immunoassays, other biochemical tests and physiological examination of the subject under treatment.

An effective in vivo treatment regimen using the conjugates of the invention may vary according to the duration, dose, frequency and route of administration, as well as the condition of the subject under treatment (i.e., prophylactic administration versus administration in response to localized or systemic infection). Accordingly, such in vivo therapy will often require monitoring by tests appropriate to the particular type of viral infection under treatment, and corresponding adjustments in the dose or treatment regimen, in order to achieve an optimal therapeutic outcome. Treatment may be monitored, e.g., by general indicators of disease and/or infection, such as complete blood count (CBC), nucleic acid detection methods, immunodiagnostic tests, viral culture, or detection of heteroduplex.

The efficacy of an in vivo administered antiviral conjugate of the invention in inhibiting or eliminating the growth of one or more types of RNA virus may be determined from biological samples (tissue, blood, urine etc.) taken from a subject prior to, during and subsequent to administration of the antisense oligomer.

2019204913 09 Jul 2019

Assays of such samples include (1) monitoring the presence or absence of heteroduplex formation with target and non-target sequences, using procedures known to those skilled in the art, e.g., an electrophoretic gel mobility assay; (2) monitoring the amount of viral protein production, as determined by standard techniques such as ELISA or 5 Western blotting, or (3) measuring the effect on viral titer, e.g. by the method of

Spearman-Karber. (See, for example, Pari, G.S. et al., Antimicrob. Agents and Chemotherapy 39(5):1157-1161, 1995; Anderson, K.P. et al., Antimicrob. Agents and

Chemotherapy 40(9):2004-2011, 1996, Cottral, G.E. (ed) in: Manual of Standard Methods for Veterinary Microbiology, pp. 60-93, 1978).

E. Preparation of the Conjugates

The morpholino subunits, the modified intersubunit linkages and oligomers comprising the same can be prepared as described in the examples and in

U.S. Patent Nos. 5,185,444 and 7,943, 762 which are hereby incorporated by reference in their entirety. The morpholino subunits can be prepared according to the following general Reaction Scheme I.

100

2019204913 09 Jul 2019

Reaction Scheme 1. Preparation of Morpholino Subunits

1. NalO₄, MeoH (aq)

2. (NH₄)₂B₄O₇,

3. Borane-triethylamine

4. Methanolic acid (p-TsOH or HCI)

Referring to Reaction Scheme 1, wherein B represents a base pairing moiety and PG represents a protecting group, the morpholino subunits may be prepared 5 from the corresponding ribinucleoside (1) as shown. The morpholino subunit (2) may be optionally protected by reaction with a suitable protecting group precursor, for example trityl chloride. The 3’ protecting group is generally removed during solid-state oligomer synthesis as described in more detail below. The base pairing poiety may be suitable protected for sold phase oligomer synthesis. Suitable protecting groups include 10 benzoyl for adenine and cytosine, phenylacetyl for guanine, and pivaloyloxymethyl for hypoxanthine (I). The pivaloyloxymethyl group can be introduced onto the N1 position of the hypoxanthine heterocyclic base. Although an unprotected hypoxanthine subunit, may be employed, yields in activation reactions are far superior when the base is protected. Other suitable protecting groups include those disclosed in co-pending U.S. 15 Application No. 12/271,040, which is hereby incorporated by reference in its entirety.

Reaction of 3 with the activated phosphorous compound 4, results in morpholino subunints having the desired linkage moiety (5). Compounds of structure 4 can be prepared using any number of methods known to those of skill in the art. For example, such compounds may be prepared by reaction of the corresponding amine and 20 phosphorous oxychloride. In this regard, the amine starting material can be prepared

101

2019204913 09 Jul 2019 using any method known in the art, for example those methods described in the Examples and in U.S. Patent No. 7,943, 762. Although the above scheme depicts preparation of linkages of type (B) (e.g., X is -NR⁸R⁹), linkages of type (A) (e.g., X is dimethyl amine) can be prepared in an analogous manner.

Compounds of structure 5 can be used in solid-phase automated oligomer synthesis for preparation of oligomers comprising the intersubunit linkages. Such methods are well known in the art. Briefly, a compound of structure 5 may be modified at the 5’ end to contain a linker to a solid support. For example, compound 5 may be linked to a solid support by a linker comprising L¹ and/or R¹⁹. An exemplary 10 method is demonstrated in Figures 3 and 4. In this manner, the oligo may comprise a 5’- terminal modification after oligomer synthsis is complete and the oligomer is cleaved from the solid support. Once supported, the protecting group of 5 (e.g., trityl) is removed and the free amine is reacted with an activated phosphorous moiety of a second compound of structure 5. This sequence is repeated untilthe desired length oligo 15 is obtained. The protecting group in the termina 5’ end may either be removed or left on if a 5’-modification is desired. The oligo can be removed from the solid support using any number of methods, or example treatment with a base to cleave the linkage to the solid support.

Peptide oligomer conjugates can be prepared by coupling the desired peptide (prepared according to standard peptide synthetic methods known in the art) with an oligomer comprising a free NH (for example the 3’ NH of amorpholino oligomer) in the presence of an appropriate activating reagent (e.g., HATU). Conjugates may be purified using a number of techniques known in the art, for example SCX chromatography.

The preparation of modified morpholino subunits and peptide oligomer conjugates are described in more detail in the Examples. The peptide oligomer conjugates containing any number of modified linkages may be prepared using methods described herein, methods known in the art and/or described by reference herein. Also described in the examples are global modifications of PMO+ morpholino oligomers 30 prepared as previously described (see e.g., PCT publication W02008036127).

102

2019204913 09 Jul 2019

F. Antisense Activity of the Oligomers

The present disclosure also provides a method of inhibiting production of a protein, the method comprising exposing a nucleic acid encoding the protein to a peptide-oligomer conjugate as disclosed herein. Accordingly, in one embodiment a 5 nucleic acid encoding such a protein is exposed to a conjugate, as disclosed herein, where the base pairing moieties Pi form a sequence effective to hybridize to a portion of the nucleic acid at a location effective to inhibit production of the protein. The oligomer may target, for example, an ATG start codon region of an mRNA, a splice site of a pre-mRNA, or a viral target sequence as described below.

In another embodiment, the disclosure provides a method of enhancing antisense activity of a peptide oligomer conjugate comprising an oligonucleotide analogue having a sequence of morpholino subunits, joined by intersubunit linkages, supporting base-pairing moieties, the method comprises conjugating a carrier peptide as described herein to the oligonucleotide.

In some embodiments, enhancement of antisense activity may be evidenced by:

(i) a decrease in expression of an encoded protein, relative to that provided by a corresponding unmodified oligomer, when binding of the antisense oligomer to its target sequence is effective to block a translation start codon for the encoded protein, or (ii) an increase in expression of an encoded protein, relative to that provided by a corresponding unmodified oligomer, when binding of the antisense oligomer to its target sequence is effective to block an aberrant splice site in a pre-mRNA which encodes said protein when correctly spliced. Assays suitable for measurement of these effects are described further below. In one embodiment, modification provides this activity in a cell-free translation assay, a splice correction translation assay in cell culture, or a splice correction gain of function animal model system as described herein. In one embodiment, activity is enhanced by a factor of at least two, at least five or at least ten.

Described below are various exemplary applications of the conjugates of the invention including antiviral applications, treatment of neuromuscular diseases, bacterial infections, inflammation and polycystic kidney disease. This description is

103

2019204913 09 Jul 2019 not meant to limit the invention in any way but serves to exemplify the range of human and animal disease conditions that can be addressed using the conjugates described herein.

G. Exemplary Therapeutic Uses of the Conjugates

The oligomers conjugated to the carrier peptide comprise good efficacy and low toxicity, thus resulting in a better therepuetic window than obtained with other oligomers or peptide-oligomer conjugates. The following description provides exemplary, but not limiting, example of therapeutic uses of the conjugates.

1. Targeting Stem-Loop Secondary Structure of ssRNA Viruses

One class of an exemplary antisense antiviral compound is a morpholino oligomer as described herein having a sequence of 12-40 subunits and a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5'-terminal end 40 bases of the positive-sense RNA strand of the targeted virus. (See, e.g., PCT Pubn. No. WO/2006/033933 or U.S. Appn. Pubn. Nos.

20060269911 and 20050096291, which are incorporated herein by reference.)

The method comprises first identifying as a viral target sequence, a region within the 5'-terminal 40 bases of the positive strand of the infecting virus whose sequence is capable of forming internal stem-loop secondary structure. There is then constructed, by stepwise solid-phase synthesis, a morpholino oligomer having a 20 targeting sequence of at least 12 subunits that is complementary to the virus-genome region capable of forming internal duplex structure, where the oligomer is able to form with the viral target sequence, a heteroduplex structure composed of the positive sense strand of the virus and the oligonucleotide compound, and characterized by a Tm of dissociation of at least 45°C and disruption of such stem-loop structure. The oligomer 25 is conjugated to a carrier peptide described herein.

The target sequence may be identified by analyzing the 5'-terminal sequences, e.g., the 5'-terminal 40 bases, by a computer program capable of performing secondary structure predictions based on a search for the minimal free energy state of the input RNA sequence.

104

2019204913 09 Jul 2019

In a related aspect, the conjugates can be used in methods of inhibiting in a mammalian host cell, replication of an infecting RNA virus having a single-stranded, positive-sense genome and selected from one of the Flaviviridae, Picomoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae or Hepeviridae 5 families. The method includes administering to the infected host cells, a virusinhibitory amount of conjugate as described herein, having a targeting sequence of at least 12 subunits that is complementary to a region within the 5'-terminal 40 bases of the positive-strand viral genome that is capable of forming internal stem-loop secondary structure. The conjugate is effective, when administered to the host cells, to form a 10 heteroduplex structure (i) composed of the positive sense strand of the virus and the oligonucleotide compound, and (ii) characterized by a Tm of dissociation of at least 45°C and disruption of such stem-loop secondary structure. The conjugate may be administered to a mammalian subject infected with the virus, or at risk of infection with the virus.

Exemplary targeting sequences that target the terminal stem loop structures of the dengue and Japanese encephalitis viruses are listed below as SEQ ID NOs: 1 and 2, respectively.

Additional exemplary targeting sequences that target the terminal stem loop structures of ssRNA viruses can also be found in US Appn. Num. 11/801,885 and 20 PCT publication WO/2008/036127 which are incorporated herein by reference.

2. Targeting the First Open Reading Frame of ssRNA Viruses

A second class of exemplary conjugates is for use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus, coronavirus, and flavivirus families having a single-stranded, positive sense genome of less than 12 kb and a first open 25 reading frame that encodes a polyprotein containing multiple functional proteins. In particular embodiments, the virus is an RNA virus from the coronavirus family or a West Nile, Yellow Fever or Dengue virus from the flavivirus family. The inhibiting conjugates comprise antisense oligomers described herein, having a targeting base sequence that is substantially complementary to a viral target sequence which spans the 30 AUG start site of the first open reading frame of the viral genome. In one embodiment of the method, the conjugate is administered to a mammalian subject infected with the

105

2019204913 09 Jul 2019 virus. See, e.g., PCT Pubn. No. WO/2005/007805 and US Appn. Pubn. No. 2003224353, which are incorporated herein by reference.

The preferred target sequence is a region that spans the AUG start site of the first open reading frame (ORF1) of the viral genome. The first ORF generally 5 encodes a polyprotein containing non-structural proteins such as polymerases, helicases and proteases. By spans the AUG start site is meant that the target sequence includes at least three bases on one side of the AUG start site and at least two bases on the other (a total of at least 8 bases). Preferably, it includes at least four bases on each side of the start site (a total of at least 11 bases).

More generally, preferred target sites include targets that are conserved between a variety of viral isolates. Other favored sites include the IRES (internal ribosome entry site), transactivation protein binding sites, and sites of initiation of replication. Complex and large viral genomes, which may provide multiple redundant genes, may be efficiently targeted by targeting host cellular genes coding for viral entry and host response to viral presence.

A variety of viral-genome sequences are available from well known sources, such as the NCBI Genbank databases. The AUG start site of ORF1 may also be identified in the gene database or reference relied upon, or it may be found by scanning the sequence for an AUG codon in the region of the expected ORF1 start site.

The general genomic organization of each of the four virus families is given below, followed by exemplary target sequences obtained for selected members (genera, species or strains) within each family.

3. Targeting Influenza Virus

A third class of exemplary conjugates are used in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. In one embodiment, the host cell is contacted with a conjugate as described herein, for example a conjugate comprising a base sequence effective to hybridize to a target region selected from the following: 1) the 5’ or 3’ terminal 25 bases of the negative sense viral RNA segments; 2) the terminal 25 bases of the 5’ or 3’ terminus of the positive sense cRNA; 3) 45 bases surrounding the AUG start codons of influenza viral mRNAs and; 4) 50 bases surrounding the splice donor or acceptor sites of influenza

106

2019204913 09 Jul 2019 mRNAs subject to alternative splicing. (See, e.g., PCT Pubn. No. WO/2006/047683;

U.S. Appn. Pubn. No. 20070004661; and PCT Appn. Num. 2010/056613 and US Appn. No. 12/945,081, which are incorporated herein by reference.)

Exemplary conjugates in this regard include conjugates comprising 5 oligomers comprising SEQ ID NO:3.

Table 4, Influenza targeting sequences that incorporate modified intersubunit linkages or terminal groups

NG-10-0038	PMOhex	CGG ThTA GAA GAC hTCA TChT TT
NG-10-0039	PMOhex	CGG ThTA GAA GAC hTCA hTCT hTT
NG-10-0096	PMOapn	CGG TaTA GAA GAC aTCA TCaT TT
NG-10-0097	PMOapn	CGG aTaTA GAA GAC aTCA aTCaT TT
NG-10-0099	PMOpyr	CGG PTPTA GAA GAC PTCA pTCpT TT
NG-10-0107	PMOthiol	CGG TSHTA GAA GAC SHTCA TCSHT TT
NG-10-0108	PMOsucc	CGG TSTA GAA GAC STCA TCST TT
NG-10-0111	PMOguan	CGG TgTA GAA GAC gTCA TCgT TT
NG-10-0141	PMOpyr	CGG TpTA GAA GAC PTCA TCPT TT
NG-10-0142	PMOpyr	CGG TpTA GAA GAC PTCA PTCPT TT
NG-10-0158	PMOglutaric	CGG TgluTA GAA GAC gluTCA TCgluT TT
NG-10-0159	PMOcyclo-glut	CGG TcpgluTA GAA GAC cP9luTCA TCcpgluT TT
NG-10-0160	PMOcholic acid	CGG TcaTA GAA GAC caTCA TCcaT TT
NG-10-0161	PMOdeoxyCA	CGG TdcaTA GAA GAC dcaTCA TCdcaT TT
NG-10-0180	PMOapn	TTaT CGA CAaT CGG TaTA GAA GAC aTCA T
NG-10-0174	PMOm	CGG TmTA GAA GAC mTCA TCmT TT
NG-10-0222	PMO MeT	CGG TMeTA GAA GAC +TCA TC+T TT
NG-10-0223	PMO FarnT	CGG TFarnTA GAA GAC +TCA TC+T TT
NG-10-0538	PMOapn-trityl	CGG TaTA GAA GAC aTCA TCaT TT
NG-10-0539	PMOapn-trityl	CGG TpTA GAA GAC PTCA TCPT TT
NG-10-0015	PMO	CGG TTA GAA GAC TCA TCT TT
NG-11-0170	PMOplus	CGG +TTA GAA GAC +TCA TC+T TT
NG-11-0145	PMOplusbenzhydryl	CGG T+TA GAA GAC +TCA TC+T TT**
NG-11-0148	PMOisopropylPip	CGG TiprpipTA GAA GAC iprpipTCA TCiprpipT TT
NG-11-0173	PMOpyr	CGG pTTA GAA GAC pTCA TCpT TT
NG-11-0291	Trimethyl Gly	CGG T*+TA GAA GAC *+TCA TC*+T TT

107

2019204913 09 Jul 2019 **3’-benzhydryl; *+ linkages are trimethyl glycine acylated at the PMOplus linkages; PMOm represents T bases with a methyl group on the 3-nitrogen position.

The conjugate s are particularly useful in the treatment of influenza virus infection in a mammal. The o conjugate may be administered to a mammalian subject 5 infected with the influenza virus, or at risk of infection with the influenza virus.

4. Targeting Viruses of the Picomaviridae family

A fourth class of exemplary conjugates are used in inhibition of growth of viruses of the Picomaviridae family and in the treatment of a viral infection. The conjugates are particularly useful in the treatment of Enterovirus and/or Rhinovirus 10 infection in a mammal. In this embodiment, the conjugates comprise morpholino oligomers having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within one of two 32 conserved nucleotide regions of the viral 5' untranslated region. (See, e.g., PCT Pubn. Nos. WO/2007/030576 and WO/2007/030691 or 15 copending and co-owned US Appn. Nums. 11/518,058 and 11/517,757, which are incorporated herein by reference.) An exemplary targeting sequence is listed below as SEQ NO: 6.

5. Targeting Viruses of the Flavivirus family

A fifth class of exemplary conjugates are used in inhibition of replication 20 of a flavivirus in animal cells. An exemplary conjugate of this class comprises a morpholino oligomer of between 8-40 nucleotide bases in length and having a sequence of at least 8 bases complementary to a region of the vims' positive strand RNA genome that includes at least a portion of the 5’-cyclization sequence (5'-CS) or 3’-CS sequences of the positive strand flaviviral RNA. A highly preferred target is the 3'-CS 25 and an exemplary targeting sequence for dengue vims is listed below as SEQ ID NO: 7. (See, e.g., PCT Pubn. No. (WO/2005/030800) or copending and co-owned US Appn. Num. 10/913,996, which are incorporated herein by reference.)

108

2019204913 09 Jul 2019

6. Targeting Viruses of the Nidovirus family

A sixth class of exemplary conjugates are used in inhibition of replication of a nidovirus in virus-infected animal cells. An exemplary conjugate of this class comprises a morpholino oligomer containing between 8-25 nucleotide bases, and 5 having a sequence capable of disrupting base pairing between the transcriptional regulatory sequences (TRS) in the 5' leader region of the positive-strand viral genome and negative-strand 3' subgenomic region (See, e.g., PCT Pubn. No. WO/2005/065268 or U.S. Appn. Pubn. No. 20070037763, which are incorporated herein by reference.)

7. Targeting of Filoviruses

In another embodiment, one or more conjugates as described herein can be used in a method of in inhibiting replication within a host cell of an Ebola virus or Marburg virus, by contacting the cell with a conjugate as described herein, for example a conjugate having a targeting base sequence that is complementary to a target sequence composed of at least 12 contiguous bases within an AUG start-site region of a positive15 strand mRNA, as described further below.

The filovirus viral genome is approximately 19,000 bases of singlestranded RNA that is unsegmented and in the antisense orientation. The genome encodes 7 proteins from monocistronic mRNAs complementary to the vRNA.

Target sequences are positive-strand (sense) RNA sequences that span or are just downstream (within 25 bases) or upstream (within 100 bases) of the AUG start codon of selected Ebola virus proteins or the 3' terminal 30 bases of the minus-strand viral RNA. Preferred protein targets are the viral polymerase subunits VP35 and VP24, although L, nucleoproteins NP and VP30, are also contemplated. Among these early proteins are favored, e.g., VP35 is favored over the later expressed L polymerase.

In another embodiment, one or more conjugates as described herein can be used in a method of in inhibiting replication within a host cell of an Ebola virus or Marburg virus, by contacting the cell with a conjugate as described herein having a targeting base sequence that is complementary to a target sequence composed of at least 12 contiguous bases within an AUG start-site region of a positive-strand mRNA of the

Filovirus mRNA sequences. (See, e.g., PCT Pubn. No. WO/2006/050414 or U.S. Patent Nos. 7,524,829 and 7,507,196, and continuation applications with US Apn. Nos:

109

2019204913 09 Jul 2019

12/402,455; 12/402,461; 12/402,464; and 12/853,180 which are incorporated herein by reference.)

8. Targeting of Arenaviruses

In another embodiment, a conjugate as described herein can be used in a method for inhibiting viral infection in mammalian cells by a species in the Arenaviridae family. In one aspect, the conjugates can be used in treating a mammalian subject infected with the virus. (See, e.g., PCT Pubn. No. WO/2007/103529 or U.S. Patent No. 7,582,615, which are incorporated herein by reference.)

Table 5 is an exemplary list of targeted viruses targeted by conjugates of the invention as organized by their Old World or New World Arenavirus classification.

Table 5. Targeted Arenaviruses

Family	Genus	Virus
Arenaviridae	Arenavirus	Old World Arenaviruses
		Lassa virus (LASV)
		Lymphocytic choriomeningitis virus (LCMV)
		Mopeia virus (MOPV)
		New World Arenaviruses
		Guanarito virus (GTOV)
		Junin virus (JUNV)
		Machupo virus (MACV)
		Pichinide virus (PICV)
		Pirital virus (PIRV)
		Sabia virus (SABV)
		Tacaribe virus (TCRV)
		Whitewater Arroyo virus (WWAV)

The genome of Arenaviruses consists of two single-stranded RNA segments designated S (small) and L (large). In virions, the molar ratio of S- to L15 segment RNAs is roughly 2:1. The complete S-segment RNA sequence has been determined for several arenaviruses and ranges from 3,366 to 3,535 nucleotides. The complete L-segment RNA sequence has also been determined for several arenaviruses and ranges from 7,102 to 7,279 nucleotides. The 3' terminal sequences of the S and L

110

2019204913 09 Jul 2019

RNA segments are identical at 17 of the last 19 nucleotides. These terminal sequences are conserved among all known arenaviruses. The 5'-terminal 19 or 20 nucleotides at the beginning of each genomic RNA are imperfectly complementary with each corresponding 3' end. Because of this complementarity, the 3' and 5' termini are 5 thought to base-pair and form panhandle structures.

Replication of the infecting virion or viral RNA (vRNA) to form an antigenomic, viral-complementary RNA (vcRNA) strand occurs in the infected cell. Both the vRNA and vcRNA encode complementary mRNAs; accordingly, Arenaviruses are classified as ambisense RNA viruses, rather than negative- or positive10 sense RNA viruses. The ambisense orientation of viral genes are on both the L- and Ssegments. The NP and polymerase genes reside at the 3' end of the S and L vRNA segments, respectively, and are encoded in the conventional negative sense (i.e., they are expressed through transcription of vRNA or genome-complementary mRNAs). The genes located at the 5' end of the S and L vRNA segments, GPC and Z, respectively, 15 are encoded in mRNA sense but there is no evidence that they are translated directly from genomic vRNA. These genes are expressed instead through transcription of genomic-sense mRNAs from antigenomes (i.e., the vcRNA), full-length complementary copies of genomic vRNAs that function as replicative intermediates.

An exemplary targeting sequence for the arenavirus family of viruses is 20 listed below as SEQ ID NO: 8.

9. Targeting of Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is the single most important respiratory pathogen in young children. RSV-caused lower respiratory conditions, such as bronchiolitis and pneumonia, often require hospitalization in children less than one25 year-old. Children with cardiopulmonary diseases and those born prematurely are especially prone to experience severe disorders from this infection. RSV infection is also an important illness in elderly and high-risk adults, and it is the second-most commonly identified cause of viral pneumonia in older persons (Falsey, Hennessey et al. 2005). The World Health Organization estimates that RSV is responsible for 64 30 million clinical infections and 160 thousand deaths annually worldwide. No vaccines are currently available for the prevention of RSV infection. Although many major

111

2019204913 09 Jul 2019 advances in our understanding of RSV biology, epidemiology, pathophysiology, and host-immune-response have occurred over the past few decades, there continues to be considerable controversy regarding the optimum management of infants and children with RSV infection. Ribavirin is the only licensed antiviral drug for treating RSV 5 infection, but its use is limited to high-risk or severely-ill infants. The utility of

Ribavirin has been limited by its cost, variable efficacy, and tendency to generate resistant viruses (Marquardt 1995; Prince 2001). The current need for additional effective anti-RSV agents is well-acknowledged.

It is known that peptide conjugated PMO (PPMO) can be effective in inhibiting RSV both in tissue culture and in an in vivo animal model system (Lai, Stein et al. 2008). Two antisense PPMOs, designed to target the sequence that includes the 5'-terminal region and translation start-site region of RSV L mRNA, were tested for anti-RSV activity in cultures of two human airway cell lines. One of them, (RSVAUG-2; SEQ ID NO 10), reduced viral titers by >2.0 logio. Intranasal (i.n.) treatment of BALB/c mice with RSV-AUG-2 PPMO before the RSV inoculation produced a reduction in viral titer of 1.2 logio in lung tissue at day 5 postinfection (p.i.), and attenuated pulmonary inflammation at day 7 postinfection. These data showed that RSV-AUG-2 provided potent anti-RSV activity worthy of further investigation as a candidate for potential therapeutic application (Lai, Stein et al. 2008). Despite the success with RSV-AUG-2 PPMO as described above, it is desirable to use conjugates as disclosed herein to address toxicity associated with previous peptide conjugates. Therefore, in another embodiment of the present invention, one or more conjugates as described herein can be used in a method of inhibiting replication within a host cell of RSV, by contacting the cell with a conjugate as described herein, for example a conjugate having a targeting base sequence that is complementary to a target sequence composed of at least 12 contiguous bases within an AUG start-site region of anmRNA from RSV, as described further below.

The L gene of RSV codes for a critical component of the viral RNA dependent RNA polymerase complex. Antisense PPMO designed against the sequence 30 spanning the AUG translation start-site codon of the RSV L gene mRNA in the form of

RSV-AUG-2 PPMO is complementary to sequence from the ‘gene-start’ sequence (GS) present at the 5’ terminus of the L mRNA to 13 nt into the coding sequence. A

112

2019204913 09 Jul 2019 preferred L gene targeting sequence is therefore complementary to any 12 contiguous bases from the 5’ end of the L gene mRNA extending 40 bases in the 3’ direction or 22 bases into the L gene coding sequence as shown below in Table 6 as SEQ ID NO: 9. Exemplary RSV L gene targeting sequences are listed below in Table 6 as SEQ ID

NOs: 10-14. Any of the intersubunit modifications of the invention described herein can be incorporated in the oligomers to provide increased antisense activity, improved intracellular delivery and/or tissue specificity for improved therapeutic activity. Exemplary oligomers sequences containing intersubunit linkages of the invention are listed below in Table 6.

Table 6. RSV target and targeting sequences

Name	Sequence (5’ to 3’)	SEQ ID NO
L target	GGGACAAAATGGATCCCATTATTAATGGAAATTCTGCTAA	9
RSV-AUG-2	TAATGGGATCCATTTTGTCCC	10
RSV-AUG3	AATAATGGGATCCATTTTGTCCC	11
RSV-AUG4	CATTAATAATGGGATCCATTTTGTCCC	12
RSV-AUG5	GAATTTCCATTAATAATGGGATCCATTTTG	13
RSV-AUG6	CAGAATTTCCATTAATAATGGGATCCATT	14
RSV- AUG3apn*	AATAAaPnTGGGAaPnTCCAaPnTTaPnTTGapnTCCC	11
RSV- AUG3guan	AATAAguanTGGGAguanTCCAguanTTguanTTGguanTCCC	11

10. Neuromuscular Diseases

In another embodiment, a therapeutic conjugate is provided for use in treating a disease condition associated with a neuromuscular disease in a mammalian subject. Antisense oligomers (e.g., SEQ ID NO: 16) have been shown to have activity 15 in the MDX mouse model for Duchene Muscular Dystrophy (DMD). Exemplary oligomer sequences that incorporate the linkages used in some embodiments are listed below in Table 7. In some embodiments, the conjugates comprise an oligomer selected from:

(a) an antisense oligomer targeted against human myostatin, 20 having a base sequence complementary to at least 12 contiguous bases in a target region

113

2019204913 09 Jul 2019 of the human myostatin mRNA identified by SEQ ID NO: 18, for treating a muscle wasting condition, as described previously (See, e.g., U.S. Patent Apn. No. 12/493,140, which is incorporated herein by reference; and PCT publication W02006/086667). Exemplary murine targeting sequences are listed as SEQ ID NOs: 19-20; and (b) an antisense oligomer capable of producing exon skipping in the DMD protein (dystrophin), such as a PMO having a sequence selected from SEQ ID NOs: 22 to 35, to restore partial activity of the dystrophin protein, for treating DMD, as described previously (See, e.g., PCT Pubn. Nos. WO/2010/048586 and WO/2006/000057 or U.S. Patent Publication No. US09/061960 all of which are incorporated herein by reference).

Several other neuromuscular diseases can be treated using the modified linkages and terminal groups of the present invention. Exemplary compounds for treating spinal muscle atrophy (SMA) and myotonic dystrophy (DM) are discussed below.

SMA is an autosomal recessive disease caused by chronic loss of alphamotor neurons in the spinal cord and can affect both children and adults. Reduced expression of survival motor neuron (SMN) is responsible for the disease (Hua, Sahashi et al. 2010). Mutations that cause SMA are located in the SMN1 gene but a paralogous gene, SMN2, can allow viability by compensating for loss of SMN1 if expressed from 20 an alternative splice form lacking exon 7 (delta7 SMN2). Antisense compounds targeted to inton 6, exon 7 and intron 7 have all been shown to induce exon 7 inclusion to varying degrees. Antisense compounds targeted to intron 7 are preferred (see e.g., PCT Publication Nos. WO/2010/148249, WO/2010/120820, WO/2007/002390 and US Patent No. 7838657). Exemplary antisense sequences that target the SMN2 pre-mRNA 25 and induce improved exon 7 inclusion are listed below as SEQ ID NOs: 36-38. It is contemplated that selected modifications of these oligomer sequences using the modified linkages and terminal groups described herein would have improved properties compared to those known in the art. Furthermore, it is contemplated that any oligomer targeted to intron 7 of the SMN2 gene and incorporating the features of the 30 present invention has the potential to induce exon 7 inclusion and provide a therapeutic benefit to SMA patients.Myotonic Dystrophy type 1 (DM1) and type 2 (DM2) are dominantly inherited disorders caused by expression of a toxic RNA leading to

114

2019204913 09 Jul 2019 neuromuscular degeneration. DM1 and DM2 are associated with long polyCUG and polyCCUG repeats in the 3’-UTR and intron 1 regions of the transcript dystrophia myotonica protein kinase (DMPK) and zinc finger protein 9 (ZNF9), respectively (see e.g., W02008/036406). While normal individuals have as many as 30 CTG repeats, 5 DM1 patients carry a larger number of repeats ranging from 50 to thousands. The severity of the disease and the age of onset correlates with the number of repeats. Patients with adult onsets show milder symptoms and have less than 100 repeats, juvenile onset DM1 patients carry as many as 500 repeats and congenital cases usually have around a thousand CTG repeats. The expanded transcripts containing CUG repeats 10 form a secondary structure, accumulate in the nucleus in the form of nuclear foci and sequester RNA-binding proteins (RNA-BP). Several RNA-BP have been implicated in the disease, including muscleblind-like (MBNL) proteins and CUG-binding protein (CUGBP). MBNL proteins are homologous to Drosophila muscleblind (Mbl) proteins necessary for photoreceptor and muscle differentiation. MBNL and CUGBP have been 15 identified as antagonistic splicing regulators of transcripts affected in DM1 such as cardiac troponin T (cTNT), insulin receptor (IR) and muscle-specific chloride channel (C1C-1).

It is known in the art that antisense oligonucleotides targeted to the expanded repeats of the DMPK gene can displace RNA-BP sequestration and reverse 20 myotonia symptoms in an animal model of DM1 (W02008/036406). It is contemplated that oligomers incorporating features of the present invention would provide improved activity and therapeutic potential for DM1 and DM2 patients. Exemplary sequences targeted to the polyCUG and polyCCUG repeats described above are listed below as SEQ ID NOs: 39-55 and further described in US Appn. No. 13/101,942 which is 25 incorporated herein in its entirety.

Additional embodiments of the present invention for treating neuralmuscular disorders are anticipated and include oligomers designed to treat other DNA repeat instability genetic disorders. These diseases include Huntington’s disease, spino-cerebellar ataxia, X-linked spinal and bulbar muscular atrophy and 30 spinocerebellar ataxia type 10 (SCAIO) as described in W02008/018795.

115

2019204913 09 Jul 2019

Table 7. M23D sequences (SEQ ID NO: 15) that incorporate modified intersubunit linkages and/or 3’ and/or 5’ terminal groups

NG	PMO-X Modification	51	Sequence	31
NG100383	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	triphenylacetyl
NG100325	triphenylphos	OH	GGC CAA ACC FCG GCF TAC CFG AAA T	triphenylphos
NG100272	PMO-famesyl	OH	GGC CAA ACC TCG GCT TAC CTG AAA T	farnesyl
NG100102	PMO	OH	GGC CAA ACC TCG GCT TAC CTG AAA T	trityl
NG100330	trimethoxybenz oyl	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	trimethoxybenzoyl
NG100056	PMOplus 5 '-pol	EG3	GGC C+A+A +ACC TCG GCT TAC CTG AAA T	H
NG070064	PMO-3'-trityl	H- Pip	GGC CAA ACC TCG GCT TAC CTG AAA T	trityl
NG100382	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	triphenylpropionyl
NG100278	PMOpyr	EG3	GGC CAA ACC pTCG GCpT pTACCpTGAAApT	H
NG100210	PMOapn	EG3	GGC CaAaA aACC TCG GCT TAC CTG AAA T	H
NG100098	PMOpyr	EG3	GGC CAA ACC PTCG GCPT TAC CpTG AAA T	H
NG100070	PMOapn	EG3	GGC CAA ACC aTCG GCaT TAC CaTG AAA aT	H
NG100095	PMOapn	EG3	GGC CAA ACC aTCG GCaT aTAC CaT G AAA aT	H
NG100317	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	farnesyl
NG-	PMO triMe Gly	EG3	GGC CAA ACC FCG GCF	trimethyl Glycine

116

2019204913 09 Jul 2019

NG	PMO-X Modification	51	Sequence	31
100477			TAC CFG AAA F
NG100133	PMOapn	OH	GGC CaAA aACC TCG GCT TAC CTG AAA aT	H
NG100387	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	2-OH, diphenylacet
NG100104	PMOguan	EG3	GGC CAA ACC TCG GCT TAC CgT G AAA T	C8
NG100420	PMOplus methyl	EG3	GGC CAA ACC m+TCG GCm+T TAC Cm+TG AAA in+T	Trityl
NG100065	PMOtri	EG3	GGC CAA ACC ‘TCG GC‘T TAC CT G AAA T	H
NG100607	PMO-X	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	9-fluorenecarboxyl
NG100060	PMOcp	EG3	GGC CAA ACC cpTCG GCcpT TAC CcpT G AAA T	H
NG100162	PMO- COCH2SH	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	COCH2SH
NG100328	diphenylacetyl	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	diphenylacetyl
NG100134	PMOapnPMOtri	OH	GGC CaAA aACC ‘TCG GCT ‘TAC C‘TG AAA ‘T	H
NG100386	PMO	DPA	GGC CAA ACC TCG GCT TAC CTG AAA T	5'-diphenylac,3'- trity
NG070064	PMO-3'-trityl	H- Pip	GGC CAA ACC TCG GCT TAC CTG AAA T	trityl
NG100059	PMOcp	EG3	GGC CAA ACC cpTCG GCepT epTAC CepT Q AAA cpy	H
NG100135	PMOtri	OH	GGC CAA ACC ‘TCG GC‘T ‘TAC CTG AAA ‘T	H
NG100168	PMOapn PMOcys	OH	GGC CAA ACC TCG GCT TAC CTG AAA SHcT	H

117

2019204913 09 Jul 2019

NG	PMO-X Modification	&	Sequence	31
NG100113	PMOapnPMOtri	OH	GGC CAA ACC aTCG GCT ‘TAC CTG AAA aT	H
NG100385	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	diphenylphosphor yi
NG100279	PMO	OH	GGC CAA ACC TCG GCT TAC CTG AAA T	geranyl
NG100055	PMOplus disp	EG3	GGC C+AA +ACC +TCG GCT TAC C+TG AAA T	H
NG100105	PMOsucc	EG3	GGC CAA ACC STCG GGT TAC CST G AAA T	Cs
NG100805	PMO-X	EG3	GGC CAA ACC e‘p!ptCG GCEtpipT TAC CEtpipTG AAA Etpip^	H
NG100811	PMO-X	EG3	GGC CAA ACC p>r(JMeTCG QQpyrQMey '|7\Q' QPyrQMeyQ AAA pyQMeT	H
NG100057	PMOplus 3'-pol	EG3	GGC CAA ACC TCG GCT TAC C+TG +A+A+A T	H
NG100625	PMO-X	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	5- carboxyfluorescein
NG100804	dimer	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	dimerized
NG100066	PMOtri	EG3	GGC CAA ACC ‘TCG GCT TAC C‘T G AAA ‘T	H
NG100280	PMO disulfide	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	COCHiCHiSSPy
NG100212	PMOapn	EG3	GGC CaAaA aACC aTCG GCaT aTaAC CaTG aAaAaA aT	H
NG100156	3'-MeOtrityl	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	MeO-Tr
NG100062	PMOhex	EG3	GGC CAA ACC hTCG GChT TAC ChT G AAA hT	H
NG- 11-	PMO-X	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	guanidinyl

118

2019204913 09 Jul 2019

NG	PMO-X Modification	51	Sequence	31
0043
NG100206	PMOplus	EG3	GGC C+A+A +ACC +TCG GC+T +T+AC C+TG +A+A+A +T	H
NG100383	PMO	EG3	GGC CAA ACC TCG GCT TAC CTG AAA T	triphenylacetyl
NG100325	triphenylphos	OH	GGC CAA ACC FCG GCF TAC CFG AAA T	triphenylphos
NG100272	PMO-famesyl	OH	GGC CAA ACC TCG GCT TAC CTG AAA T	farnesyl

^Dimerized indicates the oligomer is dimerized by a linkage linking the 3 ’ ends of the two monomers. For example, the linkage may be -COCH2CH2-S-CH(CONH2)CH2-CO-NHCH2CH₂CO- or any other suitable linkage. EG3 refers to a triethylene glycol tail (see e.g., conjugates in examples 30 and 31).

11. Antibacterial Applications

The invention includes, in another embodiment, a conjugate comprising an antibacterial antisense oilgomer for use in treating a bacterial infection in a mammalian host. In some embodiments, the oligomer comprises between 10-20 bases and a targeting sequence of at least 10 contiguous bases complementary to a target 10 region of the infecting bacteria’s mRNA for acyl carrier protein (acpP), gyrase A subunit (gyrA), ftsZ, ribosomal protein S10 (rpsJ), leuD, mgtC, pirG, pcaA, and cmal genes, where the target region contains the translational start codon of the bacterial mRNA, or a sequence that is within 20 bases, in an upstream (i.e., 5’) or downstream (i.e., 3’) direction, of the translational start codon, and where the oligomer binds to the 15 mRNA to form a heteroduplex thereby to inhibit replication of the bacteria.

12, Modulating Nuclear Hormone Receptors

In another embodiment the present invention relates to compositions and methods for modulating expression of nuclear hormone receptors (NHR) from the nuclear hormone receptor superfamily (NHRSF), mainly by controlling or altering the 20 splicing of pre-mRNA that codes for the receptors. Examples of particular NHRs include glucocorticoid receptor (GR), progesterone receptor (PR) and androgen receptor

119

2019204913 09 Jul 2019 (AR). In certain embodiments, the conjugates described herein lead to increased expression of ligand-independent or other selected forms of the receptors, and decreased expression of their inactive forms.

Embodiments of the present invention include conjugates comprising oligomers, for example oligomers that are complementary to selected exonic or intronic sequences of anNHR, including the “ligand-binding exons” and/or adjacent introns of a NHRSF pre-mRNA, among other NHR-domains described herein. The term “ligandbinding exons” refers to exon(s) that are present in the wild-type mRNA but are removed from the primary transcript (the “pre-mRNA”) to make a ligand-independent 10 form of the mRNA. In certain embodiments, complementarity can be based on sequences in the sequence of pre-mRNA that spans a splice site, which includes, but is not limited to, complementarity based on sequences that span an exon-intron junction. In other embodiments, complementarity can be based solely on the sequence of the intron. In other embodiments, complementarity can be based solely on the sequence of 15 the exon. (See, e.g., US Appn. Num. 13/046,356, which is incorporated herein by reference.)

NHR modulators may be useful in treating NHR-associated diseases, including diseases associated with the expression products of genes whose transcription is stimulated or repressed by NHRs. For instance, modulators of NHRs that inhibit AP20 1 and/or NF-κΒ can be useful in the treatment of inflammatory and immune diseases and disorders such as osteoarthritis, rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, transplant rejection, and graft vs. host disease, among others described herein and known in the art. Compounds that antagonize transactivation can be useful in treating metabolic diseases associated with increased 25 levels of glucocorticoid, such as diabetes, osteoporosis and glaucoma, among others. Also, compounds that agonize transactivation can be useful in treating metabolic diseases associated with a deficiency in glucocorticoid, such as Addison’s disease and others.

Embodiments of the present invention include methods of modulating nuclear NHR activity or expression in a cell, comprising contacting the cell with a conjugate comprising the carrier protein and an antisense oligomer composed of morpholino subunits linked by phosphorus-containing intersubunit linkages joining a

120

2019204913 09 Jul 2019 morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, wherein the oligonucleotide contains between 10-40 bases and a targeting sequence of at least 10 contiguous bases complementary to a target sequence, wherein the target sequence is a pre-mRNA transcript of the NHR, thereby modulating activity or 5 expression of the NHR. In certain embodiments, the oligomer alters splicing ofthe premRNA transcript and increases expression of a variant of the NHR. In some embodiments, the oligomer induces full or partial exon-skipping of one or more exons of the pre-mRNA transcript. In certain embodiments, the one or more exons encode at least a portion of a ligand-binding domain of the NHR, and the variant is a ligand 10 independent form of the NHR. In certain embodiments, the one or more exons encode at least a portion of a transactivation domain of the NHR, and the variant has reduced transcriptional activation activity. In certain embodiments, the one or more exons encode at least a portion of a DNA-binding domain of the NHR. In certain embodiments, the one or more exons encode at least a portion of an N-terminal 15 activation domain of the NHR. In certain embodiments, the one or more exons encode at least a portion of a carboxy-terminal domain of the NHR. In specific embodiments, the variant binds to NF-KB, AP-1, or both, and reduces transcription of one or more of their pro-inflammatory target genes.

In certain embodiments, the oligomer agonizes a transactivational 20 transcriptional activity of the NHR. In other embodiments, the oligomer antagonizes a transactivational transcriptional activity of the NHR. In certain embodiments, the oligomer agonizes a transrepression activity of the NHR. In other embodiments, the oligomer antagonizes a transrepression activity of the NHR. In specific embodiments, the oligomer antagonizes a transactivational transcriptional activity of the NHR and 25 agonizes a transrepression activity of the NHR. (See, e.g., US Appn. Num. 61/313,652, which is incorporated herein by reference.)

121

2019204913 09 Jul 2019

EXAMPLES

Unless otherwise noted, all chemicals were obtained from SigmaAldrich-Fluka. Benzoyl adenosine, benzoyl cytidine, and phenylacetyl guanosine were obtained from Carbosynth Eimited, UK.

Synthesis of PMO, PMO+, PPMO and PMO containing further linkage modifications as described herein was done using methods known in the art and described in pending U.S. applications Nos. 12/271,036 and 12/271,040 and PCT publication number WO/2009/064471, which are hereby incorporated by reference in their entirety.

PMO with a 3’ trityl modification are synthesized essentially as described in PCT publication number WO/2009/064471 with the exception that the detritylation step is omitted.

EXAMPEE 1

ZE/fZ-BUTYL 4-(2,2,2-TRIFLUOROACETAMIDO)PIPERIDINE-1 -CARBOXYLATE

TFAHN—( NBoc

To a suspension of Ze/7-butyl 4-aminopiperidine-l-carboxylate (48.7 g, 0.243 mol) and DIPEA (130 mF, 0.749 mol) in DCM (250 mF) was added ethyl trifluoroacetate (35.6 mF, 0.300 mol) dropwise while stirring. After 20 hours, the solution was washed with citric acid solution (200 mF x 3, 10 % w/v aq) and sodium 20 bicarbonate solution (200 mF x 3, cone aq), dried (MgSCfi), and filtered through silica (24 g). The silica was washed with DCM and the combined eluant was partially concentrated (100 mF), and used directly in the next step. APCI/MS ealed. for C12H19F3N2O3 296.1, found m!z = 294.9 (M-l).

122

EXAMPLE 2

2019204913 09 Jul 2019

2,2,2-trifluoro-N-(piperidin-4-yl)acetamide hydrochloride

TFAHN

To a stirred DCM solution of the title compound of Example 1 (100 mL) was added dropwise a solution of hydrogen chloride (250 mL, 1.0 mol) in 1,4-dioxane (4 M). Stirring was continued for 6 hours, then the suspension was filtered, and the solid washed with diethyl ether (500 mL) to afford the title compound (54.2 g, 96% yield) as a white solid. APCI/MS calcd. for C7H11F3N2O 196.1, found m/z = 196.9 (M+l).

EXAMPLE 3 (4-(2,2,2-trifluoroacetamido)piperidin- 1 -yl)phosphonic dichloride

TFAHN

To a cooled (ice/water bath) suspension of the title compound of Example 2 (54.2 g, 0.233 mol) in DCM (250 mL) was added dropwise phosphorus oxychloride (23.9 mL, 0.256 mol) and DIPEA (121.7 mL, 0.699 mol) and stirred. After minutes, the bath was removed and with continued stirring the mixture allowed to warm to ambient temperature. After 1 hour, the mixture was partially concentrated (100 mL), the suspension filtered, and the solid washed with diethyl ether to afford the title compound (43.8 g, 60% yield) as a white solid. The elutant was partially 20 concentrated (100 mL), the resulting suspension filtered, and the solid washed with diethyl ether to afford additional title compound (6.5 g, 9% yield). ESEMS calcd. for l-(4-nitrophenyl)piperazine derivative C17H22CIF3N5O4P 483.1, found m/z = 482.1 (ΜΙ)·

123

EXAMPLE 4

2019204913 09 Jul 2019

TFAHN

((2S,6S)-6-((R)-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl)-4tritylmorpholin-2-yl)methyl (4-(2,2,2-trifluoroacetamido)piperidin- 1 yl)phosphonochloridate r° NH

Ν' “

CPh₃

To a stirred, cooled (ice/water bath) solution of the title compound of Example 3 (29.2 g, 93.3 mmol) in DCM (100 mL) was added dropwise over 10 minutes a DCM solution (100 mL) of Mo(Tr)T # (22.6 g, 46.7 mmol), 2,6-Lutidine (21.7 mL, 187 mmol), and 4-(dimethylamino)pyridine (1.14 g, 9.33 mmol). The bath was allowed 10 to warm to ambient temperature. After 15 hours, the solution was washed with a citric acid solution (200 mL x 3, 10 % w/v aq), dried (MgSCti), concentrated, and the crude oil was loaded directly onto column. Chromatography [S1O2 column (120 g), hexanes/EtOAc eluant (gradient 1:1 to 0:1), repeated x 3] fractions were concentrated to provide the title compound (27.2 g, 77% yield) as a white solid. ESI/MS calcd. for the 15 l-(4-nitrophenyl)piperazine derivative C46H50F3N8O8P 930.3, found m/z = 929.5 (M-l).

EXAMPLE 5 ((2S,6R)-6-(6-benzamido-9H-purin-9-yl)-4-tritylmorpholin-2-yl)methyl (4(2,2,2-trifluoroacetamido)piperidin- 1 -yl)phosphonochloridate

TFAHN

The title compound was synthesized in a manner analogous to that described in Example 4 to afford the title compound (15.4 g, 66% yield) as a white

124

2019204913 09 Jul 2019 solid. ESI/MS calcd. for l-(4-nitrophenyl)piperazine derivative C53H53F3N11O7P

1043.4, found m!z= 1042.5 (M-l).

EXAMPLE 6 (R)-methyl( 1 -phenylethyl)phosphoramidic dichloride

To a cooled (ice/water bath) solution of phosphorus oxychloride (2.83 mL, 30.3 mmol) in DCM (30 mL) was added sequentially, drop wise, and with stirring 2,6-lutidine (7.06 mL, 60.6 mmol) and a DCM solution of (R)-(+)-7V,adimethylbenzylamine (3.73 g, 27.6 mmol). After 5 minutes, the bath was removed and 10 reaction mixture allowed to warm to ambient temperature. After 1 hour, the reaction solution was washed with a citric acid solution (50 mL x 3, 10 % w/v aq), dried (MgSCU), filtered through S1O2 and concentrated to provide the title compound (3.80 g) as a white foam. ESI/MS calcd. for l-(4-nitrophenyl)piperazine derivative C19H25N4O4P

404.2, found m!z= 403.1 (M-l).

EXAMPLE 7 (S)-METHYL( 1 -phenylethyl)phosphoramidic dichloride

The title compound was synthesized in a manner analogous to that described in Example 6 to afford the title compound (3.95 g) as a white foam. ESI/MS 20 calcd. for l-(4-nitrophenyl)piperazine derivative C19H25N4O4P 404.2, found mJz = 403.1 (M-l).

125

EXAMPLE 8

2019204913 09 Jul 2019 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl methyl((R)- 1 phenylethyl)phosphoramidochloridate

The title compound was synthesized in a manner analogous to that described in Example 4 to afford the title chlorophosphoroamidate (4.46 g, 28% yield) as a white solid. ESI/MS calcd. for C38H4OCIN4O5P 698.2, found m/z = 697.3 (M-l). EXAMPLE 9 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl methyl((S)-1phenylethyl)phosphoramidochloridate

The title compound was synthesized in a manner analogous to that described in Example 4 to afford the title chlorophosphoroamidate (4.65 g, 23% yield) as a white solid. ESI/MS calcd. for C38H4OCIN4O5P 698.2, found mlz = 697.3 (M-l).

126

EXAMPLE 10

2019204913 09 Jul 2019 (4-(PYRROLIDIN-1 -YL)PIPERIDIN-1 -YL)PHOSPHONIC DICHLORIDE HYDROCHLORIDE

To a cooled (ice/water bath) solution of phosphorus oxychloride (5.70 mL, 55.6 mmol) in DCM (30 mL) was added 2,6-lutidine (19.4 mL, 167 mmol) and a DCM solution (30 mL) of 4-(l-pyrrolidinyl)-piperidine (8.58 g, 55.6 mmol) and stirred for lhour. The suspension was filtered and solid washed with excess diethyl ether to afford the title pyrrolidine (17.7 g, 91% yield) as a white solid. ESI/MS calcd. for 1-(4nitrophenyl)piperazine derivative C19H30N5O4P 423.2, found mlz = 422.2 (M-l).

EXAMPLE 11 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl (4-(pyrrolidin- 1 -yl)piperidin- 1 yl)phosphonochloridate hydrochloride

To a stirred, cooled (ice/water bath) solution of the dichlorophosphoramidate 8 (17.7 g, 50.6 mmol) in DCM (100 mL) was added a DCM solution (100 mL) of Mo(Tr)T # (24.5 g, 50.6 mmol), 2,6-Lutidine (17.7 mL, 152 mmol), and 1-methylimidazole (0.401 mL, 5.06 mmol) dropwise over 10 minutes. The bath was allowed to warm to ambient temperature as suspension was stirred. After 6 hours, the suspension was poured onto diethyl ether (1 L), stirred 15 minutes, filtered and solid washed with additional ether to afford a white solid (45.4 g). The crude product was purified by chromatography [S1O2 column (120 gram), DCM/MeOH eluant (gradient 1:0 to 6:4)], and the combined fractions were poured onto diethyl ether (2.5 L), stirred 15 min, filtered, and the resulting solid washed with additional ether to afford

127

2019204913 09 Jul 2019 the title compound (23.1 g, 60 % yield) as a white solid. ESI/MS calcd. for 1-(4nitrophenyl)piperazine derivative C48H57N8O7P 888.4, found m/z = 887.6 (M-l).

EXAMPLE 12

3-(tert-butyldisulfanyl)-2-(isobutoxycarbonylamino)propanoic ACID

To S-teH-butylmercapto-L-cysteine (lOg, 47.8mmol) in CH3CN (40mL) was added K2CO3 (16.5g, 119.5mmol) in H2O (20mL). After stirring for 15 minutes, /'.so-butyl chloroformate (9.4mL, 72mmol) was injected slowly. The reaction was allowe to run for 3 hours. The white solid was filtered through Celite; the filtrate was 10 concentrated to remove CH3CN. The residue was dissolved in ethyl acetate (200mL), washed with IN HC1 (40ml X 3), brine (40 X 1), dried over Na2SC>4. Desired product (2) was obtained after chromatography (5% MeOH/DCM).

EXAMPLE 13

TERT-BUTYL 4-(3 -(TERT-BUTYLDISULFANyl)-215 (ISOBUTOXYCARBONYLAMINO)PROPANAMIDO)PIPERIDINE-1 -CARBOXYLATE

To the acid (compound 2 from Example 12, 6.98g, 22.6mmol) in DMF (50ml was added HATU (8.58g, 22.6mmol). After 30 min, Hunig base (4.71ml, 27.1mmol) and l-Boc-4-amino piperidine (5.43g, 27.1mmol) were added to the 20 mixture. The reaction was continued stirring at RT for another 3h. DMF was removed at high vacuum, the crude residue was dissolved in EtAc (300ml), washed with H2O (50ml X 3). The final product (3) was obtained after ISCO purification (5% MeOH/DCM).

128

EXAMPLE 14

2019204913 09 Jul 2019

ISOBUTYL 3 -(TERT-BUTYLDISULFANyl)- 1 -oxo-1 -(piperidin-4-ylamino)propan-2YLCARBAMATE

To compound 3 prepared in Example 13 (7.085g, 18.12mmol) was added 30ml of 4M HCl/Dioxane. The reaction was completed after 2h at RT. The HC1 salt (4) was used for the next step without further purification.

EXAMPLE 15

ISOBUTYL 3-(tert-butyldisulfanyl)- 1 -(1 -(dichlorophosphoryl)piperidin-410 YLAMINO)-1 -OXOPROP AN-2-YLC ARB AMATE

To compound 4 prepared in Example 15 (7.746g, 18.12mmol) in DCM (200ml) at -78 °C was slowly injected POCfi (1.69ml, 18.12mmol) under Ar, followed by the addition of Et3N (7.58ml, 54.36mmol). The reaction was stirred at RT for 5h, 15 concentrated to remove excess base and solvent. The product (5) was given as white solid after ISCO purification (50% EtAc/Hexane).

129

EXAMPLE 16

2019204913 09 Jul 2019 isobutyl 3-(tert-butyldisulfanyl)- 1 -(1 -(chloro(((2S,6R)-6-(5-methyl-2,4dioxo-3 ,4-dihydropyrimidin- 1 (2H)-yl)-4-tritylmorpholin-2yl)methoxy)phosphoryl)piperidin-4-ylamino)-1-oxopropan-2-ylcarbamate

To l-((2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl)-5methylpyrimidine-2,4(lH,3H)-dione (moT(Tr)) (5.576g, 10.98mmol) in DCM (100ml) at 0°C, was added lutidine (1.92ml, 16.47mmol) and DMAP (669mg, 5.5mmol), followed by the addition of 4 (6.13g, 12.08mmol). The reaction was left stirring at RT 10 for 18h. The desired product (6) was obtained after ISCO purification (50% EtAc/Hexane).

EXAMPLE 17 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl hexyl(methyl)phosphoramidochloridate

Cl

A DCM (80ml) solution of N-hydroxylmethylamine (4.85ml, 32mmol) was cooled down to -78°C under N2. A solution of phosphoryl chloride (2.98ml, 32mmol) in DCM (10ml), followed by a solution of Eb,N (4.46ml, 32mmol) in DCM (10ml), was added slowly. The stirring was continued while the reaction was allowed 20 to warm to RT overnight. The desired product (1) was given as clear oil after ISCO purification (20% EtAc/Hexane).

130

2019204913 09 Jul 2019

To moT(Tr) (5.10g, 10.54mmol) in DCM (100ml) at 0°C, was added lutidine (3.68ml, 31.6mmol) and DMAP (642mg, 5.27mmol), followed by the addition of 1 (4.89g, 21.08mmol). The reaction was left stirring at RT for 18h. The desired product (2) was obtained after ISCO purification (50% EtOAc/Hexane).

EXAMPLE 18 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl dodecyl(methyl)phosphoramidochloridate

Cl \ I

The title compound was prepared according to the general procedures described in Examples 6 and 8.

EXAMPLE 19 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl morpholinophosphonochloridate

o N-P=o

The title compound was prepared according to the general procedures described in Examples 6 and 8.

131

EXAMPLE 20

2019204913 09 Jul 2019 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4tritylmorpholin-2-yl)methyl (S)-2-(methoxymethyl)pyrrolidin- 1 YLPHOSPHONOCHLORIDATE

The title compound was prepared according to the general procedures described in Examples 6 and 8.

EXAMPLE 21 ((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-410 tritylmorpholin-2-yl)methyl 4-(3 ,4,5-trimethoxybenzamido)piperidin- 1 YLPHOSPHONOCHLORIDATE

To l-Boc-4-piperidine (lg, 5mmol) in DCM (20ml) was added Hunig base (1.74ml, lOmmol), followed by the addition of 3,4,5-trimethoxybenzoyl chloride (1.38g, 6mmol). The reaction was run at RT for 3h, concentrated to remove solvent and excess base. The residue was dissolved in EtAc (100ml), washed with 0.05N HC1 (3 X

132

2019204913 09 Jul 2019

15ml), sat. NaHCCh (2 X 15ml), dried over Na2SO4. Product (1) was obtained after ISCO purification (5% MeOH/DCM).

To 7 was added 15ml of 4N HCl/Dioxane, reaction was terminated after 4h. 8 was obtained as white solid.

A DCM (20ml) solution of 8 (1.23g, 4.18mmol) was cooled down to 78°C under N2. A solution of phosphoryl chloride (0.39ml, 4.18mmol) in DCM (2ml), followed by a solution of ΕΤ,Ν (0.583ml, 4.18mmol) in DCM (2ml), was added slowly. The stirring was continued while the reaction was allowed to warm to RT overnight. The desired product (9) was obtained after ISCO purification (50% EtAc/Hexane).

To moT(Tr) (1.933g, 4.0mmol) in DCM (20ml) at 0°C, was added lutidine (0.93ml, 8mmol) and DMAP (49mg, 0.4mmol), followed by the addition of 9 (1.647g, 4mmol). The reaction was left stirring at RT for 18h. The desired product (10) was obtained after ISCO purification (50% EtAc/Hexane).

EXAMPLE 22

Synthesis of cyclophosphoramide containing subunit (^CPT)

The moT subunit (25 g) was suspended in DCM (175 ml) and NMI (Nmethylimidazole, 5.94 g, 1.4 eq.) was added to obtain a clear solution. Tosyl chloride was added to the reaction mixture, and the reaction progress was monitored by TLC 20 until done (about 2 hours). An aqueous workup was performed by washing with 0.5 M citric acid buffer (pH=5), followed by brine. The organic layer was separated and dried

133

2019204913 09 Jul 2019 over Na2SO4. Solvent was removed with a rotavaporator to obtain the crude product which was used in the next step without further purification.

The moT Tosylate prepared above was mixed with propanolamine (lg/10 ml). The reaction mixture was then placed in an oven at 45 °C overnight 5 followed by dilution with DCM (10 ml). An aqueous workup was performed by washing with 0.5 M citric acid buffer (pH=5), followed by brine. The organic layer was separated and dried over Na2SO4. Solvent was removed with a rotavaporator to obtain the crude product. The curde product was analyzed by NMR and HPLC and determined to be ready for the next step without further purification.

The crude product was dissolved in DCM (2.5 ml DCM/g, 1 eq.) and mixed with DIEA (3 eq.). This solution was cooled with dry ice-acetone and POCfi was added dropwise (1.5 eq.). The resultant mixture was stirred at room temperature overnight. An aqueous workup was performed by washing with 0.5 M citric acid buffer (pH=5), followed by brine. The organic layer was separated and dried over Na2SO4.

Solvent was removed with a rotavaporator to obtain the crude product as a yellowish solid. The crude product was purified by silica gel chromatography (crude product/silica=l to 5 ratio, gradient DCM to 50% EA/DCM), and fractions were pooled according to TLC analysis. Solvent was removed to obtain the desired product as a mixture of diastereomers. The purified product was analyzed by HPLC (NPP quench) 20 and NMR (H-l and P-31 ).

The diastereomeric mixture was separated according to the following procedure. The mixture (2.6 g) was dissolved in DCM. This sample was loaded on a RediSepRf column (80 g normal phase made by Teledyne Isco) and eluted with 10% EA/DCM to 50% EA/DCM over 20 minutes. Fractions were collected and analyzed by 25 TLC. Fractions were pooled according to TLC analysis, and solvent was removed with a rotavaporator at room temperature. The diastereomeric ratio of ther pooled fractions was determined by P-31 NMR and NPP-TFA analysis. If needed, the above procedure was repeated until the diastereomeric ratio reached 97%.

134

2019204913 09 Jul 2019

EXAMPLE 23

Global cholic acid modification of PMOplus

c₄h₅no₃

Mol. Wt.: 115.09

4.0 g

34.8 mmol

C₇H_wN₂

Mol. Wt.: 122.17

c₈h₁₈cin₃

Mol. Wt.: 191.70

5.6 g

29.3 mmol g

8.2 mmol

MW: 7076

09DE14-J(A7 to F7)

OH

Chemical Formula: C28H43NO7

Molecular Weight: 505.64352

NG-0 9-0367 plus site 3'-end H mg

2.8 umol

404-152 mg ummol

Molecu lar Weig ht: 391.56

7076+4*391

7467

7858

8249

8640

The succinimide activated cholic acid derivative was prepared according to the following procedure. Cholic acid (12 g, 29.4 mmol), N-hydroxysuccinimide (4.0 g,34.8 mmol), EDCI (5.6 g, 29.3 mmol), and DMAP (1 g, 8.2 mmol) were charged to a round bottom flask. DCM (400 ml) and THF (40 ml) were added to dissolve. The reaction mixture was stirred at room temperature overnight. Water (400 ml) was then 10 added to the reaction mixture, the organic layer separated and washed with water (2X

400 ml), followed by sat. NaHCCb (300 ml) and brine (300 ml). The organic layer was then dried over Na₂SO4. Solvent was removed with rotavaporator to obtain a white solid. The crude product was dissolved in chloroform (100 ml) and precipitated into heptane (1000 ml). The solid was collected by filtration, analyzed by HPLC and NMR 15 and used without further purification.

An appropriate amount of PMOplus (20 mg, 2.8 μηιοί) was weighed into a vial (4 ml) and dissolved in DMSO (500 ul). The activated cholate ester (13 mg, 25

135

2019204913 09 Jul 2019 μηιοί) was added to the reaction mixture according to the ratio of two equivalent of active ester per modification site followed by stirring at room temperature overnight. Reaction progress was determined by MALDI and HPLC (C-18 or SAX).

After the reaction was complete (as determined by disappearance of starting PMOplus), 1ml of concentrated ammonia was added to the reaction mixture once the reaction is complete. The reaction vial was then placed in an oven (45 ° C) overnight (18 hours) followed by cooling to room temperature and dilution with 1% ammonia in water (10 ml). This sample was loaded on to an SPE column (2 cm), and the vial rinsed with 1% ammonia solution (2X 2ml). The SPE column was washed with 10 1% ammonia in water (3X 6ml), and the product eluted with 45% acetonitrile in 1% ammonia in water (6 ml). Fractions containing oligomer were identified by UV optical density measurement. Product was isolated by lyophilization. Purity and identity were determined by MALDI and HPLC (C-18 and/or SAX).

This same procedure is applicable to deoxycholic acid activation and 15 conjugation to a PMO⁺.

EXAMPLE 24

Global Guanidinylation of PMOplus

An appropriate amount of PMOplus (25 mg, 2.8 qmol) was weighed into a vial (6 ml). lH-Pyrozole-l-carboxamidine chloride (15 mg, 102 qmol) and potassium 20 carbonate (20 mg, 0.15 mmol) were added to the vial. Water was added (500 ul), and the reaction mixture was stirred at room temperature overnight (about 18 hours). Reaction completion was determined by MALDI.

Once complete, the reaction was diluted with 1% ammonia in water (10 ml) and loaded on to an SPE column (2 cm). The vial was rinsed with 1% ammonia 25 solution (2X 2ml), and the SPE column was washed with 1% ammonia in water (3X 6ml). Product was eluted with 45% acetonitrile in 1% ammonia in water (6 ml). Fractions containing oligomer were identified by UV optical density measurement. Product was isolated by lyophilization. Purity and identity were determined by MALDI and HPLC (C-18 and/or SAX).

136

2019204913 09 Jul 2019

EXAMPLE 25

Global thioacetyl modification of PMOplus (M23D)

10Feb16-J(D1)

NG-09-0719

M23D plus site 3'-end H

Chemical Formula: C₈H_gNO₅S Exact Mass: 231.0

SATA

N-succinimidyl-S-acetylthioacetate

DMSO

500 Ul mg

2.3 umol mg umol eq.

Exact Mass: 117.0 9178

Ammonolysis

B ’

Exact Mass: 75.0 8860

8935

9010

An appropriate amount of PMOplus (20 mg, 2.3 μηιοί) was weighed in 5 to a vial (4 ml) and dissolved in DMSO (500 ul). N-succinimidyl-S-acetylthioacetate (SATA) (7 mg, 28 μηιοί) was added to the reaction mixture, and it was allowed to stir at room temperature overnight. Reaction progress was monitored by MALDI and HPLC.

Once complete, 1% ammonia in water was added to the reaction 10 mixture, and it was stirred at room temperature for 2 hours. This solution was loaded on to an SPE column (2 cm), The vial was rinsed with 1% ammonia solution (2X 2ml), and the SPE column was washed with 1% ammonia in water (3X 6ml). Product was eluted with 45% acetonitrile in 1% ammonia in water (6 ml). Fractions containing oligomer were identified by UV optical density measurement. Product was isolated by 15 lyophilization. Purity and identity were determined by MALDI and HPLC (C-18 and/or SAX).

137

2019204913 09 Jul 2019

EXAMPLE 26

Global Succinic Acid modification of PMOplus

MW: 8710

10FE02-R(A7)

NG-09-0719

mg

100 umol 3 plus site 3'-end H mg

3.7 umol

Chemical Formula: C4H4O3

Molecular Weight: 100.07276

Chemical Formula: ΟθΗ₁₃ΝΟ

Molecular Weight: 115.17352 d=0.91

100 umol mg ul

DMSO NH₃-H₂O

500 ul

Chemical Formula: C4H5O3*

Molecular Weight: 101.08070 8710+4*100

8810

8910

9010

9110

An appropriate amount of PMOplus (32 mg, 3.7 μηιοί) was weighed in to a vial (4 ml) and dissolved in DMSO (500 ul). N-ethyl morpholino (12 mg, 100 μηιοί) and succinic anhydride (10 mg, 100 μηιοί) were added to the reaction mixture, and it was allowed to stir at room temperature overnight. Reaction progress was monitored by MALDI and HPLC.

Once complete, 1% ammonia in water was added to the reaction 10 mixture, and it was stirred at room temperature for 2 hours. This solution was loaded on to an SPE column (2 cm), The vial was rinsed with 1% ammonia solution (2X 2ml), and the SPE column was washed with 1% ammonia in water (3X 6ml). Product was eluted with 45% acetonitrile in 1% ammonia in water (6 ml). Fractions containing oligomer were identified by UV optical density measurement. Product was isolated by 15 lyophilization. Purity and identity were determined by MALDI and HPLC (C-18 and/or SAX).

The above procedure is applicable to glutartic acid (glutaric anhydride) and tetramethyleneglutaric acid (tetramethyleneglutaric anhydride) modification of PMOplus as well.

138

2019204913 09 Jul 2019

O.^ -O-

CK -O-

Glutaric anhydride

Tetramethylenglutaric anhydride

EXAMPLE 27

Preparation of an Oligonucleotide Analogue Comprising a Modified Terminal Group

To a solution of a 25-mer PMO containing a free 3’-end (27.7 mg, 3.226 μηιοί) in DMSO (300μΕ) was added farnesyl bromide(1.75pl, 6.452 μηιοί) and diisopropylethylamine (2.24 qL, 12.9 μηιοί). The reaction mixture was stirred at room temperature for 5 hours. The crude reaction mixture was diluted with 10 mL of 1% aqueous NH4OH, and then loaded onto a 2 mL Amberchrome CG300M column. The 10 column was then rinsed with 3 column volumes of water, and the product was eluted with 6 mL of 1:1 acetonitrile and water (v/v). The solution was then lyophilized to obtain the title compound as a white solid.

EXAMPLE 28

Preparation of Morpholino Oligomers

Preparation of trityl piperazine phenyl carbamate 35 (see Figure 3): To a cooled suspension of compound 11 in dichloromethane (6 mL/g 11) was added a solution of potassium carbonate (3.2 eq) in water (4 mL/g potassium carbonate). To this two-phase mixture was slowly added a solution of phenyl chloroformate (1.03 eq) in dichloromethane (2 g/g phenyl chloroformate). The reaction mixture was warmed to 20 20 °C. Upon reaction completion (1-2 hr), the layers were separated. The organic layer was washed with water, and dried over anhydrous potassium carbonate. The product 35 was isolated by crystallization from acetonitrile. Yield = 80%

Preparation of carbamate alcohol 36: Sodium hydride (1.2 eq) was suspended in l-methyl-2-pyrrolidinone (32 mL/g sodium hydride). To this suspension 25 were added triethylene glycol (10.0 eq) and compound 35 (1.0 eq). The resulting slurry was heated to 95 °C. Upon reaction completion (1-2 hr), the mixture was cooled to 20 °C. To this mixture was added 30% dichloromethane/methyl tert-butyl ether (v:v) and

139

2019204913 09 Jul 2019 water. The product-containing organic layer was washed successively with aqueous NaOH, aqueous succinic acid, and saturated aqueous sodium chloride. The product 36 was isolated by crystallization from dichloromethane/methyl tert-butyl ether/heptane. Yield = 90%.

Preparation of Tail acid 37: To a solution of compound 36 in tetrahydrofuran (7 mL/g 36) was added succinic anhydride (2.0 eq) and DMAP (0.5 eq). The mixture was heated to 50 °C. Upon reaction completion (5 hr), the mixture was cooled to 20 °C and adjusted to pH 8.5 with aqueous NaHCO3. Methyl tert-butyl ether was added, and the product was extracted into the aqueous layer. Dichloromethane was 10 added, and the mixture was adjusted to pH 3 with aqueous citric acid. The productcontaining organic layer was washed with a mixture of pH=3 citrate buffer and saturated aqueous sodium chloride. This dichloromethane solution of 37 was used without isolation in the preparation of compound 38.

Preparation of 38: To the solution of compound 37 was added N15 hydroxy-5-norbornene-2,3-dicarboxylic acid imide (HONB) (1.02 eq), 4dimethylaminopyridine (DMAP) (0.34 eq), and then 1-(3-dimethylaminopropyl)-N'ethylcarbodiimide hydrochloride (EDC) (1.1 eq). The mixture was heated to 55 °C. Upon reaction completion (4-5 hr), the mixture was cooled to 20 °C and washed successively with 1:1 0.2 M citric acid/brine and brine. The dichloromethane solution 20 underwent solvent exchange to acetone and then to Ν,Ν-dimethylformamide, and the product was isolated by precipitation from acetone/ Ν,Ν-dimethylformamide into saturated aqueous sodium chloride. The crude product was reslurried several times in water to remove residual Ν,Ν-dimethylformamide and salts. Yield = 70% of 38 from compound 36. Introduction of the activated “Tail” onto the disulfide anchor-resin was 25 performed in NMP by the procedure used for incorporation of the subunits during solid phase synthesis.

Preparation of the Solid Support for Synthesis of Morpholino Oligomers: This procedure was performed in a silanized, jacketed peptide vessel (custom made by ChemGlass, NJ, USA) with a coarse porosity (40-60 pm) glass frit, overhead stirrer, 30 and 3-way Teflon stopcock to allow N2 to bubble up through the frit or a vacuum extraction. Temperature control was achieved in the reaction vessel by a circulating water bath.

140

2019204913 09 Jul 2019

The resin treatment/wash steps in the following procedure consist of two basic operations: resin fluidization and solvent/solution extraction. For resin fluidization, the stopcock was positioned to allow N2 flow up through the frit and the specified resin treatment/wash was added to the reactor and allowed to permeate and 5 completely wet the resin. Mixing was then started and the resin slurry mixed for the specified time. For solvent/solution extraction, mixing and N2 flow were stopped and the vacuum pump was started and then the stopcock was positioned to allow evacuation of resin treatment/wash to waste. All resin treatment/wash volumes were 15 mL/g of resin unless noted otherwise.

To aminomethylpolystyrene resin (100-200 mesh; ~1.0 mmol/g N2 substitution; 75 g, 1 eq, Polymer Labs, UK, part &1464-X799) in a silanized, jacketed peptide vessel was added l-methyl-2-pyrrolidinone (NMP; 20 ml/g resin) and the resin was allowed to swell with mixing for 1-2 hr. Following evacuation of the swell solvent, the resin was washed with dichloromethane (2 x 1-2 min), 5% diisopropylethylamine in

25% isopropanol/dichloromethane (2 x 3-4 min) and dichloromethane (2 x 1-2 min).

After evacuation of the final wash, the resin was fluidized with a solution of disulfide anchor 34 in l-methyl-2-pyrrolidinone (0.17 M; 15 mL/g resin, ~2.5 eq) and the resin/reagent mixture was heated at 45 °C for 60 hr. On reaction completion, heating was discontinued and the anchor solution was evacuated and the resin washed with 120 methyl-2-pyrrolidinone (4 x 3-4 min) and dichloromethane (6 x 1-2 min). The resin was treated with a solution of 10% (v/v) diethyl dicarbonate in dichloromethane (16 mL/g; 2 x 5-6 min) and then washed with dichloromethane (6 x 1-2 min). The resin 39 (see Figure 4) was dried under a N2 stream for 1-3 hr and then under vacuum to constant weight (± 2%). Yield: 110-150% of the original resin weight.

Determination of the Loading of Aminomethylpolystyrene-disulfide resin: The loading of the resin (number of potentially available reactive sites) is determined by a spectrometric assay for the number of triphenylmethyl (trityl) groups per gram of resin.

A known weight of dried resin (25 ± 3 mg) is transferred to a silanized 30 25 ml volumetric flask and ~5 mL of 2% (v/v) trifluoroacetic acid in dichloromethane is added. The contents are mixed by gentle swirling and then allowed to stand for 30 min. The volume is brought up to 25 mL with additional 2% (v/v) trifluoroacetic acid in

141

2019204913 09 Jul 2019 dichloromethane and the contents thoroughly mixed. Using a positive displacement pipette, an aliquot of the trityl-containing solution (500 pL) is transferred to a 10 mL volumetric flask and the volume brought up to 10 mL with methanesulfonic acid.

The trityl cation content in the final solution is measured by UV 5 absorbance at 431.7 nm and the resin loading calculated in trityl groups per gram resin (pmol/g) using the appropriate volumes, dilutions, extinction coefficient (ε: 41 pmollcm-1) and resin weight. The assay is performed in triplicate and an average loading calculated.

The resin loading procedure in this example will provide resin with a 10 loading of approximately 500 pmol/g. A loading of 300-400 in pmol/g was obtained if the disulfide anchor incorporation step is performed for 24 hr at room temperature.

Tail loading: Using the same setup and volumes as for the preparation of aminomethylpolystyrene-disulfide resin, the Tail can be introduced into the molecule. For the coupling step, a solution of 38 (0.2 M) in NMP containing 4-ethylmorpholine 15 (NEM, 0.4 M) was used instead of the disulfide anchor solution. After 2 hr at 45 °C, the resin 39 was washed twice with 5% diisopropyl ethylamine in 25% isopropanol/dichloromethane and once with DCM. To the resin was added a solution of benzoic anhydride (0.4 M) and NEM (0.4 M). After 25 min, the reactor jacket was cooled to room temperature, and the resin washed twice with 5% diisopropylethylamine 20 in 25% isopropanol/dichloromethane and eight times with DCM. The resin 40 was filtered and dried under high vacuum. The loading for resin 40 is defined to be the loading of the original aminomethylpolystyrene-disulfide resin 39 used in the Tail loading.

Solid Phase Synthesis: Morpholino Oligomers were prepared on a 25 Gilson AMS-422 Automated Peptide Synthesizer in 2 mL Gilson polypropylene reaction columns (Part # 3980270). An aluminum block with channels for water flow was placed around the columns as they sat on the synthesizer. The AMS-422 will alternatively add reagent/wash solutions, hold for a specified time, and evacuate the columns using vacuum.

For oligomers in the range up to about 25 subunits in length, aminomethylpolystyrene-disulfide resin with loading near 500 pmol/g of resin is preferred. For larger oligomers, aminomethylpolystyrene-disulfide resin with loading

142

2019204913 09 Jul 2019 of 300-400 μηιοΐ/g of resin is preferred. If a molecule with 5’-Tail is desired, resin that has been loaded with Tail is chosen with the same loading guidelines.

The following reagent solutions were prepared:

Detritylation Solution: 10% Cyanoacetic Acid (w/v) in 4:1 dichloromethane/acetonitrile; Neutralization Solution: 5% Diisopropylethylamine in

3:1 dichloromethane/isopropanol; Coupling Solution: 0.18 M (or 0.24 M for oligomers having grown longer than 20 subunits) activated Morpholino Subunit of the desired base and linkage type and 0.4 Μ N ethylmorpholine, in 1,3-dimethylimidazolidinone. Dichloromethane (DCM) was used as a transitional wash separating the different 10 reagent solution washes.

On the synthesizer, with the block set to 42 °C, to each column containing 30 mg of aminomethylpolystyrene-disulfide resin (or Tail resin) was added 2 mL of 1-methyl-2-pyrrolidinone and allowed to sit at room temperature for 30 min. After washing with 2 times 2 mL of dichloromethane, the following synthesis cycle was 15 employed:

Step	Volume	Delivery	Hold time
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
Detritylation	1.5 mL	Manifold	15 seconds
DCM	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds
DCM	1.5 mL	Manifold	30 seconds
Coupling	350 uL - 500 uL	Syringe	40 minutes
DCM	1.5 mL	Manifold	30 seconds
Neutralization	1.5 mL	Manifold	30 seconds

143

2019204913 09 Jul 2019

Step	Volume	Delivery	Hold time
Neutralization	1.5 mL	Manifold	30 seconds
DCM	1.5 mL	Manifold	30 seconds
DCM	1.5 mL	Manifold	30 seconds
DCM	1.5 mL	Manifold	30 seconds

The sequences of the individual oligomers were programmed into the synthesizer so that each column receives the proper coupling solution (A,C,G,T,I) in the proper sequence. When the oligomer in a column had completed incorporation of its 5 final subunit, the column was removed from the block and a final cycle performed manually with a coupling solution comprised of 4-methoxytriphenylmethyl chloride (0.32 M in DMI) containing 0.89 M 4-ethylmorpholine.

Cleavage from the resin and removal of bases and backbone protecting groups: After methoxytritylation, the resin was washed 8 times with 2 mL l-methyl-210 pyrrolidinone. One mL of a cleavage solution consisting of 0.1 Μ 1,4-dithiothreitol (DTT) and 0.73 M triethylamine in l-methyl-2-pyrrolidinone was added, the column capped, and allowed to sit at room temperature for 30 min. After that time, the solution was drained into a 12 mL Wheaton vial. The greatly shrunken resin was washed twice with 300 gL of cleavage solution. To the solution was added 4.0 mL cone aqueous 15 ammonia (stored at -20 °C), the vial capped tightly (with Teflon lined screw cap), and the mixture swirled to mix the solution. The vial was placed in a 45 °C oven for 16-24 hr to effect cleavage of base and backbone protecting groups.

Initial Oligomer Isolation: The vialed ammonolysis solution was removed from the oven and allowed to cool to room temperature. The solution was 20 diluted with 20 mL of 0.28% aqueous ammonia and passed through a 2.5x10 cm column containing Macroprep HQ resin (BioRad). A salt gradient (A: 0.28% ammonia with B: 1 M sodium chloride in 0.28% ammonia; 0-100% B in 60 min) was used to elute the methoxytrityl containing peak. The combined fractions were pooled and further processed depending on the desired product.

Demethoxytritylation of Morpholino Oligomers: The pooled fractions from the Macroprep purification were treated with 1 Μ H3PO4 to lower the pH to 2.5. After initial mixing, the samples sat at room temperature for 4 min, at which time they

144

2019204913 09 Jul 2019 are neutralized to pH 10-11 with 2.8% ammonia/water. The products were purified by solid phase extraction (SPE).

Amberchrome CG-300M (Rohm and Haas; Philadelphia, PA) (3 mL) is packed into 20 mL fritted columns (BioRad Econo-Pac Chromatography Columns 5 (732-1011)) and the resin rinsed with 3 mL of the following: 0.28% NH4OH/80% acetonitrile; 0.5M NaOH/20%ethanol; water; 50 mM H3PO4/80% acetonitrile; water; 0.5 NaOH/20% ethanol; water; 0.28% NH4OH.

The solution from the demethoxytritylation was loaded onto the column and the resin rinsed three times with 3-6 mL 0.28% aqueous ammonia. A Wheaton vial 10 (12 mL) was placed under the column and the product eluted by two washes with 2 mL of 45% acetonitrile in 0.28% aqueous ammonia. The solutions were frozen in dry ice and the vials placed in a freeze dryer to produce a fluffy white powder. The samples were dissolved in water, filtered through a 0.22 micron filter (Pall Life Sciences, Acrodisc 25 mm syringe filter, with a 0.2 micron HT Tuffryn membrane) using a 15 syringe and the Optical Density (OD) was measured on a UV spectrophotometer to determine the OD units of oligomer present, as well as dispense sample for analysis. The solutions were then placed back in Wheaton vials for lyophilization.

Analysis of Morpholino Oligomers: MALDI-TOF mass spectrometry was used to determine the composition of fractions in purifications as well as provide 20 evidence for identity (molecular weight) of the oligomers. Samples were run following dilution with solution of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), 3,4,5trihydoxyacetophenone (THAP) or alpha-cyano-4-hydoxycinnamic acid (HCCA) as matrices.

Cation exchange (SCX) HPLC was performed using a Dionex ProPac 25 SCX-10, 4x250mm column (Dionex Corporation; Sunnyvale, CA) using 25 mM pH=5 sodium acetate 25% acetonitrile (Buffer A) and 25 mM pH=5 sodium acetate 25% acetonitrile 1.5 M potassium chloride (buffer B) (Gradient 10-100% B in 15 min) or 25 mM KH2PO4 25% acetonitrile at pH=3.5 (buffer A) and 25 mM KH2PO4 25% acetonitrile at pH=3.5 with 1.5 M potassium chloride (buffer B) (Gradient 0-35% B in 30 15 min). The former system was used for positively charged oligomers that do not have a peptide attached, while the latter was used for peptide conjugates.

145

2019204913 09 Jul 2019

Purification of Morpholino Oligomers by Cation Exchange Chromatography: The sample is dissolved in 20 mM sodium acetate, pH=4.5 (buffer A) and applied to a column of Source 30 cation exchange resin (GE Healthcare) and eluted with a gradient of 0.5 M sodium chloride in 20 mM sodium acetate and 40% 5 acetonitrile, pH=4.5 (buffer B). The pooled fractions containing product are neutralized with cone aqueous ammonia and applied to an Amberchrome SPE column. The product is eluted, frozen, and lyophilized as above.

EXAMPLE 29

Preparation of an Exemplary Conjugate

The peptide sequence AcReG was prepared according to standard peptide syhtentic methods known in the art. To a solution of the PMO (NG-05-0225, 3’-H: M23D : 5’-EG3, a sequence for binding to exon 23 of the mdx mouse, 350 mg, 1 eq), AcR6G (142 mg, 2 eq), HATU (31 mg, 2 eq) in DMSO (3 mL) was added diisopropylethylamine (36 pL, 5eq) at room temperature. After 1 hour, the reaction was worked up and the desired peptide-oligomer conjugate was purified by SCX chromatography (eluting with a gradient: A: 20 mM NaH2PO4 in 25% acetonitrile/H2O, pH 7.0; B: 1.5 M guanidine HC1 and 20 mM NaH2PO4 in 25% acetonitrile/H2O, pH 7.0). The combined fractions were subjected to solid phase extraction (IM NaCl, followed by water elution). The conjugate was obtained as a 20 white powder (257 mg, 65.5% yield) after lyophilization.

EXAMPLE 30

Treatment of MDX mice with exemplary Conjugates of the invention

The MDX mouse is an accepted and well-characterized animal model for

Duchene muscular dystrophy (DMD) containing a mutation in exon 23 of the 25 dystrophin gene. The M23D antisense sequence (SEQ ID NO: 15) is known to induce exon 23 skipping and restoration of functional dystrophin expression. MDX mice were dosed once (50 mg/kg) by tail vein injection with one of the following conjugates:

1. 5’-EG3-M23D-BX(RXRRBR)₂ (AVI5225);

2. 5’-EG3-M23D-G(R)s (NG-11-0045);

146

2019204913 09 Jul 2019

3. 5’-EG3-M23D-G(R)₆(NG-l 1-0009);

4. 5’-EG3-M23D-G(R)₇ (NG-11-0010); or

5. 5’-EG3-M23D-G(R)₈ (NG-11-0216) wherein M23D is a morpholino olionucleotide having the sequence

GGCCAAACCTCGGCTTACCTGAAAT and “EG3” refers to the following structure:

linked to the 5’ end of the oligomer via a piperazine linker (i.e., structure XXIX).

One week post-injection, the MDX mice were sacrificed and RNA was extracted from various muscle tissues. End-point PCR was used to determine the 10 relative abundance of dystrophin mRNA containing exon 23 and mRNA lacking exon 23 due to antisense-induced exon skipping. Percent exon 23 skipping is a measure of antisense activity in vivo. Figures 5 and 6 show shows the results from the quadriceps (QC, Figures 5A and 6A), diaphragm (DT, Figures 5B and 6B) and heart (HT, Figures 5C and 6C), respectively one week post-treatment. The dose response between AVI15 5225 and the other conjugates was similar. Amongst the arginine series, the ReG peptide has the highest efficacy in quadriceps and diaphragm and was similar to the other arginine series peptides in heart.

EXAMPLE 31

BUN Levels and Survival Rates of Mice Treated with Exemplary Conjugates

Mice were treated with the conjugates described in Example 30, and

KIM-1 levels, BUN levels and survival rate were determined according to the general procedures described in Example 32 below and known in the art. Surprisingly, Figure 7A shows that all glycine linked conjugates had significantly lower BUN levels than the XB linked conjugate (AVI-5225). In addition, mice treated with glycine linked conjugates survived longer at higher doses than the XB linked conjugate (Figure 7B), with the RsG conjugate being the least tolerated of the arginine polymers. All mice treated with the ReG conjugate (NG-11-0009) survived at doses up to 400mg/kg (data not shown).

147

2019204913 09 Jul 2019

The KIM-1 (Figure 8A) and Clusterin (Figure 8B) levels of mice treated with the glycine linked conjugates was significantly lower than mice treated with AVI5225. This data indicates that the conjugates of the present invention have lower toxicity than prior conjugates, and as shown above in Example 30, the efficacy of the 5 conjugates is not decreased. Accordingly, the present conjugates have a better therapeutic window than other known conjugates and are potentially better drug candidates.

EXAMPLE 32

Toxicology of Exemplary Conjugates

Four exemplary conjugates of the invention were tested for their

toxicology in mice.	The conjugates were as follows:
1.	5’-EG3-M23D-BX(RXRRBR)2 (AVI5225);
2.	5’-EG3-M23D-G(RXRRBR)2 (NG-11-0654);
3.	5’-EG3-M23D-BX(R)6 (NG-11-0634); and
15 4.	5’-EG3-M23D-G(R)6 (NG-11-0009)
wherein M23D	is a morpholino olionucleotide having the sequence

GGCCAAACCTCGGCTTACCTGAAAT and “EG3” refers to the following structure:

linked to the 5’ end of the oligomer via a piperazine linker (i.e., structure XXIX).

Eight week old male mice (C57/BL6; Jackson Laboratories , 18-22 grams) were treated with the above conjugates formulated in saline. The mice were acclimated for a minimum of five days prior to the commencement of the experimental procedures.

The animals were housed up to 3 per cage in clear polycarbonate microisolator cages with certified irradiated contact bedding. The cages conformed to standards set forth in the Animal Welfare Act (with all amendments) and the Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, D.C., 2010.

148

2019204913 09 Jul 2019

Animals were randomized into treatment groups based on cage weights specified in the table below. Group allocation was documented in the study records.

Table 8. Toxicology Study Design

Group n=3	Oligo	Dose per injection (mg/kg)	Regimen	Route of Admin.
1	NG-11-0654	50
2	NG-11-0654	too
3	NG-11-0654	150
4	NG-11-0654	200
5	NG-11-0634	50
6	NG-11-0634	100
7	NG-11-0634	150	Single injection	Tail Vein, i.v. 200 pl
8	NG-11-0634	200
9	NG-11-0009	50
10	NG-11-0009	100
11	NG-11-0009	150
12	NG-11-0009	200
13	AVI-5225	25
14	AVI-5225	50
15	AVI-5225	100
16	Vehicle	0

The day of dosing on the study was designated as Study Day 1.

Conjugate was administered via tail vein as a slow push bolus (~5 seconds). All animals were dosed over two days. Groups 1-8 were dosed on the first day and Groups 9-16 were dosed on the second day. Treatment Groups (TG) 13-16 were dosed per the table above. Results from these TGs did not affect progression to other TG.

The first 2 TG of each conjugate were dosed per the table above. If all animals in lOOmg/kg group died then the remaining TGs of that test article would not be dosed and the study would end. If at least one animal survived 2 hours post-dose in the lOOmg/kg group, then the 150mg/kg group was dosed. If all animals in the 150mg/kg group died then the remaining TGs of that test article would not be dosed and the study would end.

If at least one animal survived 2 hours post-dose in the 150mg/kg group, then the 200mg/kg group was dosed.

Animals were observed for moribundity and mortality once daily. Any animal showing signs of distress, particularly if death appeared imminent was humanely

149

2019204913 09 Jul 2019 euthanized according to Numira Biosciences Standard Operating Procedures. Body weights were recorded on the day after arrival, the day of dosing, and the day of necropsy. Detailed clinical observations were conducted and recorded at 0 minutes, 15 minutes, and 2 hours post-dose to assess tolerability of injections.

Blood samples (maximum volume, approximately ImL) were obtained from all animals via cardiac puncture 3 days post-dose prior to necropsy. Blood samples were collected into red top microtainer tubes and held at room temperature for at least 30 minutes but no longer than 60 minutes prior to centrifugation. Samples were centrifuged at approximately 1500-2500 rpm for 15-20 minutes to obtain serum.

Animals unlikely to survive until the next scheduled observation were weighed and euthanized. Animals found dead were weighed and the time of death was estimated as closely as possible. Blood and tissue samples were not collected.

Day 3 (2 days post-dose), all animals were humanely euthanized with carbon dioxide. Euthanasia was performed in accordance with accepted American 15 Veterinary Medical Association (AVMA) guidelines on Euthanasia, June 2007.

The partial gross necropsy included examination and documentation of findings. All external surfaces and orifices were evaluated. All abnormalities observed during the collection of the tissues were described completely and recorded. No additional tissues were taken.

The right and left kidneys were collected. Tissues were collected within minutes or less of euthanasia. All instruments and tools used were changed between treatment groups. All tissues were flash frozen and stored at < -70°C as soon as possible after collection.

Kidney injury marker data was obtained as follows. RNA from mouse kidney tissue was purified using Quick Gene Mini80 Tissue Kit SII (Fuji Film). Briefly, approximately 40 mg of tissue was added to 0.5 ml lysis buffer (5 μΐ 2-mercaptoethanol in 0.5 ml lysis buffer) in a MagnaLyser Green Bead vial (Roche) and homogenized using MagNA Lyser (Roche) with 2 sets of 3x 3800 RPM and 3 sets of lx 6500 RPM. Samples were cooled on ice 3-4 minutes between each low speed set and between each higher speed run. Homogenates were centrifuged 5 minute at 400 x g at room temperature. The homogenate was immediately processed for RNA purification according to the Quick Gene Mini80 protocol. Samples underwent an on-column DNA

150

2019204913 09 Jul 2019 digestion with DNase I (Qiagen) for 5 minutes. Total RNA was quantitated with a NanoDrop 2000 spectrophotometer (Thermo Scientific).

qRT-PCR was performed using Applied Biosystems reagents (One-step

RT-PCR) and pre-designed primer/probe sets (ACTB, GAPDH, KIM-1, Clusterin 5 FAM reporter)

Reagent	Company	Cat. No.
One-step PCR kit	Applied Biosystems	4309169
GAPDH mouse primer/probe set	Applied Biosystems	4352932E
KIM-1 mouse primer/probe set	Applied Biosystems	Mm00506686 ml

Each reaction contained the following(30 ul total):

15ul 2x qRT-PCR Buffer from ABI One-Step Kit

1.5ul Primer/Probe mix

8.75 ul Nuclease-free water

0.75ul 40x multiscript + RNase inhibitor

4ul RNA template (lOOng/ul)

The qRT One-Step Program was run as follows:

1. 48C for 30 minutes

2. 95 C for 10 minutes

3. 95C for 15 seconds

4. 60C for 1 minute

5. Repeat Steps 3-4 39 times for a total of 40 cycles

Samples were run in triplicate wells and averaged for further analysis.

Analysis was performed using AACt method. Briefly, Experimental ACt [Ct(Target) Ct(Reference)] subtracted by Control ACt [Ct(Target) - Ct(Reference)]= AACt. Fold change range calculated: 2^A-(AACt+SD) to 2^A-(AACt-SD). Control=vehicle treated animal group (pooled), Target=KIM-l; Reference=GAPDH; SD=

Sqrt[(SDtarget^A2)+(SDref^A2)].

Results of KIM data are shown in Figure 10. Conjugates comprising carrier peptides with terminal glycines had lower KIM concentrations with the ReG peptide having the lowest. Both the terminal G and the presence of unnatural amino acids (aminohexanoic acid) appear to play a role in the toxicity of the conjugates.

151

2019204913 09 Jul 2019

Frozen serum samples were sent on dry ice to IDEXX Laboratories (West Sacramento, CA) for processing. Serum dilution was performed per IDEXX Standard Operating Procedures (SOPs) when necessary. Blood chemistry results were were analyzed. Blood urea nitrogen levels are shown in Figure 11. Again, the G-linked 5 conjugate had lower BUN levels and the both the terminal G and overall peptide sequence appear to play a role in the toxicological profile of the conjugates.

Kidney tissues (approx. 150 mg) were weighed accurately in a 2 mL screw cap vial partially filled with ceramic beads. Five volume parts Tissue PE LB buffer (G Biosciences) containing 10 U/mL Proteinase K (Sigma) were added to 1 part 10 tissue. Samples were homogenized with a Roche MagnaLyser (4 x 40 sec @ 7,000 rpm, with cooling between runs) and incubated for 30 min at 40°C. When required, tissue homogenates were diluted with BSAsal (3mg/mL BSA + 20mM NaCl) to bring high sample concentrations into the calibration range.

Calibration samples were prepared by spiking a solution of 3 mg/mL of 15 BSA in 20 mM NaCl with known amounts of an appropriate analytical reference standard. Duplicate sets of eight samples each were prepared. The ULOQ was 40 pg/mL and LLOQ was 0.065536 pg/mL. An internal standard (NG-07-0775) was added to all samples except some blank samples designated as double blanks (no drug, no internal standard). Samples were extracted by vortexing 100 pL aliquots with 3 20 volumes of methanol.

After centrifugation (15 min, 14,000 rpm) supernatants were transferred to new tubes and dried in a Speedvac. Dried samples were reconstituted with an appropriate amount of FDNA (5’ d FAM-ATTTCAGGTAAGCCGAGGTTTGGCC 3’) in [10 mM Tris pH 8.0 + 1 mM EDTA + 100 mM NaCl] - acetonitrile (75-25).

Samples were analyzed on the Dionex UltiMate 3000 HPLC using anion-exchange chromatography (Dionex DNAPac 4x250 mm column). Injection volume was 5 pL. Mobile phase was composed of 20% acetonitrile and 80% water containing 25 mM Tris pH 8.0 and a gradient of increasing NaCl concentration. Flow rate was 1 mL/min, and run time was 10 min per sample. The fluorescence detector 30 was set to EX 494 nm and EM 520 nm. Peak identification was based on retention time. Peak height ratios (analyte:internal standard) were used for quantitation. Calibration curves were calculated based on the averaged response factors of duplicate

152

2019204913 09 Jul 2019 calibration samples (one set run at the beginning of the batch, the other at the end of the batch. Linear curve fit with 1/x weighting factor was used. Blank samples (calibration sample with no reference compound added) and double blank samples (on internal standard added) were used to ensure assay specificity and absence of carryover.

Figure 12 shows that kidney concentrations were similar amongst the tested conjugates.

The above data shows that conjugates of the invention have similar efficacy and improved toxicity compared to other conjugates. Figures 9A-D summarizes these results with respect to an ReG conjugate (NG-11-0009).

The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be 20 construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be 30 taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (35)

1. A conjugate comprising:

(a) a carrier peptide comprising amino acid subunits; and (b) a nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid;

wherein:

two or more of the amino acid subunits are positively charged amino acids, the carrier peptide comprises a glycine (G) or proline (P) amino acid subunit at a carboxy terminus of the carrier peptide, no more than seven contiguous amino acid subunits are arginine, and the carrier peptide is covalently attached to the nucleic acid analogue.

2. The conjugate of claim 1, wherein the carrier peptide comprises a glycine amino acid at the carboxy terminus.

3. The conjugate of claim 1, wherein the carrier peptide comprises a proline amino acid at the carboxy terminus.

4. The conjugate of claim 1, wherein the carrier peptide comprises from 4 to 40 amino acid subunits.

5. The conjugate of claim 1, wherein the carrier peptide comprises from 6 to 20 amino acid subunits.

6. The conjugate of claim 1, wherein the positively charged amino acids are histidine (H), lysine (K), arginine (R) or combinations thereof.

7. The conjugate of claim 1, wherein at least one of the positively charged amino acids is arginine.

154

WO 2012/150960

PCT/US2011/061282

2019204913 09 Jul 2019

8. The conjugate of claim 1, wherein each of the amino acid subunits, except the carboxy terminal glycine or proline, are positively charged amino acids.

9. The conjugate of claim 1, wherein each of the positively charged amino acids is arginine.

10. The conjugate of claim 1, wherein at least one of the positively charged amino acids is an arginine analog, the arginine analog being a cationic a-amino acid comprising a side chain of the structure R^aN=C(NH2)R^b, where R^a is H or R^c; R^b is R^c, NH2, NHR, or N(R^C)2, where R^c is lower alkyl or lower alkenyl and optionally comprises oxygen or nitrogen or R^a and R^b may together form a ring; and wherein the side chain is linked to the amino acid via R^a or R^b.

11. The conjugate of claim 1, wherein at least 20% of the amino acid subunits are positively charged amino acids.

12. The conjugate of claim 1, wherein at least 50% of the amino acid subunits are positively charged amino acids.

13. The conjugate of claim 1, wherein at least 80% of the amino acid subunits are positively charged amino acids.

14. The conjugate of claim 1, wherein all of the amino acid subunits, except the carboxy terminal glycine or proline are positively charged amino acids.

15. The conjugate of claim 1, wherein the carrier peptide comprises the sequence (R^d)_m, wherein R^d is independently, at each occurrence, a positively charged amino acid and m is an integer ranging from 2 to 12.

16. The conjugate of claim 15, wherein R^d is independently, at each occurrence, arginine, hystidine or lysine.

155

WO 2012/150960

PCT/US2011/061282

2019204913 09 Jul 2019

17. The conjugate of claim 15, wherein each R^d is arginine.

18. The conjugate of claim 1, wherein each amino acid subunit, except the carboxy terminal glycine or proline, is arginine.

19. The conjugate of claim 1, wherein the carrier peptide comprises at least one hydrophobic amino acid, the hydrophobic amino acid comprising a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or aralkyl side chain wherein the alkyl, alkenyl and alkynyl side chain includes at most one heteroatom for every six carbon atoms.

20. The conjugate of claim 19, wherein the carrier peptide comprises two or more hydrophobic amino acids.

21. The conjugate of claim 19, wherein the carrier peptide comprises two or more conitugous hydrophobic amino acids.

22. The conjugate of claim 19, wherein at least one of the hydrophobic amino acids is phenylalanine.

23. The conjugate of claim 19, wherein each of the hydrophobic amino acids are phenylalanine.

24. The conjugate of claim 1, wherein the carrier peptide comprises at least one neutral amino acid having the following structure (Y^b):

-C(O)-(CHR^e)_n-NH(Y^b) wherein n is 2 to 7 and each R^e is independently, at each occurrence, hydrogen or methyl.

156

WO 2012/150960

PCI7US2011/061282

2019204913 09 Jul 2019

25. The conjugate of claim 24, wherein the carrier peptide comprises the sequence [(R^dY^bR^d)x(R^dR^dY^b)y]_z, wherein R^d is independently, at each occurrence, a positively charged amino acid and x and y are independently, at each occurrence, 0 or 1, provided that x + y is 1 or 2 and z is an interger ranging from 1 to 6.

26. The conjugate of claim 25, wherein R^d is independently, at each occurrence, arginine, histidine or lysine.

27. The conjugate of claim 25, wherein each R^d is arginine.

28. The conjugate of claim 25, wherein at least one Y^b is 6aminohexanoic acid or β-alaninc.

29. The conjugate of claim 1, wherein the carrier peptide comprises the sequence ILFQY.

30. The conjugate of claim 1, wherein the carrier peptide comprises the sequence ILFQ, IWFQ or ILIQ.

31. The conjugate of claim 1, wherein the carrier peptide comprises the sequence PPMWS, PPMWT, PPMFS or PPMYS.

32. The conjugate of claim 1, wherein the carrier peptide comprises at least one of alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine or threonine.

33. The conjugate of claim 1, wherein the carrier peptide comprises an acetyl, benzoyl or steroyl moiety at the amino terminus of the carrier peptide.

34. The conjugate of claim 1, wherein each of the amino acid subunits are natural amino acids.

157

WO 2012/150960

PCT/US2011/061282

2019204913 09 Jul 2019

35. The conjugate of claim 1, wherein the uncharged backbone comprises a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3’-end of one morpholino ring structure to a 5’-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to the target nucleic acid, wherein the intersubunit linkages have the following general structure (I):